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Dr David Tucker 
Assessing the cellular and adhesive interactions in in vitro models 
of mantle cell lymphoma 
Mantle cell lymphoma (MCL) is a rare lymphoproliferative disorder (LPD) that has very 
poor survival. Like other LPDs, the neoplastic cells of MCL have an intimate 
dependence upon accessory cells within haematopoietic tissues. Understanding and 
exploiting the tissue-relationships of the mantle cells may therefore lead to further 
new approaches to treatment. This study work has set out to construct an in vitro 
system to model relevant aspects of the tissue-dependent behaviour of the neoplastic 
mantle cells, seeking to establish the link between in vitro behaviour and clinical 
phenotype, and establishing the feasibility of this system to study the effects of 
different therapeutic interventions. 
The first experimental chapter employs relevant mouse and human stromal models to 
mirror the tissue environment of MCL in vivo. Testing relevant agents, the work 
establishes that the system can identify different behaviour between indolent and 
aggressive forms of MCL, and demonstrates a particular importance for CD40 ligand 
both in the proliferation and survival of the neoplastic mantle cells, but shows also 
how these effects are modulated by the soluble factors interleukin-4 (IL-4) and the toll-
like receptor-9 ligand (TLR9-L). The second experimental chapter examines the 
adhesion molecules expressed on MCL cells. Considerable variation in the level of 
expression is observed between cases, but overall the cases express particularly high 
levels of the integrin receptors LFA-1 (detected by alpha chain CD11a) and VLA-4 
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(detected by alpha chain CD49d). Cases also showed a significant difference in overall 
adhesion and chemokine-receptor expression between cases that had either a nodal or 
leukaemic clinical pattern, although no single adhesion molecule was characteristic of 
clinical phenotype.  The final experimental chapter looked at 3-D culture of MCL.  
Within tissues MCL grows in a 3-D rather than 2-D matrix and it is recognised that cells 
employ different forms of adhesion and migration within the different spatial 
environments. This chapter establishes the feasibility of growing cells in 3-D systems 
and looks at optimal conditions to preserve and examine the cellular characteristics of 
cells within a 3-D environment. 
Overall, this thesis demonstrates the feasibility and pathobiological relevance of ex 
vivo culture of MCL cells giving insights into the factors that drive MCL survival and 
proliferation and the correlation between in vitro behaviour and clinical phenotype.  It 
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1. CHAPTER 1 - INTRODUCTION 
 An Overview of Mantle Cell Lymphoma 
1.1
Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma (NHL) subtype comprising 6-
8% of all NHL cases with an approximate incidence of 0.4 per 100,000 in Europe and 
the USA.  The median age at diagnosis is 68 years and the disease has a propensity for 
older males  of approximately 3:1.1–3  Patients with MCL typically present with diffuse 
lymphadenopathy.  Extranodal involvement is a common feature, with the peripheral 
blood, bone marrow and gastro-intestinal tract all frequently involved.4 
Mantle cell lymphoma has striking clinical and biological heterogeneity and can be 
broadly subdivided into classical, aggressive MCL and a less common indolent 
subtype.5,6 
The classical, aggressive form of MCL has a progressive, nodal and symptomatic clinical 
phenotype and a striking tendency to disseminate throughout the body, infiltrating 
both the reticuloendothelial system and extranodal sites.  It is often at an advanced 
stage at diagnosis requiring immediate treatment.4,7 
The less common indolent form of MCL tends to remain quiescent and stable for 
prolonged periods, often years, without the need for treatment, and is characterized 
by a leukaemic, non-nodal and non-symptomatic clinical phenotype.8  The MCL cells 
also have a distinct genetic and molecular character, including a simple karyotype and 
often demonstrate somatic hypermutation of the IgVH gene segments, suggesting 
experience of the germinal centre.5,9,10 
Treatment for MCL depends on the fitness of the patient and the stage of the disease.  
Localised disease can sometimes be treated with local radiotherapy, whereas 
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widespread disease is generally treated with intensive cytoreductive therapy 
incorporating a monoclonal antibody specific for CD20 together with a high-dose 
cytarabine-based regimen, often consolidated by an autologous stem-cell transplant in 
first remission.11–13  There is no standard of care for patients unfit for intensive therapy 
or for patients at relapse, however the landscape of therapy has recently been 
dramatically changed with the development of several novel targeted therapies  
Regardless of treatment type, MCL is generally regarded as an incurable disease and 
most cases behave aggressively with a pattern of diminishing returns from sequential 
lines of therapy and ultimately, a poor prognosis.14–16 
Mantle cell lymphoma therefore represents an unmet clinical need in haemato-
oncology.  Recent advances in the understanding of the molecular pathogenesis and 
cell-signalling pathways in MCL together with the introduction of new small molecule 
inhibitors have led to encouraging progress in the treatment of this disease (reviewed 
in Appendices 1 and 2).17 
1.1.1 The Biological Characteristics of Mantle Cell Lymphoma 
The genetic hallmark of MCL is the t(11;14)(q13;q32) chromosomal translocation.  This 
translocation brings the cell-cycle regulator, CCND1 (11q13), under control of the 
immunoglobulin heavy chain (IGH) locus, (14q32) resulting in constitutive over-
expression of cyclin D1.3,7  Cyclin D1 binds to cyclin-dependent kinases 4 and 6 (CDK4 & 
6) which phosphorylate retinoblastoma protein (RB1) leading to activation of the E2F 
transcription factors which, in turn, upregulate the progression through the early 
phases of the cell cycle, promoting unchecked proliferation.7,18 
Although the t(11;14) translocation is the common pathological change and diagnostic 
hallmark of MCL, other genetic and molecular aberrations are probably necessary for 
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disease progression.19,20  Mutations in the INK4a/CDK/RB1 and ARF/MDM2/p53 
cellular pathways are often detected, as well as aberrant expression of the SOX11 
transcription factor, all of which contribute to genetic instability, unregulated 
proliferation and inhibition of differentation.6,19,21,22  Hypermutation of the 
immunoglobulin heavy chain gene is usually absent in MCL, however, a proportion of 
MCL cases, (up to 40% in some series) carry mutated IgVH genes, suggesting that some 
cases of MCL also have experience of the germinal centre. 23 
1.1.2 Histopathological Features of Mantle Cell Lymphoma 
Mantle cell lymphoma cells possess distinct histological characteristics.  The classical 
tumours show a proliferation of small to medium sized lymphocytes with irregular 
nuclei and inconspicuous nucleoli.  Less commonly, mantle cells may have blastoid 
morphology with a round nucleus, finely dispersed chromatin and more prominent 
nucleoli.  Some cases have larger cells with irregular and pleomorphic nuclei and 
distinct, small nucleoli (Figure 1-1).7 
1.1.3 The Immunophenotype of Mantle Cell Lymphoma Cells 
MCL cells demonstrate a mature B cell profile by immunophenotyping with moderate-
strong expression of surface immunoglobulins (IgM/D, predominantly lambda), B-cell 
associated antigens such as CD19, CD20, CD22, CD79 and the T-cell and chronic 
lymphocytic leukaemia (CLL)-associated antigen CD5.  However they do not usually 
express CD23 (a cell surface molecule for B cell activation and growth); CD10, which is 
expressed on germinal centre-associated lymphocytes, or BCL6, a transcription factor 
associated with lymphoid follicle germinal centre formation and maintenance.3  The 
characteristic immunophenotype is useful in diagnosis and differentiation from other 
forms of B-NHL and will be used in this study to identify primary MCL cells when 




 The Tissue Microenvironment in Mantle Cell Lymphoma 
1.2
The tissue microenvironment is recognised as a key component in evolution of many 
forms of cancer.24–26  In addition to the intrinsic proliferative capacity of MCL cells, 
there is growing evidence that MCL cells, like other forms of lymphoma are dependent 
on a complex network of signals provided by a supportive and protective niche in 
which the tumour cells, like their healthy counterparts, can thrive.27–31 
The MCL microenvironment is generally limited to the adult lymphoreticular system, 
specifically, the primary lymphoid organs (bone marrow), and the secondary lymphoid 
organs (lymph nodes, spleen and mucosa-associated lymphoid tissues).  
Microscopically, this is characterised by populations of T cells, macrophages, follicular 
dendritic cells (FDCs) and mesenchymal stromal cells (MSCs) surrounded by a loose 
meshwork of fibrous connective tissue (or trabecula bone in the marrow) supplied by 
sinusoids, (enlarged, endothelium-lined spaces) through which lymph percolates.  All 
these cellular components are present to varying degrees in the bone-marrow and 
primary and secondary lymphoid tissue which make up the protective niche of MCL 
cells. 
The theory of MCL dependence on the tissue microenvironment comes from 
observations both of the clinical and histopathological characteristics of MCL and from 
direct observations of the cellular biology of the disease. 
1.2.1 The microenvironment plays key roles in controlling lymphocyte 
adhesion and migration and a protective role against cytotoxic agents 
From a clinical perspective, MCL is often at an advanced stage when symptoms or signs 
develop.4  This is due, in part, to the lymphoma cell's ability to migrate to and colonise 
widely within the lymphoreticular system.  This process of migration and homing is 
dependent on attraction, retention and release of lymphocytes into tissues.  This 
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requires dynamic changes in the expression of surface receptors which can respond to 
chemokine gradients generated by MSCs and associated macrophages within the 
microenvironment.  There is good evidence of the importance of this homing and 
migration relationship between lymphoma cells and the tissue microenvironment.19,32–
36 
An increase in resistance to cytotoxins has been demonstrated in neoplastic B cells in 
response to interactions with cells within the microenvironment, an observation which 
has been termed cell-adhesion mediated drug resistance (CAM-DR).  It has been 
demonstrated that malignant B cells which express adhesion integrins, such as VLA-4- 
and VLA-5-fibronectin receptors, are relatively drug-resistant when pre-adhered to 
fibronectin (FN) compared with cells grown in suspension.37  Mantle cell lymphoma 
cells have been shown to express high levels of surface adhesion markers, such as 
CXCR4, CXCR5 and VLA-4 (CD49d), which are thought to be important in maintaining 
the cells in their tissue microenvironment and facilitating protection from external 
toxins.28  Blockade of VLA-4 and CXCR4 adhesion has been demonstrated to increase 
sensitivity to chemotherapy in MCL cell lines.38  Several investigators have also 
demonstrated that beyond adhesion to a stromal cell layer in the ex vivo 
microenvironment, MCL cells appear to actively migrate beneath a protective stromal 
cell layer, a phenomenon termed pseudoemperipolesis (emperipolesis being the 
presence of an intact cell within the cytoplasm of another cell).  Pseudoemperipolesis 
potentially affords further protection from chemotherapy and immune 
surveillence.28,31,39 
Cell adhesion-mediated drug resistance is potentially one of the key mechanisms 
behind the persistence of disease after conventional chemotherapy.  Indeed 
26 
 
protection by adhesion to accessory cells may be responsible for the characteristic 
relapses observed in MCL.  It is possible therefore, that the use of targeted molecular 
therapies, which block external microenvironmental signals and impair homing and 
adhesion, may provide a therapeutic solution to the problem of residual disease after 
treatment in MCL. 
1.2.2 Interactions with T-cells in the microenvironment: the importance of 
CD40-ligand 
Follicular T helper cells (FTH) are one of the key cellular components of the MCL 
microenvironment.  In order for the adaptive immune system to initiate a response to 
antigen, a sequence of intracellular signals between B and TH cells is required.  The 
initial signal involves engagement of the FTH cell receptor with either polypeptides 
presented on the surface of antigen presenting cells (APCs) in association with major-
histocompatibility complex II (MHC II), or the binding of native antigen (i.e. one not yet 
processed by an APC) to the cognate B-cell receptor (BCR).  This triggers the 
proliferative steps in B-cell development.  This initiation step is unnecessary in MCL 
cells because of their constitutively active B-cell receptor (BCR) complex.40 
The second signal involves co-stimulatory signals between activated TH-cells and APCs 
or B cells.  One of these co-stimulatory signals occurs when CD40-ligand (CD40-L) (also 
known as CD154), engages with the CD40-receptor on B cells.  The CD40-L is a 
transmembrane protein (MW 32-39kDa) and a member of the tumour necrosis factor 
(TNF) superfamily.  It is expressed primarily by activated T cells and B cells.  Under 
certain inflammatory conditions, CD40-L is also expressed on numerous other cell 




Histologically, engagement of CD40/CD40L initiates a germinal centre-type response 
stimulating the normal B cell to seed the germinal centre (GC) and undergo somatic 
hypermutation.42  B cells with high antigen affinity through their BCR are subsequently 
engaged by FTH cells through the BCR and CD40 synapse and encouraged to survive.  
So potent is the survival signal across the CD40 synapse that it has been demonstrated 
that GC B cells can be rescued from apoptosis in vitro by the administration of 
agonistic anti-CD40 antibody or CD40-L.  This survival mechanism has been 
demonstrated to involve the induction of the pro-survival BCL proteins, thus protecting 
the B cell from Fas-ligand mediated apoptosis.43,44  The engagement of CD40-L to CD40 
also induces the activation of other cellular processes through upregulation of 
transcription factors including nuclear factor kB (NF kB); activation of the mitogen-
activated protein kinases (MAPKs) and the phosphoinositide 3-kinase (PI3k) and PLC-
gamma pathways.45 
However the literature on the role of CD40-ligation in malignant B-cells is 
controversial.  In Burkitt’s lymphoma, a tumour of the GC, CD40-ligation results in Fas-
induction and initiation of apoptosis.46  Cell growth is also directly suppressed by CD40-
ligation in other aggressive forms of B-cell lymphoma.47  However, in more indolent 
forms, such as CLL, CD40-ligation can inhibit apoptosis and prolong cell survival in 
vitro.48  Published data already exists supporting a role for CD40-L in the development 
of a model for MCL culture ex vivo.49 
Therefore CD40-L could represent a mode of enhancing cell culture ex vivo, and in this 
study, the role of CD40-ligand will be explored. 
1.2.3 The role of Toll-like Receptors 
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Antigen bound to the BCR can be internalised, processed and represented as peptides 
on the surface of the B cell in association with MHC class II molecules. This complex 
then engages with antigen-specific TH cells which cause the B cell to proliferate and its 
progeny to differentiate into antibody secreting cells.  These antigens are known as 
thymus-dependent (TD) antigens. 
Although activated TH cells are required for B cell responses to most protein antigens, 
some microbial components, such as lipopolysaccharide (LPS) can activate B-cells in 
the absence of a second TH cell signal.  In these cases, the second signal is provided 
either directly by recognition of a common microbial constituent or by a non-thymus 
derived accessory cell in conjunction with massive cross-linking of B cell receptors 
which would occur when a B-cell binds repeating epitopes on the bacterial cell.  These 
antigens, often microbial cell-wall components, are known as thymus-independent 
antigens (TI antigens). 
T-cell independent antigens are divided into type 1, intrinsically mitogenic, such as LPS, 
and type 2, non-mitogenic-repeating unit molecules such as polysaccharides or their 
haptenated derivatives.50 
Toll-like receptor 9 (TLR-9) is expressed on antigen-naïve B-cells, including MCL cells 
and can recognise TI antigens, such as LPS, which are intrinsically mitogenic.51  Through 
activation of TLR-9, T-cell independent antigens can initiate a cascade of intracellular 
events in B-cells, including phosphorylation of cytoplasmic tyrosine kinases resulting in 
enhanced proliferation and differentiation.52–54  There is also evidence that the 




1.2.4 The role of Interleukin 4 
Interleukin 4 (IL-4) is a pleiotropic cytokine which regulates T and B cell responses, 
including proliferation, survival and gene expression.57  It is produced by T-cells, mast 
cells and bone marrow stromal cells.  It is made in response to immunologic 
recognition, principally by CD4+ T lymphocytes, mediating much of its action in short 
range interactions between target cells and IL-4 producing T cells.58  Interleukin-4 is 
responsible for stimulating resting B cells to undergo DNA synthesis in association with 
IgM activation and has the capacity to cause B cell blasts to enter S phase.57,59  In 
addition to stimulating proliferative responses, IL-4 has been shown to inhibit 
apoptosis and maintain cell viability in B-cells, including their malignant counterparts 
by the upregulation of BCL-2 expression.60–62  A combination of CD40-L and IL-4, also 
secreted by activated Th2 cells, is known to stimulate B cell proliferation in vitro and 
these molecules have been demonstrated to synergise in driving clonal expansion in 
normal B-cells and proliferative responses in MCL cells.49,63 
These observations provide the rationale for the use of IL-4 and TLR-9 in combination 
with CD40-ligand as a model for stimulating proliferation and survival in primary MCL 
cells ex vivo. 
 Adhesion and Migration in MCL 
1.3
It is agreed that the persistence of disease and early relapses observed characteristic 
of MCL indicate that neoplastic cells in vivo must be partly protected from the effect of 
immunochemotherapy and novel agents.  One of the reasons for this relative 
resistance to therapy could be the ability of MCL cells to migrate from their site of 
origin and invade and colonise extra-nodal sites, such as the bone marrow, where the 
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microenvironment has protective effects.4  This is achieved by the dynamic expression 
of surface adhesion molecules. 
In vivo evidence of the role of adhesion in MCL comes from observations of the effects 
of BCR blockade within clinical trials.  A rise in the peripheral blood lymphocyte count 
is a characteristic feature of therapy with the BTK-inhibitor, ibrutinib.  In the phase II 
study of ibrutinib for relapsed MCL, this lymphocytosis peaked at a median of 4 weeks 
of treatment and gradually decreases over the subsequent 15 to 18 weeks.64  This is 
associated with a reduction in the expression of the chemo-receptor, CD184 (CXCR4), 
(which is directly involved in B-cell homing and adhesion to the lymphoid tissues) and a 
fall in plasma chemokines, CCL22, CCL4 and CXCL14.65  This rise in lymphocytes in the 
blood appears to be particularly marked in patients with disease involving the bone 
marrow, particularly those with >30% marrow involvement compared with those with 
no bone marrow involvement.66 
In vitro studies have demonstrated that adhesion to cultured stromal cell layers can 
protect malignant B cells from apoptosis induced by chemotherapy.  Equally, blockade 
of the BCR, which down-regulates expression of receptors, such as CXCR4 which 
adheres MCL cells to bone marrow and nodal stromal cells, has been shown to 
reverses these protective effects.28,30,67 
It is hypothesised, therefore, that expression of adhesion receptor molecules, plays an 
important role in protecting MCL cells from therapy by maintaining malignant cells 
within the relative sanctuary of sites such as the bone marrow, leading to residual 
disease and early relapse.  Therefore mobilisation of MCL cells away from sites of 




Chapter 4 of this study examines the adhesion molecule profile of a series of cases of 
primary MCL, with a view to better characterising the expression of surface adhesion 
receptors and how this might change in response to stromal cell culture and the effect 
of drugs, such as ibrutinib. 
1.3.1 An overview of cellular adhesion molecules 
Cellular adhesion molecules (CAMs) are groups of ligands and receptors involved in cell 
homing and migration.  Activities of cells such as adhesion, migration, homing and 
proliferation are controlled by dynamic expression of adhesion molecules,  intracellular 
modification of signal transmission (inside-out signalling) and integrin clustering which 
results in increased affinity for ligand.68  These processes allow the cells of the immune 
system to circulate freely as non-adherent cells in the blood and lymph, patrolling the 
body for infectious organisms and congregate as adherent cells in lymphoid organs as 
well as crossing endothelial and basement membrane barriers to aggregate at sites of 
infection. 
Most CAMs belong to one of four major adhesion molecule families, comprising the 
integrins, the cadherins, the selectins and the immunoglobulin superfamily.  The 
receptors which are thought to play a role in the adhesion and migration of MCL are 
briefly discussed below. 
The integrins are a family of heterodimeric membrane glycoproteins expressed on the 
surface of a diverse range of cells.  They act as receptors for extracellular matrix 
components.  The term integrin was originally coined to reflect the role of this 
receptor in integrating the intracellular cytoskeleton with the extracellular matrix.69  
They also play an important role in intracellular adhesion , interacting with members of 
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the immunoglobulin superfamily such as intracellular adhesion molecules-1, -2 and -3, 
(ICAM-1, ICAM-2, ICAM-3) and vascular cell adhesion molecule-1 (VCAM-1).70 
Structurally, integrins consist of two non-covalently associated sub-units, α and β.  
Original classification included three subfamilies, (β1 integrins or very late activation 
proteins (VLA); β2 integrins or leucams and β3 integrins or cyto-adhesins) in which a 
common β subunit interacts with a number of different subunits.71,72 
Most integrins are able to bind more than one ligand (for example, VLA-1 binds 
collagen and laminin, VLA-3 binds collagen, laminin and FN).  Binding requires both 
subunits and also requires activation of the integrin receptor by specific signals such as 
T cell activation resulting in a conformational change enabling the integrins to bind 
their ligands.73 
1.3.2 Adhesion Molecule Expression in Mantle Cell Lymphoma 
Given that many subtypes of NHL including MCL appear to arise from an equivalent 
stage of normal B-cell development, it would be logical to assume that malignant cells 
use the same CAMs in migration and homing as their non-malignant counterparts.  
Although most cases of MCL arise from lymphoid tissue, they can also display a 
leukaemic phase characterised by the presence of lymphoma cells in the peripheral 
blood.  Changes in expression of CAMs on the cell surface are likely to have an 
important role in this behaviour. 
Relatively little is known about the expression of CAMs on the surface of MCL cells.  In 
an evaluation of expression of 10 adhesion molecules on a variety of NHL subtypes in 
the leukemic phase, including MCL, showed marked heterogeneity in expression 
between subtypes.  Primary MCL cells demonstrated lower expression of CD11c and 
CD49c and higher expression of CD49d and CD11b when compared with CLL cells.  
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When MCL cells were compared with marginal zone lymphoma (MZL) cells, marginal B 
cell lymphoma demonstrated higher expression of CD11a, CD11c, CD18, CD29 and 
CD54.74  A description of the cellular adhesion molecules considered relevant to MCL is 





Molecule Description Ligands 
CD183 
(CXCR3) 
G protein-coupled transmembrane receptor expressed primarily on activated T cells and NK 
cells, preferentially on TH1 cells.  It binds to CXCL-9, -10 and -11 through which it is able to 
elicit influx of intracellular calcium and activate phosphoinositide 3-kinase and mitogen-
activated protein kinase (MAPK).  CXC ligands are IFN-induced and produced locally in the 
lymphoid microenvironment. 





Forms part of the integrin, lymphocyte function associated antigen (LFA-1), expressed on all 
leukocytes.  Involved in extravasation, antigen presentation and T-lymphocyte alloantigen-
induced proliferation.75  Reportedly expressed on MCL and MZL cells more than CLL and 






Integrin alpha-4subunit (CD49d) combines with B1 subunit (CD29) to form VLA-4.  VLA-4 is 
expressed on resting lymphocytes and monocytes and functions as both a matrix and cell 
receptor.  As a matrix receptor it binds to fibronectin at a different site than that recognised by 
VLA-5 (CD49e).  As a cell receptor, it binds to VCAM-1, which is induced by inflammatory 
mediators on the endothelium.  Reportedly expressed on MCL and MZL cells more than CLL 





A member of the immunoglobulin superfamily, normally with a lower expression in peripheral 
blood compared with lymph node mononuclear cells.  Lower expression has been 
demonstrated to correlate with leukaemic / disseminated disease and extranodal involvement 




A single chain transmembrane protein found in most lymphocytes.  Its low affinity binding 
facilitates the capture, rolling and slow-rolling steps of leukocyte recruitment to the region of 
inflammation which in turn is followed by firm adhesion and transmigration.  Low expression 





A member of Ig superfamily expressed on antigen presenting cells (APCs), particularly 
macrophages which binds to LFA-2 on T cells and reinforces adhesion between T cells and 
APCs.80  Expressed on haematopoietic and non-haematopoietic cells and overexpressed in 






Cd49e combines with beta 1 to form VLA-5 which binds the extracellular matrix protein 
fibronectin and aids adhesion within the lymph node and bone marrow. 
Fibronectin 
CD11c CD11c combines with beta 2 subunit (CD18) to form Mac-1: expressed mainly on myeloid cells 
and is involved in phagocytosis of infectious agents, transendothelial migration of phagocytes 
and activation of neutrophils and monocytes.  Higher rates of splenic involvement in CLL 
patients have been reported with strong 11c expression; over expressed in HCL and splenic 







High level expression is demonstrated on primary MCLs which is down-regulated by BTK-
inhibitor ibrutinib.65  Stromal cells in secondary lymphoid tissues constitutively express 
chemokines such as CXCL12, providing guidance for B cell positioning within distinct nodal 
compartments.   CXCL12 has been demonstrated to induce actin polymerisation in MCL cells 
and induce a chemotactic response which can be inhibited by blocking the receptor CXCR4, 




A G protein-coupled transmembrane receptor. High level expression has been demonstrated 
on primary MCLs together with CXCR4 and VLA-4.28  Thought to be used by MCL cells to 
disseminate by interaction, trafficking and homing to secondary lymphoid tissues via ligands 
CXCL12 and CXCL13.  Ligands for CXCR4, 5 and VLA-4 may trigger the pseudoemperipolesis 
phenomenon.33 
CXCL12, 13 
Table 1-1  A summary of the adhesion molecules and their respective ligands considered 
important in MCL. (NK – Natural Killer cells; MZL – marginal zone lymphoma; CLL – chronic 
lymphocytic leukaemia; FDC – follicular dendritic cells; ICAM – intracellular adhesion molecule; HCL 
– hairy cell leukaemia; BTK – Brutons tyrosine kinase.  
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 3-Dimensional Tissue Culture Models for the Study of Mantle Cell 
1.4
Lymphoma 
The complex 3-dimensional (3-D) matrix of the lymph-node or bone marrow is critical 
in maintaining mantle cell lymphoma cells.  Within this structure, stromal cells and 
other cellular components of the tissue micro-environment provide essential signals 
which govern tumour cell survival, migration and proliferation.  However it is from a 2-
dimensional (2-D) cell culture model that a large amount of data and subsequent 
understanding of cellular interactions in tumour biology has been gained.   
It is generally recognised that 2-D models are not fully representative of the complex 
3-D microenvironment found in living organisms and many of the functional structures 
and signals specifically developed to allow migration, proliferation, and differentiation 
may change significantly under 2-D conditions. 
While attempts have been made to develop models with the 3-D characteristics of the 
bone marrow microenvironment in other diseases130,131, there is little or no 
published data on 3-D culture models in MCL.  Given the critical importance that the 
micro-environment plays in MCL homeostasis and the differences observed in cellular 
behaviour in other malignancies between 2-D and 3-D models, it would seem logical to 
attempt to design and establish a 3-D model in vitro for the further study of MCL.  To 
that end, the final chapter of this thesis will explore the development of a 3-D model 
for the study of MCL. 
 Summary of Introduction and Aims of this thesis 
1.5
MCL is a rare form of NHL with a poor prognosis for patients.  In addition to its intrinsic 
oncogenic mutations, signals from accessory cells within the lymphoma 
microenvironment are important in propagating survival and proliferation and in 
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protecting cells from therapy.  Development of an ex vivo model for study of MCL cells 
and their microenvironment is therefore an important goal. 
The aims of this thesis were: 
 to develop and test a system to simulate MCL growth in vitro with particular 
focus on the role of accessory cells, both murine and human, in which survival 
and proliferation of primary MCL cells can be studied; 
 to examine the effects of microenvironmental stimuli thought to be important 
to MCL growth within this system, specifically the relationship between MCL 
cells and CD40-L, IL-4 and TLR-9 ligand; 
 to characterise the CAM expression profile of a series of primary human MCL 
cases and examine the effect of accessory-cell culture models and therapeutic 
interventions on this profile; 
 to develop a 3-D, ex vivo culture model that reflects the lymphoma 
microenvironment and can be used for the study of MCL survival, proliferation 
and CAM expression.  
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2. CHAPTER 2 - MATERIALS AND METHODS 
 Introduction 
2.1
The materials and methods employed for this thesis can be broadly divided into the 
collection, storage and culture of primary MCL cells from human donors; the culture of 
murine stromal cells and human stromal cells as supportive layers; the methods used 
to assess survival and proliferation of primary MCL cells under different conditions in 
different microenvironments and the use of flow cytometry to assess adhesion 
molecule profiling.  The development of a 3-D model for the testing of primary MCL 
cells is a novel method and is therefore described in a separate chapter (Chapter 5). 
 Obtaining Primary MCL Cells 
2.2
The Clinical Haematology Trials Department at Derriford Hospital, Plymouth is a major 
referral centre for patients with NHL with specialist interest and wide experience in the 
management of MCL, participating in numerous early and advanced-phase clinical 
trials.  Between 50 and 75 patients, are referred each year for treatment opinions and 
many are enrolled locally in studies for the treatment of MCL.  The current clinical 
trials portfolio includes five studies for patients with MCL, both untreated and relapsed 
using novel agents (defined as active compounds, complexes or molecules that have 
not previously been approved by the Food and Drug Administration (FDA) or European 
Medicines Agency (EMA) for the treatment of MCL) alone or in combination with each 
other or established immunochemotherapy. 
The Derriford Clinical Trials department has a particular expertise in the use of BTK-
inhibitors in MCL.  Between January 2015 and December 2016, 29 patients with MCL 
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were enrolled into clinical trials at Derriford and ten patients initiated therapy using 
BTK-inhibitors. 
It is from this general cohort of patients with MCL, that participants were recruited to 
donate peripheral blood for this research.  After appropriate informed consent, 
patients with both untreated and relapsed and refractory disease were recruited to 
the database and then asked to donate samples of blood or bone marrow at the time 
of routine sampling. 
 Ethical Approval, Informed Consent and Confidentiality 
2.3
Ethical approval for this research was sought from and granted by the NHS Health 
Research Authority National Research Ethics Service Committee East of England – 
Cambridge East following review of all documentation.  
All potential participants were given a comprehensive patient information sheet with 
time to read and ask questions.  Once the patient had read and understood the 
information sheet, and their questions had been answered, formal consent was 
obtained for tissue sample donation to the local biobank (Integrated Research 
Application System project I.D. number 145245).  The patient information sheet and 
patient consent forms can be found in the Appendix. 
2.3.1 Confidentiality and Record Keeping  
Signed copies of the patient consent forms were duplicated and maintained in the 
patients clinical notes with a copy kept securely within a folder in the clinical trials 
office.  A pseudo-anonymised database of patient samples (identified by patient initials 
and hospital number) was maintained on a secure, hard drive within Plymouth 
University and Peninsula School of Medicine and Dentistry (PUPSMD) accessible only 
to designated investigators directly involved in research on these samples after 
39 
 
appropriate Good Clinical Practice in Medical Research and Human-Tissue Authority 
training. 
2.3.2 Collection of whole blood or bone marrow samples 
The majority of the tissue samples obtained for this project were in the form of 
peripheral venous blood or liquid bone marrow aspirates.  These samples were 
obtained during routine venesection or during a routine bone marrow biopsy from 
patients with an established diagnosis of MCL. 
After obtaining informed consent, peripheral venous blood samples were collected by 
phlebotomy performed by the clinical research team.  Liquid bone marrow samples 
were obtained as additional samples at the end of routine diagnostic or restaging 
bone-marrow biopsies.  Therefore no additional invasive procedure was required.  
Whole blood and bone marrow samples were collected into 4.0mL Vacutainer plastic 
whole blood tubes (BD Biosciences Cat.) containing 7.2mg of the chelating agent 
K2EDTA (di-potassium ethylenediaminetetraacetic acid) to prevent clotting within the 
tube.  A summary of the subjects from whom primary MCL cells were obtained for this 











Prior Treatment Indolent / 
aggressive 
disease 
MCL01 66 f t(11;14) CD5/19+ Stage IV, nodal; WCC 
300x109/L 
None Aggressive 
MCL02 68 m (t11;14) 
cyclin D1 





MCL03 74 m cyclin D1 CD5/19+ Stage IV WCC 30x109/L None Aggressive 
MCL04 65 f (t11;14) CD19+ Leukaemic, MCL; WCC 
280x109/L 
None Indolent 
MCL05 63 f t(11;14) CD5/19+ Leukaemic MCL, 
splenomegaly 
None Aggressive 
MCL06 64 f t(11;14) CD5/19+ Stage IV 
WCC 30x109/L 
None – but refractory to 
treatment 
Aggressive 
MCL07 65 m t(11;14) 
cyclin D1 
CD19+ Leukaemic MCL; WCC 
30x109/L 
None Indolent 





MCL09 70 m cyclin D1 CD5/19+ Stage IV 
WCC 190x109/L 
Immunochemotherapy Aggressive 
MCL10 54 m t(11;14) 
cyclin D1 
CD5/19+ Stage IV 
WCC variable† 
Immunochemotherapy Aggressive 
MCL11 60 f cyclin D1 CD5/19+ Stage IV Immunochemotherapy Aggressive 





MCL13 64 m cyclin D1 
t(11;14) 
CD5/19+ Leukaemic; WCC 152x109/L None Indolent 
MCL14 62 m cyclin D1 
t(11;14) 
CD5/19+ Leukaemic; Stage II  Local radiotherapy Indolent 
MCL15 70 f cyclin D1 
t(11;14) 
CD5/19+ Stage III, nodal None Aggressive 
MCL16 70 f cyclin D1 
t(11;14) 
CD5/19+ Stage IV, nodal None Aggressive 
MCL17 74 m cyclin D1 
t(11;14) 
CD5/19+ Stage IV, nodal Immunochemotherapy Aggressive 
MCL18 91 m cyclin D1 
t(11;14) 
CD5/19+ Stage IV, nodal Immunochemotherapy Aggressive 
MCL19 71 m cyclin D1 
t(11;14) 
CD5/19+ stage IV, nodal Immunochemotherapy Aggressive 
MCL20 63 m cyclin D1 
t(11;14) 
CD5/19+ stage III, nodal  Immunochemotherapy Aggressive 
MCL21 70 m cyclin D1 
t(11;14) 
CD5/19+ stage III, nodal Immunochemotherapy Aggressive 
MCL22 60 m cyclin D1 
t(11;14) 
CD5/19+ stage IV, nodal Multiple lines including BTK-
inhibitor 
Aggressive 
MCL23 60 m cyclin D1 
t(11;14) 
CD5/19+ stage IV, nodal Allogeneic Stem cell 
transplant 
Aggressive 
MCL24 77 f cyclin D1 
t(11;14) 
CD5/19+ stage III, nodal None Aggressive 
Table 2-1  Primary MCL Subjects’ Clinical and Biological Characteristics.  MCL subject demographics, diagnostic 
molecular data, immunophenotyping of PBMCs and clinical disease summary of cases of MCL from which PBMCs 
and / or bone marrow MCL cells were obtained for use in adhesion profile experiments.  
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 Separation of Peripheral Blood Mononuclear Cells from Whole 
2.4
Blood and Liquid Bone Marrow Samples 
Peripheral blood mononuclear cells (PBMCs) were separated from whole blood by 
centrifugation using a density gradient medium. 
Background 
Boyum first described the method of centrifugation across a density gradient medium 
for mononuclear cell isolation from circulating blood and bone marrow cells in 1968.83  
The technique employs mixtures of polysaccharide and a radiopaque contrast medium 
such as Ficoll-paque.  Ficoll-paque is a solution of polysucrose and sodium diatrizoate 
that has been adjusted to density of 1.077±0.001 g/mL.  The use of this medium 
facilitates the rapid recovery of viable mononuclear cells from small volumes of blood. 
During centrifugation of the bilayer (one phase blood, one phase ficoll-paque) 
erythrocytes and granulocytes are aggregated by polysucrose and rapidly sediment; 
whereas, lymphocytes and other mononuclear cells remain at the plasma/ficoll-paque 
interface. There is negligible contamination by erythrocytes and most of the 
extraneous platelets are removed by centrifuging at a low speed during the washing 
steps. 
Reagents 
 sterile phosphate buffered saline (PBS) (Fisher Scientific) 
 complete RPMI (Roswell Park Memorial Institution) media + glutamax (Gibco) 
containing 10% fetal calf serum (FCS) (heat inactivated, qualified grade, (Fisher 
Scientific), and 1% Streptomycin penicillin (Sigma) 
 ficoll-paque-1077 (Fisher Scientific) (stored at 2-8 0C and protected from light) 
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Materials and Equipment 
 EDTA vacutainer tubes (Becton and Dickinson) 
 centrifuge (Heraeus Function Line Laboratory Centrifuge) 
 DFC 3000G phase contrast microscope (Leica) 
 15ml and 50ml Falcon conical-bottom flasks (Fisher Scientific) 
 pipettes, 10ml serologic, (Pasteur) (Fisher Scientific) 
 haemocytometer and trypan-blue (Fisher Scientific) 
Complete RPMI medium was prepared by adding 5mls of streptomycin and 50mls of 
FCS to 450mls of RPMI 1640 medium.  Blood or bone marrow aspirate was collected in 
EDTA vacutainers and processed within 6 hours, with the exception of cells from 
subject MCL08 which had to be couriered from Cardiff in EDTA vacutainers overnight.  
In this case, viability was assessed on arrival using flow cytometry and annexin V 
labelling and found to be >95% (Materials and Methods 2.8).  The PBS and media were 
warmed in a water bath to 370c. 
Equal amounts of PBS and anticoagulated blood were mixed in 50ml falcon tubes 
before 10mls of ficoll-paque was measured into 50ml centrifuge tubes. The diluted 
blood was then slowly dripped onto the ficoll-paque forming a layer of blood floating 
on the top ensuring not to disturb the interface between the two layers. The tubes 
were centrifuged at 2000 revolutions per minute (rpm) for 30 minutes with no brake. 
The serum layer was then removed and discarded. 
The buffy coat (mononuclear band) was transferred into a 15 ml falcon tube and 10mls 
of sterile PBS was added.  The tube was then centrifuged at 1400 rpm for 10 minutes 
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with no brake. The supernatant was discarded and the cell pellet was re-suspended in 
2mls of PBS or media.  The numbers of cells were counted using a haemocytometer. 
2.4.1 Cell Counting 
A sample of 40µL (microlitres) of cell suspension was added to an equal volume of 
trypan blue solution (staining dead cells blue but reduced by viable cells leaving them 
unstained) prior to a 10µL sample being loaded onto a graduated haemocytometer.  
Viable cells were counted in each quadrant to obtain an average which is doubled to 
account for dilution to give a cell count x104/mL. 
 Freezing and Storing Isolated Peripheral Blood Mononuclear Cells 
2.5
Once isolated and quantified, PBMCs could be cryopreserved for future use. 
Reagents 
 freezing medium (FCS (heat inactivated, qualified grade, (Fisher Scientific) 
containing 10% dimethyl-sulfoxide solution (DMSO) (Corning™) 
Materials and Equipment 
 haemocytometer with trypan blue (Fisher Scientific) 
 CryoPure 2.0mL sterile cryotubes (Sarstedt) 
 Mr Frosty™ freezing container (Thermo Scientific™)  
 centrifuge (Heraeus Function Line Laboratory Centrifuge) 
 DFC 3000G phase contrast microscope (Leica) 
 vapour-phase liquid nitrogen storage system 
2.5.1 Cryopreservation 
The cell suspension was centrifuged at 1700 rpm for 10 minutes at room temperature.  
The supernatant was discarded and the cell pellet was resuspended in freezing 
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medium, in order to prevent cell rupture by the formation of intracellular ice crystals, 
at 2x107/mL, volumes of 1000µL were aliquoted into sterile cryotubes.  Tubes were 
then frozen slowly (1oC – 3oC per minute in a freezing container to -80oC for 24hours 
before being transferred to liquid nitrogen for long-term storage. 
2.5.2 Thawing Cryopreserved Cells  
Cryovials were removed from liquid nitrogen storage using appropriate safety 
precautions.  Cryovials were rapidly thawed at 37OC water bath until only a sliver of ice 
remained in each vial.  The entire contents of the vial were then transferred into 
10mLs of pre-warmed complete RPMI medium in order to dilute any remaining DMSO.  
Cells were then washed by centrifugation (1700 rpm for 5 minutes, brake on) and 
resuspended in 10mLs of complete RPMI before a cell count was performed.  The same 
protocol was followed for the storage of MCL cell lines. 
 Methods for Murine Cell Culture 2.6
For the experiments involving murine fibroblasts and primary MCL cells, RPMI medium 
was used.  Complete RPMI medium is suitable for the culture of a variety of 
mammalian cells and is widely used to culture mantle cell lines and primary MCL cells.  
In this study the RPMI medium used was modified with the amino acid L-glutamine 
(300mg/L) and a phenol-red dye.  RPMI contains biotin, vitamin B12 and para-
aminobenzoic acid (PABA) in addition to the vitamins inositol and choline.  However it 
contains no lipids, proteins or growth factors and therefore is routinely supplemented 
with 10% FCS. 
Reagents 
 complete RPMI 1640 with GlutaMAXTM medium (Gibco) (supplemented with 
10% FCS (Fisher Scientific) and 1% penicillin/streptomycin (Invitrogen) 
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 trypsin-EDTA,(0.5% Trypsin 5.3mM EDTA 4Na) (Invitrogen) 
 sterile PBS 
Materials and Equipment 
 adherent murine stromal cells: CD40-ligand-transfected (CD40L-T) and control 
CD40-ligand-non-transfected (CD40L-NT) cells (kind gift from Professor M Dyer, 
Leicester, UK) 
 25cm2 and 75cm2 vented flat-bottom culture flasks (Fisher Scientific) 
 humidified incubator (ThermoScientific) maintained at 37oC with 5% CO2 
 linear accelerator for irradiation (Varian) 
 DFC 3000G phase contrast microscope (Leica Microsystems) 
2.6.1 Protocol for Culture of Murine Fibroblasts 
Murine-derived stromal cells cultured as an adherent monolayer on a plastic surface 
provide important supportive signals to human primary cells which support growth 
and proliferation during ex vivo culture.84,85 
In these experiments, adherent murine stromal cells (CD40L-T and control CD40L-NT 
cells) were cultured in vented flasks as a monolayer and subsequently loosened from 
the plastic by trypsinisation, harvested and used to create a monolayer of stromal cells 
on the floor of standard 24 well plates, onto which primary MCL cells were added for 
co-culture experiments. 
2.6.2 Passaging Murine Fibroblasts 
Adherent murine stromal cells were cultured in 75cm2 vented, flat-bottom flasks in 
complete RPMI medium in a humidified incubator maintained at 37oC with 5% CO2.  
The stromal cell layer was inspected for confluence every 48 hours and split using a 1:5 
dilution with fresh media every 3 days using the following method. 
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The spent medium was discarded and the stromal cell layer was gently washed with 
sterile PBS.  The adherent stromal cell layer was detached from the surface of the 
culture flask by the addition of 5mLs of trypsin-EDTA to a 75cm2 flask.  The flask was 
incubated at 37oC for 5 to 10 minutes.  Once the cells had been loosened from the cell 
surface, a 20% volume of the total suspension was then added to 25mLs of fresh media 
for on-going culture.  The trypsin was neutralised within the fresh culture medium.  
The flask was labelled with the appropriate passage number and returned to the 
incubator.  Cells were split to a maximum of 25 passages before being discarded. 
2.6.3 Protocol for Seeding Murine Fibroblasts for Use with Primary Mantle 
Cells 
Adherent murine fibroblasts were loosened from the plastic surface of the culture flask 
as previously described.  The cell suspension was transferred from the flask to a 50mL 
conical-bottomed falcon tube where the cells were washed with PBS (via 
centrifugation and resuspension in PBS and a cell count was performed as previously 
described).  A suspension of the desired density was then transferred in 1mL aliquots 
to the wells of a standard flat-bottomed 24 well plate and returned to the incubator.  
Once desired confluence had been achieved, (70% to 80% coverage of the floor of the 
well as determined by light microscopy), the plate was irradiated in order to arrest 
further stromal growth and prevent overgrowth of the primary MCL cells. 
2.6.4 Protocol for Irradiation of Bone Marrow Fibroblasts 
Murine bone marrow fibroblasts proliferate relatively quickly compared with human 
marrow fibroblasts or human peripheral blood mononuclear cells.  Therefore a long-
term coculture experiment is complicated by overgrowth and media exhaustion by the 
murine fibroblasts.  In order to prevent this, bone marrow cells are often irradiated 
once monolayer achieves desired confluence in order to arrest further proliferation.86 
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The 24 well plate was transferred to a linear accelerator.  The plate was then irradiated 
using 6MV photons at machine isocentre. The sample was at a depth of 5cm in a solid 
water phantom and the field size used was 20cm2. The dose delivered to the sample 
was 15Gy (Gray) in a single fraction.  This prevented further significant proliferation 
during ongoing culture.87 
 
 
Figure 2.1.  Phase-contrast images of murine fibroblast monolayers. CD40-ligand non-transfected 
(CD40L-NT) and transfected (CD40L-T) murine fibroblasts were seeded at 1x104/mL and irradiated 
with 15Gy when reached 70% – 80% confluence (x20 magnification). 
  
Murine fibroblasts CD40L-NT 
Murine fibroblasts CD40L-T 
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2.6.5 Establishing Cell Surface Expression of CD40-Ligand on Stromal Cells 
To demonstrate CD40L expression on the CD40L-T murine stromal cells the stromal 
cells were labelled with phycoerythrin (PE)-conjugated, mouse-anti-human CD40L 
monoclonal antibody and visualised using fluorescent microscopy (Figure 2.1). 
Reagents 
 adherent murine stromal cells: CD40L-T and control CD40L-NT cells (kind gift 
from Professor M Dyer, Leicester, UK) 
 4% paraformaldehyde (PFH) in PBS 
 complete RPMI medium 
 Vectashield hard set mounting media with DAPI (4′,6-diamidino-2-
phenylindole) 
 PE-conjugated mouse-anti-human CD40L monoclonal antibody (BD 
Pharmingen™) 
Materials and Equipment 
 standard 24 well flat-bottomed culture plates (Fisher) 
 5mm coverslips and microscope slides (Fisher) 
 fluorescent microscope (Leica Microsystems) 
CD40L-NT and CD40L-T stroma were cultured on 5mm coverslips within standard 24 
well plates in complete RPMI medium for 48 hours until 75% confluence.  The media 
was discarded and the coverslips were removed from the wells.  50µL of PE-conjugated 
mouse-anti-human CD40-ligand monoclonal antibody was added to each coverslip and 
incubated in the dark for 20 minutes.  The coverslips were washed with PBS before 
being fixed with 200µL of 4% PFH/PBS for 10 minutes.  The coverslips were washed 
with PBS and air-dried for 24 hours.  25µL of Vectashield hard set mounting media with 
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DAPI (4′,6-diamidino-2-phenylindole) mounting media was added and the slips were 
mounted on standard glass slides and allowed to set.  The slides were then visualised 
by fluorescent microscopy using LAS AF Version: 2.6.3 software (Leica Microsystems).  
The images below (Figure 2-2) validate that the CD40-ligand transfected murine 
fibroblasts express CD40-L on their cell surface whereas the CD40-L non-transfected 
murine fibroblasts do not. 
 
Figure 2-2. Fluorescent microscopy comparison of CD40L-transfected/non-transfected murine 
stromal cells.  Murine stromal cells cultured until confluent then stained with PE-conjugated 
mouse-anti-human CD40-ligand monoclonal antibody.  Cells were then fixed and mounted with 
prolonged DAPI .  Top images – CD40-L non-transfected fibroblasts; bottom images – CD40-L 
transfected fibroblasts.  Left images – cells stained with DAPI alone (blue); right images – cells 
stained with DAPI (blue) and PE-anti-CD40-ligand (red).  
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2.6.6 Co-culture of Primary MCL Cells with Murine Stromal Cells 
After seeding and irradiation of a confluent layer of CD40L-NT / T murine stromal cells 
within a standard 24 well plate, primary human MCL PBMCs were seeded onto the 
monolayers and maintained at 37oC with 5% CO2 for 8 days for assessment of survival 
and proliferation.  To selected wells, co-stimulation with 3 µM of Toll-like-receptor-9 
ligand (TLR9) (tlrl-2006-1, InvivoGen) or 50ng/mL of recombinant human interleukin-4 
(IL-4), (AD-200-04, PeproTech), was also applied (concentrations as per manufacturers 
recommendations). 
2.6.6.1 Human Toll-Like Receptor-9 ligand Validation 
CpG (Cytosine-phosphate-Guanine) oligonucleotides (ODNs) are TLR-ligands. They 
comprise of synthetic ODNs containing unmethylated CpG di-nucleotides in specific 
sequence contexts (5’-Cytosine-phosphate-Guanine-3’ motifs).  These motifs are 
present at a 20-fold greater frequency in bacterial DNA than human DNA, (where the 
cytosine in the dinucleotide motifs is usually methylated).  Unmethylated CpG ODNs 
can be detected by TLRs on the lymphocyte surface and serve to trigger vigorous 
immune-stimulatory responses.  The synthetic CpG-ODN, ODN 2006, (also known as 
ODN 7909) is a class-B CpG ODN which binds and activates human TLR-9 without 
inducing strong interferon-alpha production from dendritic cells. 
In order to establish that the presence of ODNs does not induce apoptosis per se, an 
ODN2006 control (ODN 2137, InvivoGen), which contains GpC (5’-Guanine-phosphate-
Cytosine-3’) dinucleotides instead of CpGs was used as a negative control together 
with ODN 2006 (InvivoGen). This confirmed no increase in apoptosis over the DMSO 





 complete RPMI 1640 with GlutaMAXTM medium (Gibco) (supplemented with 
10% FCS (Fisher Scientific) and 1% penicillin/streptomycin (Invitrogen) 
 sterile PBS 
 haemocytometer with trypan blue 
 primary MCL PBMCs isolated and stored as previously described. 
Materials and Equipment 
 standard, flat-bottomed 24 well sterile plates 
 adherent murine stromal cells: CD40L-T and control CD40L-NT cells (kind gift 
from Professor M Dyer, Leicester, UK) 
 humidified incubator (Thermo-Scientific) maintained at 37oC with 5% CO2 
 DFC 3000G phase contrast microscope (Leica Microsystems) 
 CCD grayscale camera (Leica DFC3000 G) (Leica Microsystems) 
 LAS AF Version: 2.6.3 software (Leica Microsystems) 
Protocol for Co-culture 
The spent medium was discarded from the wells containing the murine stromal cell 
layers and the monolayers were washed with 1mL of sterile PBS.  The cryopreserved 
primary human MCL cells were thawed and resuspended in complete RPMI medium.  A 
MCL PBMC suspension was prepared using pre-warmed complete RPMI medium and 
the cell density was adjusted to 4x106/mL.  1mL of the cell suspension was added to 
each well containing the murine stromal monolayers. 
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To selected wells, 3 µM of ODN 2006 human TLR9 ligand in 3µL DMSO or 50ng/mL of 
recombinant human IL-4 (PeproTech) in 5µL of DMSO was added.  To the remaining 
wells, 5µL of DMSO was added as vehicle control. 
The plates were then returned to the incubator and maintained at 37oC with 5% CO2 in 
the dark.  The plates were inspected by light microscopy every 24 hours and the 
contents were assessed for survival and proliferation of MCL PBMCs after 8 days of 
culture. 
Examples of the appearance of these co-cultures by phase-contrast light microscopy 
are displayed below (Figure 2-3). 
 
Figure 2-3.  Subject MCL08 PBMCs co-cultured with CD40-ligand demonstrate evidence of cluster 
formation after 7 days.  Cells seeded in complete RPMI at 4x10
6
/mL on CD40-ligand-transfected (CD40L-
T) murine fibroblasts after irradiation on a 24 well plate.  Cultures were stimulated at baseline with 3µM 
TLR9 ligand (middle) and 50ng/ml Interleukin-4 (IL-4) (bottom).  Images taken after 24hrs (left), 4 days 
(middle) and 7 days (right)  
CD40T MCL08 + TLR9-L, D7 (x20) 
CD40T MCL08 Uns, 24hrs (x20) 
CD40T MCL08 + TLR9-L, 24hrs (x20) 
CD40T MCL08 + IL4, 24hrs (x20) 
CD40T MCL08 Uns D4 (x20) 
CD40T MCL08 + TLR9-L, D4 (x20) 
CD40T MCL08 + IL4, D 4 (x20) 
CD40T MCL08 Uns D7 (x20) 
CD40T MCL08 + IL4, D7 (x20) 
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 Human Bone Marrow Fibroblasts 
2.7
Culture of human bone marrow stroma was performed using a protocol and culture 
medium based on a validated method previously published by Nicol et al.88 
2.7.1 Obtaining Human Bone Marrow Fibroblasts 
Liquid bone marrow aspirate was obtained as samples in excess of clinical need from 
patients with underlying lymphoproliferative disorders undergoing routine 
investigative and diagnostic bone marrow biopsies.  Several variables among patients 
undergoing routine bone marrow sampling, such patient age, comorbidity, prior 
chemotherapy, current disease status and amount and quality of bone marrow sample 
obtained made obtaining a consistently healthy bone and abundant marrow supply 
challenging.  Because of this, the ability of bone marrow fibroblasts to grow in vitro 
using a standard, validated long-term culture protocol, was found to be highly variable, 
with some patient samples growing much better than others.  This was not always 
predicable according to disease status, age or prior therapies. 
2.7.2 Separation of Human Bone Marrow Fibroblasts from Whole Bone 
Marrow Samples 
Whole bone marrow samples were obtained from patients as previously described.  
The samples, (4–8 mLs of whole liquid bone marrow) were transferred from the clinic 
to the laboratory in EDTA-containing blood vacutainer tubes within 4 hours of 
sampling and processed on the same day by ficoll-separation using the method 
previously described.  
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2.7.3 Establishment of Human Bone Marrow Stroma 
2.7.3.1 Preparation of complete long-term culture medium (LTCM) 
Reagents 
 Iscove’s Modified Dulbecco’s Medium (IMDM) containing 1% 
penicillin/streptomycin (Invitrogen) 
 hydrocortisone – final concentration 5x10-7 M (183uM/50ml) 
 10% Qualified grade FCS (Gibco) 
 10% horse serum (Gibco) 
 
Aliquots of IMDM were thawed when required. To each 40ml aliquot were added 5mls 
FCS, 5mls horse serum and 180l working dilution hydrocortisone. 
2.7.3.2 Culture of human bone marrow stromal layers 
Whole bone marrow aspirate samples were ficoll-separated to produce a buffy coat 
layer and the plasma, fat and buffy coat layer removed from the red cells. The buffy 
coat preparation was either cryopreserved in qualified-grade FCS containing 10% 
DMSO or adjusted to 3x106/ml in long-term culture medium consisting of IMDM 
supplemented with 10% FCS, 10% horse serum and 5x10-7M hydrocortisone (complete 
LTCM). 
Bone marrow stromas were established in vented 25cm2 culture flasks incubated at 
37C in 5% CO2 for 5 days without disturbance. Marrow cultures were fed by half 
medium changes on days 10, 14, 21 and 28. After 1-2 weeks in culture it was usually 




2.7.3.3 Trypsinisation of marrow 
Reagents 
 trypsin-EDTA, (0.5% Trypsin 5.3mM EDTA 4Na) (Invitrogen) 
 sterile PBS 
Established stromal layers were removed from the flasks by trypsinisation when the 
stroma was fully confluent, usually between day 28 and 35 of culture. The flasks were 
agitated gently, the medium removed and the stroma washed twice with sterile PBS to 
remove any remaining supernatant cells and serum. Stromal layers were incubated at 
37C for 10 minutes with 8ml 0.5% trypsin per flask to detach the cells from the flask. 
The trypsin was inactivated with 1ml FCS and the cells washed twice with IMDM 
containing 2% FCS. It was important to work quickly through each phase of 
trypsinisation to avoid cell injury or death due to over trypsinisation. Care was taken to 
ensure that all cell clumps were disaggregated prior to the first washing step. It was 
possible to obtain 5x106 cells from each 25cm2 stroma flask although yields varied 
according to sample quality (Figure 2-4). 
2.7.3.4 Cryopreservation of established marrow stroma 
Trypsinised bone marrow stromal cells were cryopreserved in FCS containing 10% 
DMSO (one 25cm2 flask per 2ml cryogenic vial). When required cryostroma were 
thawed rapidly in a 37C water bath and the cryoprotectant diluted in 10mLs of LTCM.  
Stromal cells were washed twice before being resuspended in the appropriate medium 




Figure 2.4.  Examples of 2-D culture of human bone marrow fibroblasts from 3 different subjects 
(A, B, C):  A:  Subject following 21 days of culture; B: subject following 28 days of culture C: 
subject following 35 days of culture (mag. 10x).  A 25cm
2
 vented flasks was seeded with PBMCs 
from fresh human bone-marrow (density 5x10^6 cells/mL) in 10mLs of long-term culture 
medium after ficoll-separation from whole bone marrow aspirate.  Cells were maintained at 
37oC, 5% CO2 for 10 days without disturbance and then fed by half-medium separation on days 
10, 14, 21, 28 and weekly thereafter. 
 
 
 Assessing Survival and Proliferation by Flow Cytometry 
2.8
Introduction and General Principles 
Flow cytometry is a laser-based method for the detection of cells suspended in a 
stream of fluid which carries and aligns the cells in single file through a beam of light or 
laser.  As the cell passes through the beam, a detector converts analogue 
measurements of scattered light (forward-scattered (FS)) light which is proportional to 





granularity of the cell) as well as dye-specific fluorescence signals (emitted by 
fluorescein-conjugated antibodies) into digital signals which can be processed by a 
binary computer.  Fluorescence-activated cell sorting (FACS™) provides a method for 
sorting a heterogenous mixture of cells (such as primary MCL cells, non-malignant 
lymphocytes and stromal cells) based upon specific light scattering and fluorescence. 
Detection of Primary MCL Cells Using Cluster Differentiation Markers 
Primary MCL PBMCs express a characteristic constellation of surface markers such as 
CD5, CD19, CD20 and FMC-7 which distinguish them from normal naïve B-lymphocytes 
and also from other B-cell malignancies.3  These cells can therefore be visualised and 
identified by labelling these surface markers using ligand-specific monoclonal 
antibodies which are conjugated to a fluorochrome which will fluoresce when 
activated.  Using fluorescence associated cell sorting (FACS™) these cells can be 
visualised and quantified. 
Detection of Apoptosis Using Annexin-V 
In addition, cells undergoing apoptosis (programmed cell death) can be distinguished 
from healthy cells by their surface expression of annexin-V.  In normal viable cells, 
phosphatidylserine (PS) is located on the cytoplasmic surface of the cell membrane.  
During the immediate stages of apoptosis, PS translocates from the inner to the outer 
cell surface where it is exposed and can be detected by binding to annexin-V which can 
be detected when fluorescently labelled. 
Detection of Proliferation Using Ki-67 
The antigen Ki-67 is a nuclear protein associated with cellular proliferation and 
ribosomal transcription and can be used as a cell marker of proliferation.  During the 
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active phases of the cell cycle, Ki-67 is present but is absent from resting cells.  
Monoclonal antibodies directed against human Ki-67 can be used to determine 
proliferation levels within a population of cells by FACS when conjugated to a 
fluorochrome.  The method is complicated by the need to fix the cell and permeabilise 
the cell membrane to allow the antibody to bind its nuclear target.  This can result in 
loss of cells and therefore a larger quantity of cell suspension is generally required for 
this assay. 
Detection of Multiple Fluorochrome-Conjugated Antibodies on the Same Cell 
Because of the laser/filter configuration of the flow cytometer and the fact that 
different fluorochromes fluoresce at different wave-lengths it is possible to design an 
experiment to detect multiple fluorochrome-labelled antibodies on the same cell.  This 
is particularly useful in determining survival or proliferation of primary MCL cells when 
cultured on murine fibroblasts because MCL specific cluster differentiation markers 
can be used as well as the cell surface markers of survival and proliferation, allowing 
for more accurate determination of the desired population of cells. 
For example, mouse-anti-human CD19 antibody conjugated to the fluorochrome APC 
(allophycocyanin), mouse-anti-human CD5 antibody conjugated to PE and annexin-V 
conjugated to FITC could all be added to the same sample and used to gate on the 





2.8.1 Reagents, Materials and Equipment 
 
Reagents  
 fluorescein-conjugated, anti-human monoclonal antibodies and cellular probes 
(Table 2.2) 
 annexin-V binding buffer (BD-Biosciences) 
 FACS binding buffer (for non-annexin-V FACS) (0.5% bovine serum albumin 
(BSA) in 1x PBS solution) 
 PBS 
 staining buffer for Ki-67 Assay: 0.5% BSA/PBS 0.2% triton-X 
 4% PFH/PBS solution 
 0.5% Triton-X/PBS for cell permeabilisation 
Materials and Equipment  
 Accuri C6 Flow Cytometer(BD Biosciences) 
 Accuri C Flow Plus Software (BD Biosciences) 
 1.5mL Eppendorf tubes (Fisher Scientific) 








CD19 mouse anti-human IgG1k 555412 BD Biosciences  FITC 10 
CD19 mouse anti-human IgG1k 555413 BD Biosciences  PE 10 
CD19 mouse anti-human IgG1k 555415 BD Biosciences  APC 10 
CD5  mouse anti-human IgG1k 555355 BD Biosciences  APC 10 
CD5 mouse anti-human IgG1k 555353 BD Biosciences  PE 10 
CD3  mouse anti-human IgG2ak 555342 BD Biosciences  APC 10 
Annexin V 556419 BD Biosciences  FITC 5 
Ki-67 mouse anti-human IgG1k 556026 BD Biosciences  FITC 10 
CD11c mouse anti-human  IgG1k 555392 BD Biosciences  PE 10 
CD62L (L-selectin) mouse anti-human IgG1k 555544 BD Biosciences  PE 10 
CD49d (Integrin α4 chain) mouse anti-human 
IgG1k 
555503 BD Biosciences  PE 10 
CD49e (Integrin α5 chain) mouse anti-human 
IgG1k 
555617 BD Biosciences  PE 10 
CD11a (LFA 1α; ITGAL) mouse anti-human IgG1k 555384 BD Biosciences  PE 10 
CD58 (LFA-3) mouse anti-human IgG2ak 555921 BD Biosciences  PE 10 
CD54 (ICAM-1) mouse anti-human IgG1k 555511 BD Biosciences  PE 10 
CD183 (CXCR3) mouse anti-human IgG1k 557185 BD Biosciences  PE 10 
CD184 ( CXCR4) mouse anti-human IgG2ak 555974 BD Biosciences  PE 10 
CD185 (CXCR5) mouse anti-human IgG2b FAB190P-100 R & D Systems PE 10 
Mouse anti-human IgG1k isotype control 556026 BD Biosciences  FITC 10 
Mouse anti-human IgG1k isotype control 559320 BD Biosciences  PE 10 
Mouse anti-human IgG1k isotype control 555751 BD Biosciences  APC 10 
Mouse anti-human IgG2aκ isotype Control 555574 BD Biosciences  PE 10 
Mouse Anti-Human CD154 555697 BD Biosciences PE 10 
Table 2-2  Fluorescein-conjugated human monoclonal antibodies /probes employed in labelling, 
survival, proliferation and adhesion experiments including isotype controls.  FITC - fluorescein 
isothiocyanate; PE - phycoerythrin; APC –allophycocyanin.  
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2.8.2 Protocol for Apoptosis Assay 
Two aliquots of 100µL of cell suspension were transferred from the culture well into 
two 1.5mL Eppendorf tubes.  To one tube, 10µL of fluorescein-conjugated mouse anti-
human CD5 and mouse anti-human CD19 were added. To the second tube, 10µL of the 
appropriate isotype control antibody were added.  The tubes were gently vortexed and 
transferred to the dark at room temperature to permit binding.  After 20 minutes 5µL 
of FITC-conjugated annexin-V was added to the first tube and the tube was gently 
vortexed.  300µL of annexin-V binding buffer was added to the tubes before being 
transferred to the flow-cytometer for FACS analysis. 
2.8.3 Protocol for Proliferation Assay  
Two aliquots of 200µL of cell suspension from each sample were transferred to 
labelled 1.5mL Eppendorf tubes.  To one tube, 10µL of anti-CD19 and anti-CD5 
antibodies were added, to the second tube, appropriate isotype controls were added.  
The tubes were vortexed and incubated at room temperature in the dark for 20 
minutes.  Both tubes were then centrifuged at 7000 rpm for 3 minutes until a cell 
pellet was visible.  The supernatant was removed and the cells were resuspended in 
200µL of 4% PFH/PBS, gently vortexed and incubated in the dark at room temperature 
for 10 minutes to fix the cells. 
NB.  An initial experiment was conducted to determine the optimal time to fix the cells 
(i.e. before or after labelling with anti-CD5 / CD19 surface marker antibodies).  This 
experiment revealed that labelling the cells prior to fixation led to better visualisation 
of the surface markers by FACS after fixation and permeabilisation (data not shown). 
After a 10 minute fixation incubation the cells were washed (1mL of PBS was added 
and the tubes were centrifuged at 7000 rpm for 3 minutes to pellet the cells).  The cells 
were then resuspended in 100µL of 0.5% triton-X/PBS and gently vortexed before 
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being incubated on ice for 10 minutes to permeabilise the cell membrane.  1mL of Ki-
67 stain buffer was added and the cells were washed and resuspended in 100µL of Ki-
67 stain buffer.  10µL of FITC-conjugated anti-human Ki-67 monoclonal antibody was 
added to the test tube and 10µL of isotype control added to the control tube.  The 
tubes were vortexed and incubated in the dark for 25 minutes at room temperature.  
The cells were then washed and resuspended in 300µL of stain buffer prior to FACS 
analysis. 
2.8.4 Protocol for Cellular Adhesion Marker Assay  
For analysis of CAM profiles, 10µL of the target adhesion marker antibody or its 
corresponding isotype control were added to two separate 1.5mL Eppendorf tubes 
(Table 2.2).  In addition to labelling the target CAM, the cells were co-labelled with 
anti-CD5 / CD19 monoclonal antibodies.  100µL of cell suspension was transferred to 
the labelled Eppendorf tube and the tube was gently vortexed and incubated at room 
temperature in the dark for 25 minutes.  300µL of stain buffer was then added and the 
tube vortexed and transferred to the flow cytometer for FACS analysis.  
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 Method for Cytospin, fixation and Staining 
2.9
In order to further assess the morphology of the primary MCL PBMCs during the co-
culture experiments a sample of the cell suspension from each well of a series of four 
cases of MCL was spun onto a standard microscope slide, fixed and stained with 
modified Wright’s stain ( kindly performed by staff at the  Derriford Combined 
Laboratories) for light microscopic examination. 
Reagents 
 cell suspension of human MCL PBMCs from co-culture experiments 
 4% paraformaldehyde / PBS solution 
 mounting media (Histomount). 
Materials and Equipment 
 glass microscope slides & cover slips (Fisher Scientific) 
 Statspin Cytofuge Centrifuge (+ cartridges and filters) (Tissue-Tek®) 
 glassware for staining slides (Fisher Scientific) 
 conical bottomed 15mL falcon tubes (Fisher Scientific) 
 DFC 3000G phase contrast microscope (Leica Microsystems) 
On day 7 of co-culture experiments, the cells were agitated within the well using a 
pipette.  100µL of media containing the co-culture from designated wells was retrieved 
and added to a sterile falcon tube.  The empty well was visualised to ensure all cells 
have been retrieved and any remaining cells were retrieved by washing with PBS.  
200µL of the cell suspension was added to labelled funnels loaded with filters and 
slides within the cytofuge.  The funnels were spun gently (7000 rpm for 5 minutes) and 
the slides retrieved from the cartridges for labelling and inspection.  The cells on the 
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slides were examined by light microscopy to ensure a consistent cell density was 
achieved (defined as cells in loose contact but not overlapping to optimise visualisation 
of morphology).  Slides with excessive cell numbers were discarded, an appropriate 
dilution of the cell suspension was performed and the method was repeated until a 
satisfactory cell layer was achieved.  The slides were then labelled and a diamond 
tipped pen was used to draw round the cell layers before being air-dried overnight.  
200µL of 4% PFH/PBS was then dropped onto the cell layers and the slides were fixed 
for 15 minutes before being washed with PBS.  The slides were stained with modified 
Wright’s stain by laboratory staff in the combined laboratories at Derriford Hospital 
then cover-slipped using histomount and examined by light microscopy.  
65 
 
 Cellular Adhesion Molecule Profiling of Primary MCL Cells 
2.10
For the profiling of mononuclear cells from peripheral blood and bone marrow from 
subjects with MCL, FACS analysis of labelled cells was performed.  The cells were 
suspended in culture medium, labelled with anti-CD5 and CD19 monoclonal antibodies 
and also with a monoclonal antibody against one of a panel of CAMs before being 
incubated and then analysed by flow cytometry. 
The median fluorescence intensity (MFI) of each adhesion molecule expressed on the 
surface of the primary MCL cells was used for data analysis because the distribution of 
fluorescence intensity was not always Gaussian. 
Reagents 
 complete RPMI 1640 with GlutaMAXTM medium (Gibco) (supplemented with 
10% FCS (Fisher Scientific) and 1% penicillin/streptomycin (Invitrogen));  
 fluorescein-conjugated mouse-anti-human monoclonal antibodies (Table 2.2) 
 stain buffer (0.5% BSA in PBS) (Fisher Scientific) 
Materials and Equipment  
 Accuri C6 Flow Cytometer (BD Biosciences) 
 Accuri CFlow Plus Software (BD Biosciences) 
 1.5mL Eppendorf tubes, tips and pipettes (Fisher Scientific) 
 vortex (VortexGenie-2, Scientific Industries)  
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Peripheral blood mononuclear cells or marrow mononuclear cells were harvested from 
consenting subjects with MCL and separated from blood and plasma as previously 
described. 
Mononuclear cells were resuspended in warmed, complete RPMI medium and cell 
density was adjusted to 1x106/100µL.  Ten microlitres of FITC- or APC-conjugated 
mouse anti-human CD5 and CD19 mononuclear antibody were added to 12 labelled 
1.5mL Eppendorf tubes.  To the first ten tubes, 10 µL of PE-conjugated, mouse anti-
human monoclonal antibody specific to an individual adhesion molecule was added.  
To two tubes, 10µL of appropriate isotype control antibodies were added and one tube 
was labelled as an unstained control.  A list of the monoclonal antibodies used is 
displayed in Table 2-2. 
To each labelled tube, 100µL of cell suspension was added and the tubes were gently 
vortexed to mix before being incubated at room temperature in the dark for 20 
minutes.  Three hundred microlitres of staining buffer (0.5% BSA/PBS) was added to 




2.10.1 Analysing Flow Cytometry Data 
An example of the plots and gates used to derive the median fluorescent intensity for 
each surface adhesion marker is displayed in Figure 2-5. 
 
Figure 2-5.  An example of the plots obtained by FACS analysis used to calculate the median 
fluorescent intensity for each adhesion molecule.  Firstly, a forward / side scatter plot was 
obtained and a gate placed on the population of cells containing viable lymphocytes (top left).  The 
CD5 / CD19 positive cells within this gate were identified according to their fluorescence compared 
with the isotype control (top right and bottom left).  The median fluorescence intensity of the 
corresponding surface marker (labelled with PE fluorescein) was derived from this population.  
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  Statistical Analysis 
2.11
Data from flow cytometry experiments were analysed using Accuri CFlow Plus (BD 
Biosciences); Microsoft Excel™ and GraphPad Prism™ (version 5) software.  Apoptosis 
was assessed according to annexin-V positivity; proliferation was assessed according to 
the percentage of cells which were positive for or Ki-67 compared with negative 
isotype control within the population of CD5 / 19 positive lymphocytes.  The 
proportion of cells expressing surface adhesion markers was determined by calculation 
the median fluorescence intensity ratio (MFIR) = median fluorescence of adhesion 
antibody / median fluorescence of isotype control (presented in arbitrary units (a.u.)).  
Where a series of data is presented together, the mean value of the median 
fluorescence intensity together with the standard error of the mean is presented.  
Paired Wilcoxon signed rank tests were used to compare the mean and to derive p 
values, in which a two-tailed p value is displayed.  
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3. CHAPTER 3.  Can a tractable ex vivo culture be developed to 
support and model the growth of mantle cell lymphoma? 
 Introduction 
3.1
Mature B-lymphocytes survive, grow and proliferate within a marrow or lymph node 
microenvironment where essential signals are provided by specific accessory cells.  
These signals control essential aspects of behaviour, and there is evidence that 
accessory cells are required for extended survival/proliferation of MCL in 
vitro.12,27,39,67,89 There is also growing evidence that the tumour micro-environment 
confers resistance to MCL cells by offering protection from 
immunochemotherapy.38,39,67 
It was hypothesised, therefore, that an appropriately designed culture system would 
allow evaluation of MCL biology and cell interactions, and permit study of responses to 
drugs within an environment relevant to that encountered in vivo. 
This chapter describes the development and testing of a system to model MCL growth 
in vitro, focussing particularly on the proposed role of accessory cells that express 
relevant receptors, and on the use of soluble factors recognised to alter the of survival 
and growth of other mature B-cell neoplasms.  The ex vivo growth and survival 
characteristics of 15 distinct cases of primary MCL was therefore assessed when 
cultured in isolation or with murine and human fibroblast support testing also the role 
of fibroblast-expressed CD40 ligand (CD40-L). The soluble factors interleukin 4 (IL4) 




The CD40 ligand is a member of the tumour necrosis factor (TNF) superfamily.  It is 
expressed primarily by activated T cells and engages with the CD40 receptor on B-cells.  
It provides a major secondary signal to B-cells which stimulates survival and 
proliferation through the upregulation of major transcription factors.  It also has the 
ability to rescue B cells from apoptosis by the induction of BCL pro-survival 
proteins.45,49,90,91 Although CD40L has recognised effects in other B-lymphoproliferative 
disorders – promoting their survival or proliferation48,91,92, the molecule has not been 
widely studied in MCL and the existing evidence of its effect is conflicting47,49.    
IL-4 is a pleiotropic cytokine which regulates T-cell and B-cell responses, including 
proliferation, survival and gene expression.57  It is produced by T-cells, mast cells and 
bone marrow stromal cells.  A combination of CD40-ligand and IL-4 (also secreted by 
activated Th2 cells) is known to stimulate B cell proliferation in vitro, and these 
molecules have been demonstrated to synergise in driving clonal expansion in normal 
B-cells and proliferative responses in MCL cells.49,63  In addition to stimulating 
proliferative responses, IL-4 has been shown to inhibit apoptosis and maintain cell 
viability in B-cells, including their malignant counterparts by the upregulation of BCL-2 
expression.60,61 
TLR-9 is expressed on antigen-naïve B-cells, including MCL cells and can recognise T-
cell independent antigens, such as lipopolysaccharide (LPS), which are intrinsically 
mitogenic.51  Through activation of TLR-9, T-cell independent antigens can initiate a 
cascade of intracellular events in B-cells, including phosphorylation of cytoplasmic 
tyrosine kinases resulting in enhanced proliferation and differentiation.  There is also 
evidence that the addition of TLR-9-L with CD40-L stimulation acts synergistically to 
enhance proliferation and differentiation.52,55,56 
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These observations provide the rationale for the use of IL-4 and TLR9-L in combination 
with CD40-ligand as a model for stimulating proliferation and survival in primary MCL 
cells ex vivo. 
 Summary of Experimental Methods 
3.2
This chapter employs the culture of stromal cells ex vivo, their co-culture with primary 
MCL cells, and analysis of their survival and proliferation using flow cytometry.  The 
detailed methods are described in Materials and Methods (section 2.8). The antibodies 
and soluble factors employed are shown in Table 3-1. 
Model systems: In brief, two distinct murine fibroblast monolayers, one transfected 
with the CD40 ligand gene (labelled CD40L-T) and the other, non-transfected (CD40L-
NT), were cultured in wells of standard, 24 well plates until 70-80% confluent by visual 
inspection. Monolayers were then irradiated (15Gy single fraction) to prevent them 
overgrowing the primary MCL cells. Cell suspensions of primary MCL cells from 
individual subjects were prepared in complete RPMI media using a density of 
4x106/mL.  Following washing of the fibroblast layer, 1mL of the PBMC suspension was 
seeded onto the monolayers in the 24 well plates. In experiments examining the role 
of IL-4 and TLR9-L as stimulants of survival and proliferation, humanised Interleukin 4 
(50ng/mL) or Toll-like-receptor-9 ligand (ODN 2006) (3uM) were added to selected 
wells along with a DMSO vehicle control.  A control ODN experiment was performed 
previously to ensure oligonucleotides per se did not initiate apoptosis.  The co-cultures 
were then maintained in RPMI medium in humidified, CO2-enriched conditions at 37
oC 
for up to 8 days.  Cells were inspected and harvested at defined time points and 
analysed for rates of apoptosis and proliferation. 
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For experiments involving human bone marrow fibroblasts, separate standard 24 well 
plates were seeded with human marrow cells or CD40-L transfected murine stroma.  
The human bone marrow stroma were obtained from a patient with Waldenströms 
macroglobulinaemia, separated using ficoll-paque then cultured in in 25cm2 flasks until 
a sufficiently confluent layer was achieved.  The murine stromal layers were irradiated 
to prevent overgrowth of the primary MCL cells as previously described.  The human 
stromal layer was not irradiated because growth rates observed were much slower 
and overgrowth of the MCL cells was not anticipated over the time period of the 
experiment. 
Cell assessments: Cell survival and proliferation rates were assessed by flow cytometry 
using annexin-V as a marker of apoptosis and Ki-67 as a marker of proliferation.  
Aliquots of 100µL of cell suspension were used for annexin-V assay (approximately 
4x105 cells) and 200µL of cell suspension (approximately 8x105 cells) were used for the 
Ki-67 assay (a larger volume to account for increased cell loss during the fixation and 
permeabilisation steps).  The cells were co-labelled with fluorescein-conjugated anti-
CD5 and -CD19 monoclonal antibodies before addition of annexin-V and before 
fixation and permeabilisation for the Ki-67 assay. Primary MCL cells were distinguished 
from fibroblast cells in flow cytometry by their forward and side-scatter characteristics 
and by their co-expression of CD5 and CD19, characteristic cell surface markers of MCL 
cells, not expressed on murine or human fibroblasts. All antibodies were anti-human 
and used with corresponding isotype controls at a concentration of 10µL per test.  For 
annexin V staining, 5µL of annexin-V FITC /100µl cell suspension was used. 
Alongside flow-cytometry, the culture plates were visually inspected by light-
microscopy for morphological changes after 24 hours and subsequently every 48 hours 
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of co-culture.  Images were taken using a DM IL LED phase-contrast light microscope 
and CCD grayscale camera (Leica DFC3000 G) and processed using LAS AF Version: 
2.6.3 software (Leica Microsystems).  A further assessment employed cytospin 
morphological assessment: the primary MCL PBMCs during co-culture, 200µL samples 
of the cell suspension from selected cases was spun onto a standard microscope slide 
using a cytofuge, air-dried for 12 hours before being fixed with 4% 
paraformaldehyde/PBS and stained with modified Wright’s stain for light microscopic 
examination (Materials and Methods section 2.9). 
Data analysis: Data were analysed using Accuri CFlow Plus (BD Biosciences); Microsoft 
Excel™ and GraphPad Prism™ Version 5 software. The tests employed are described in 
the figure legend of the individual experiments.  
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CD19 mouse anti-human IgG1k 555412 BD Biosciences  FITC 10 
CD19 mouse anti-human IgG1k 555413 BD Biosciences  PE 10 
CD19 mouse anti-human IgG1k 555415 BD Biosciences  APC 10 
CD5  mouse anti-human IgG1k 555355 BD Biosciences  APC 10 
CD5 mouse anti-human IgG1k 555353 BD Biosciences  PE 10 
CD3  mouse anti-human IgG2ak 555342 BD Biosciences  APC 10 
Ki-67 mouse anti-human IgG1k 556026 BD Biosciences  FITC 10 
Mouse anti-human IgG1k isotype control 556026 BD Biosciences  FITC 10 
Mouse anti-human IgG1k isotype control 559320 BD Biosciences  PE 10 
Mouse anti-human IgG1k isotype control 555751 BD Biosciences  APC 10 
Mouse anti-human IgG2aκ isotype Control 555574 BD Biosciences  PE 10 
ODN 2006 (ODN 7909) Class B CpG 
oligonucleotide; a human TLR9 ligand 
tlrl-
2006-1 
InvivoGen n/a 3uM 




Table 3-1  Monoclonal antibodies and cell stimulants.  Monoclonal antibodies employed to label 
and assay primary MCL cells for apoptosis and proliferation experiments.  FITC - fluorescein 
isothiocyanate; PE - phycoerythrin; APC –allophycocyanin.  
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 Clinical and biological features of primary MCL cases 
3.3
The clinical and biological features of the cases used in this chapter are summarised in 
Table 3-2.  Fourteen of the subjects had peripheral blood mononuclear cells (PBMCs) 
sampled at single time-points in their disease history, either before treatment or at 
relapse.  One of the subjects, (MCL11), underwent blood sampling at diagnosis (before 
any treatment) and at first relapse after immunochemotherapy, whilst on second-line 
treatment with a BTK-inhibitor.  Because MCL cells are known to evolve new mutations 
at relapse, cells from subject MCL11 were tested and presented separately, as a 
clinically distinct sample (labelled MCL12).93 
Although the biological features of each case are uniform in terms of the diagnostic 
hallmarks (t(11;14) translocation and cyclin D1 overexpression), the cases showed 
significant clinical heterogeneity between subjects, which is a well-known feature of 
the disease.  For example, subject MCL07 was diagnosed with MCL nearly 15 years ago 
after an incidental finding of a peripheral leucocytosis (WCC 15x109/L).  However there 
were no clinical symptoms or evidence of bulky lymphadenopathy at diagnosis and 
therefore the subject was merely observed at routine appointments.  This pattern of 
observation has continued for nearly 15 years without the requirement for therapy 
and remains the case at the point of writing. 
In contrast, subject MCL08 presented with lymphadenopathy and constitutional 
symptoms at diagnosis.  This required immediate therapy, but the individual 
subsequently relapsed after a relatively short remission (less than 2 years).  After a 
second line of therapy with ibrutinib, (a BTK inhibitor), his disease again relapsed with 
a rapidly rising white cell count (200x109/L) and progressive lymphadenopathy.  It was 
at this point that his cells were harvested and cryopreserved and unfortunately no 
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further treatment was successful and the patient died shortly afterwards.  Both cases 
harboured the single t(11;14) translocation resulting in over-expression of cyclin-D1. 
The clinical variation exemplified in these two cases allows MCL cases to broadly be 
divided into indolent and aggressive forms of the disease.  For the purpose of this 
study, aggressive disease is defined as requiring treatment at or shortly after diagnosis; 
whereas indolent disease is defined as present but causing no clinically significant 
problems to the patient and not requiring treatment for 2 years from diagnosis. Where 
appropriate the samples used in this chapter have been subdivided in this way for the 
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MCL02 68 m (t11;14)+ 
cyclin D1 



























None – but refractory to 
treatment 
Aggressive 






















MCL10 54 m t(11;14)+ 
cyclin D1+ 
CD5/19+ Stage IV 
WCC variable† 
Immunochemotherapy Aggressive 
MCL11 60 f cyclin D1+ CD5/19+ Stage IV Immunochemotherapy Aggressive 








MCL13 64 m cyclin D1; 
t(11;14) 







MCL14 62 m cyclin D1; 
t(11;14) 
CD5/19+ Localised low 
volume 






MCL15 70 f cyclin D1; 
t(11;14) 
CD5/19+ Stage III None Aggressive 
Table 3-2  Primary MCL Subject Clinical and Biological Characteristics.  MCL subject demographics, 
diagnostic molecular data, immunophenotyping of PBMCs and clinical disease summary of 12 cases 
of MCL examined in this chapter. 
 
The variation of clinical features observed between cases was also apparent when 
cases were observed by light microscopy.  The cellular growth patterns of two selected 
cases (MCL07, an indolent case, and MCL08, an aggressive case) are demonstrated in 
Figure 3-1. Cells from subject MCL08, a proliferative and aggressive case of MCL, form 
clusters after four days of culture on CD40-ligand transfected murine fibroblasts 
compared with little obvious evidence of cluster formation in the CD40-ligand negative 
environment.  Cells from subject MCL07, an indolent case, fail to demonstrate any 
obvious cluster formation in the same environment over the same time period.  
It is interesting to note that an increase in proliferation was noted in the cells from 
MCL08, whereas no significant proliferation was observed in any environment for cells 
from subject MCL07 (see Table 3-4). These different behaviours not only support the 
concept of different responses to the stromal environment between clinically distinct 
cases of MCL, but also support the subsequent study of different adhesion properties 




Figure 3.1  Serial Light-Microscopy Images of Primary MCL Cells on Fibroblast Monolayers After 4 
Days of Culture.  Subjects MCL07 (indolent) and MCL08 (aggressive) PBMCs co-cultured with 
CD40-L transfected murine fibroblasts for 4 days.  Cells from MCL08 demonstrate no evidence of 
cluster formation in the CD40-L non-transfected microenvironment (A) compared with obvious 
cluster formation on the CD40-ligand transfected stromal cell layer (B).  Cells from MCL07 (indolent 
case) demonstrate no clear cluster formation in either microenvironment (C & D).  (PBMCs seeded 
in complete RPMI at 4x106/mL and cultured for 4 days on CD40-ligand non-transfected (CD40L-NT) 
murine fibroblasts (left) versus CD40L-transfected stroma (right) (Mag x20, objective lens).  
C. Subject MCL07 + CD40L-non-transfected stroma D. Subject MCL07 + CD40L-transfected stroma 
A. Subject MCL08 + CD40L-non-transfected stroma B. Subject MCL08 + CD40L-transfected stroma 
80 
 
 Primary MCL cells demonstrate increased survival when cultured 
3.4
ex vivo with CD40L-T stromal cell support compared with CD40L-
NT stroma or media alone 
To establish the effects of stromal cell support on cell survival, four cases of primary 
MCL were seeded into wells in culture media alone or with murine fibroblast cells, 
either CD40L-NT or CD40L-T.  Wells were sampled and analysed for rates of apoptosis 
after 24 hours and 3 days. Marked heterogeneity was observed, however cells co-
cultured on a murine stromal layer transfected with CD40L had the best overall 
survival. Similar rates of apoptosis were observed in cells cultured in media alone or on 
a CD40L-NT stromal layer suggesting that accessory cell support in the absence of 
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Figure 3.2  Survival of primary MCL is sustained when cultured with CD40-ligand transfected 
fibroblasts when compared to non-transfected fibroblasts or media alone.  Rates of apoptosis are 
shown for the four cases as a mean value at two time points demonstrating a protection from 
apoptosis in the presence of CD40L. 
 
Since media alone and CD40-NT did not differ in observed survival rates, subsequent 
co-culture experiments compared CD40-L-transfected murine fibroblasts as a 




 Biological characterisation of primary MCL cells cultured ex vivo 
3.5
with or without CD40L, TLR9-L or IL4 stimulation 
Building on the observation that MCL cells survive best when cultured with a stromal 
cell supportive layer ex vivo, primary MCL cells from 12 subjects were tested for 
survival and proliferation after co-culture on two different murine fibroblast 
monolayers, one transfected with the CD40L gene and the other non-transfected. 
The culture system was assessed for rates of apoptosis and proliferation using annexin-
V and Ki-67-positivity by flow cytometry.  After 8 days of culture, the contents of each 
well was removed and divided into aliquots for quantification of the surviving and 
proliferative fractions by annexin-V and Ki-67 FACS assays as previously described. The 
rate of apoptosis and proliferation for each individual primary MCL case within the 
different microenvironment is presented in Tables 3-3 and 3-4, and for apoptosis 
shown graphically in Figure 3-3 (the mean apoptosis percentage for all 12 cases 
displayed in red).  The mean proliferation and apoptosis rates derived from all the 
cases after culture with CD40L-T and CD40L-NT stroma, together with IL-4 and TLR9-L 
stimulation are compared in Figure 3.4.  
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MCL01 6 3.3 2.8 23 6.1 3.8 9.1 
MCL02 4.2 11.8 12.8 41.7 8.0 11.0 22.7 
MCL03 5.6 3.1 3.4 6.0 4.1 2.3 2.2 
MCL04 37.6 10.6 3.2 14.9 3.6 0.4 2.1 
MCL05 19.7 1.9 3.7 2.3 7.3 5.1 9.4 
MCL06 5.1 9.8 10 43.7 15.2 15.4 27 
MCL07 8.7 1.6 2.9 1.1 3.4 4.5 13.7 
MCL08 36 27.4 2.6 51.9 4.4 14.1 18.7 
MCL09 5 75.6 71.8 81 48.1 19.5 33.7 
MCL10 13.6 90.3 87.1 90.6 33.3 30 42.1 
MCL11 3.1 82.7 68.8 79.2 36.2 22 49.2 
MCL12 4.0 84.9 87.7 91.4 27.6 15.5 46.5 
Mean 12.4 33.6 29.7 43.9 16.4 11.7 23 
Table 3-3  Survival of primary MCL PBMCs after 8 days co-culture on a stromal layer. Percentage 
of apoptotic MCL PBMCs from 12 cases of primary MCL before and after 8 days of co-culture in 
different microenvironments as determined by annexin V positivity by flow cytometry. Cells were 
co-cultured with murine fibroblastsCD40L-T; or CD40L-NT after the addition of 3μM TLR9-L or 
50ng/mL of recombinant IL-4 as indicated.  
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MCL01 3.6 1.2 8.4 6.8 9 12.1 
MCL02 9.2 14.8 17.4 60 40.1 44.2 
MCL03 0.3 0.2 0.3 1.5 1.8 1.7 
MCL04 0.9 1.4 4.9 11 7.5 7.5 
MCL05 0.8 0.7 1.8 4.3 5.1 6.2 
MCL06 1.4 1.1 0.6 1.5 2.2 1.3 
MCL07 0.6 0.7 0.8 16.2 19.3 15.3 
MCL08 4.9 1.9 failed 34 29 38.2 
MCL09 0.3 0.8 0.7 0.2 0.6 0.2 
MCL10 4.9 5.4 6.3 1.7 1.3 1.2 
MCL11 0.1 0.2 0.3 0.6 0.6 0.4 
MCL12 0.3 1.2 0.9 0.8 0.9 1.4 
Mean  2.26 2.47 3.85 11.55 9.78 10.81 
Table 3-4  Proliferation of primary MCL PBMCs after 8 days co-culture. Percentage of proliferating 
MCL PBMCs from 12 cases of primary MCL before and after 8 days of co-culture in different 
microenvironments as determined by Ki-67 expression determined by flow cytometry.  Cells were 
co-cultured with murine fibroblasts CD40-T or CD40-NT with or without 3μM TLR9-L or 50ng/mL of 

























































































































































































































Figure 3.3  Rates of apoptosis for each primary MCL case before and after 8 days co-culture with 
murine fibroblasts without CD40L (CD40L-NT) and with CD40L (CD40L-T).  In addition to CD40-
ligand stimulation (B), cells shown in D also received 50ng/mL human recombinant IL-4 and cells 
shown in F also received 3μM TLR9-L at time 0.  Percentage of apoptotic cells determined by 













































































































































































Figure 3.4  A summary of proliferation (left) and apoptosis (right) of primary MCL PBMCs co-
cultured in different micro-environments.  Mean percentage of Ki67-positive MCL PBMCs and 
mean percentage of annexin-V positive MCL PBMCs (determined by FACS) from 12 cases of MCL 
after 8 days co-culture with murine fibroblasts (CD40L-transfected (CD40T) vs CD40-non-
transfected (CD40-NT) with 5µL DMSO; after addition of 50ng/mL human recombinant IL-4 or 3μM 
Toll-like receptor 9 ligand (TLR9-L).  (Mean + standard error displayed). 
 
3.5.1 Primary MCL cells exhibit heterogeneity in their ability to survive and 
proliferate ex vivo.   
There is striking variability of primary MCL cells from different cases to survive ex vivo 
(Table 3.3). Some cases show high levels of apoptosis and a clear survival benefit with 
CD40L (for example MCL09) whereas in other cases (for example MCL03) there is very 
little apoptosis with or without CD40L.  Further, survival at time zero is not predictive 
of survival after 8 days. Proliferation of MCL in culture is disappointingly low and again 
the response is heterogeneous (Table 3.4).  Overall though, both survival and 
proliferation appear to be optimised by the presence of CD40L (mean apoptosis 
CD40L-NT 33.6% vs CD40L-T 16.4% ; mean proliferation CD40L-NT 2.26% vs CD40L-T 
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11.55%).  TLR9 -L appears to enhance apoptosis possibly more so in the absence of 
CD40L (Figure 3.4).  Data for TLR9-L negative control shows no difference to DMSO 
vehicle control (data not shown).  The effects of IL4 are less clear. There is a suggestion 
that IL-4 may promote survival with a reduction in mean apoptosis by 4% (CD40L-NT) 
and 5% (CD40L-T).  The individual effects of CD40L, IL4 and TLR9-L on both apoptosis 
and proliferation are studied in more detail below. 
3.5.2 CD40-ligand significantly reduces apoptosis and enhances 
proliferation of MCL cells when cultured ex vivo 
The effect of CD40L on cell survival and proliferation was analysed in more detail 
(Figure 3.5). The effect of CD40L when analysed collectively with or without IL4 or TLR-
9-L markedly enhances survival (p=0.0007) and proliferation (p=0.0001). This 
significance is also demonstrated when only CD40L is assessed. Where apoptosis rates 
in cases cultured in the absence of CD40L were less than 5% it was deemed best to 
exclude these from analysis since additional benefit of the CD40L would be difficult to 





Figure 3.5  CD40-ligand reduces apoptosis and enhances proliferation of MCL cells when cultured 
ex vivo.  Paired Wilcoxon signed rank test comparing mean rates of apoptosis (A & C) and 
proliferation (B & D) for 12 cases of primary MCL cells cultured ex vivo with CD40-ligand non-
transfected murine fibroblasts (CD40L-NT) and CD40-ligand transfected murine fibroblasts (CD40-L-
T).  Panels A & B: all cases; Panels C & D: case set restricted to CD40L-T vs CD40L-NT. 
 
The results were subsequently analysed to see if there was any link between 
proliferation and survival. The results (Figure 3.6) clearly show that in the absence of 
CD40L there is no correlation between proliferation and survival (R 2 =0), the cases 
highlighted in red are the indolent MCL cases, however, when CD40L is present, the 
proliferative effect and protection from apoptosis are linked responses (R2=0.79). 
Therefore it is a response to CD40L rather than an intrinsic biological phenomenon of 
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Figure 3.6  In the presence of CD40-ligand, changes to proliferation and apoptosis are linked.  
These plots demonstrate a positive correlation between lower rates of survival and increased rates 
of proliferation amongst primary MCL cells cultured in the presence of CD40-L transfected murine 
fibroblasts. There is no correlation in absence of CD40L. 
 
 
3.5.3 Human interleukin-4 stimulation has a significant pro-survival effect 
but no significant effect on proliferation of primary MCL PBMCs 
cultured ex vivo 
 
A pooled analysis of the effect of IL-4 on survival and apoptosis for all 12 cases of MCL 
cultured ex vivo is shown (Figure 3.7). Overall, IL-4 appears to lead to an improvement 
in survival as determined by reduced rates of annexin-V positivity (mean apoptosis 
without IL-4 25% vs 20.9% with IL-4 p=0.037). However, IL-4 does not significantly 
affect proliferation as determined by Ki-67 positivity after 8 days of culture (mean 
proliferation 6.9% without IL-4 vs 6.1% with IL-4 p=ns). However, when the effect of IL-
4 was considered according to the presence or absence of CD40L, no significant effect 
on either survival or proliferation of primary MCL cells was evident (Figure 3.8). These 




Figure 3.7  IL-4 reduces rate of apoptosis of ex vivo cultured MCL PBMCs but has no effect on 
proliferation.  Paired Wilcoxon signed rank test comparing mean rates of apoptosis and 
proliferation determined by annexin-V and Ki-67 positivity respectively (assessed by flow-
cytometry).  Samples were subject to stimulation with 50ng/mL of recombinant human IL-4 at 
baseline and cultured on murine fibroblast monolayers in RPMI media for 8 days. Results are 
pooled for the presence or absence of CD40L. 
 
 
Figure 3.8  A subset analysis of the addition of interleukin-4 (IL-4) to primary MCL cells cultured 
with or without CD40-ligand demonstrates no significant change in survival or proliferation. 
Paired Wilcoxon signed rank test comparing mean rates of apoptosis and proliferation 
determined by annexin-V and Ki-67 positivity respectively (assessed by flow-cytometry).  
Samples were subject to stimulation with 50ng/mL IL-4 at baseline and cultured on murine 
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3.5.4 Toll-Like Receptor-9 Ligand appears to impair survival of MCL PBMCs 
but has no effect on proliferation in ex vivo culture 
A pooled analysis of survival and proliferation of all 12 cases of primary MCL cells 
cultured with or without TLR-stimulation at baseline is displayed in Figure 3.9 with a 
subset analysis of the effects of TLR stimulation according to the presence or absence 
of CD40-L shown in Figure 3.10. 
In the pooled analysis, no significant effect on proliferation could be demonstrated in 
the presence of TLR9-L (Mean proliferation 7% without TLR9-L vs 7.5% with TLR9-L, 
p=ns).  However there was evidence of a significant reduction in survival in the 
presence of TLR9-L (mean apoptosis 25% without TLR9-L, 33.5% with TLR9-L, 
p=0.0016) (Figure 3.9). When the effects of TLR9-L stimulation was sub-stratified 
according to the presence or absence of CD40L, survival is significantly reduced in both 
microenvironments and there appears to be more of an effect in the absence of 
CD40L, (mean apoptosis 33.6% without TLR9-L vs 43.9% with TLR9-L in the absence of 
CD40L (p=0.012); 16.4% without TLR9-L vs 23% with TLR9-L in the presence of CD40L 
(p=0.043)).  Although proliferation in the absence of CD40L is enhanced with TLR9-L 
(mean proliferation without TLR9-L 2%; with TLR9-L 3.9% p=0.02), proliferation rates 






Figure 3.9  TLR9L increases rates of apoptosis in ex vivo cultured primary MCL cells but has no 
effect on proliferation Paired Wilcoxon signed rank test comparing mean rates of apoptosis (A) 
and proliferation (B) determined by annexin-V and Ki-67 positivity respectively (assessed by 
flow-cytometry).  Samples were subject to stimulation with 3uM TLR-9-L at baseline and 
cultured on murine fibroblast monolayers in RPMI media for 8 days. 
 
 
Figure 3.10  TLR9L significantly increases the rate of apoptosis in primary MCL cells with a greater 
effect on cells cultured in the absence of CD40-ligand.  TLR9 stimulation appears to have no 
significant effect on proliferation. Paired Wilcoxon signed rank test comparing mean rates of 
apoptosis (A & B) and proliferation (C & D) determined by annexin-V and Ki-67 positivity 
respectively (assessed by flow-cytometry).  Samples were subject to stimulation with 3µM 
TLR9-L at baseline and cultured on murine fibroblast monolayers in RPMI media for 8 days.  A 
& C: CD40L-non-transfected stroma; B & D: CD40L-transfected stroma.  










































































































































 Subset Analysis of Survival and Proliferation of MCL Cells in ex 
3.6
vivo Culture According to the Clinical Phenotype of the MCL 
Subject 
 
The variation observed in the clinical features of subjects with MCL is one of the 
disease’s characteristic features.  Most subjects have significant constitutional 
symptoms and / or rapidly progressing lymphadenopathy, requiring treatment at or 
soon after diagnosis, whereas a minority can display an indolent, slowly progressing 
phenotype justifying a prolonged period of watchful waiting before treatment.94 
Although there is marked heterogeneity between cases, these subtypes of MCL can be 
broadly identified allowing a clinical and biological comparison.  There is no universally 
accepted definition of these subtypes, but a useful definition of aggressive disease is 
that requiring treatment at or shortly after diagnosis; whereas indolent disease can be 
defined as present but causing no clinically significant problems to the patient and not 
requiring treatment for 2 years or more from diagnosis. The subject samples used in 
these experiments have been divided in this way, then analysed according to their 
survival and proliferation profiles ex vivo. 
The mean apoptotic and proliferating fractions of the cultured PBMCs according to 
clinical phenotype in both the CD40L positive and negative stromal environment are 




3.6.1 Rates of apoptosis are intrinsically higher in the proliferative subset 
and significantly reduced in the presence of CD40-Ligand.  Apoptosis 
rates are low in the indolent MCL cases and unaffected by the presence 
of CD40-Ligand 
 
More proliferative forms of MCL have a variable, but higher intrinsic rate of apoptosis 
than the indolent cases (mean percentage of apoptotic cells = 44% vs 4.6% 
respectively).  In the presence of CD40L this is significantly reduced in the aggressive 
forms (21%, p=<0.001).  Indolent cases have a relatively low rate of apoptosis (mean = 












































Figure 3.11  Comparison of effect of CD40-ligand on survival of primary MCL cells from clinically 
aggressive versus indolent disease cases.  The MCL cells have been co-cultured on murine fibroblasts 
for 8 days prior to harvest and assay for Annexin V positivity by flow cytometry.  Scatter dot plots 
showing percentage apoptotic cells in each environment with mean and standard deviation. A Wilcoxon 
t-test (paired signed rank) was used to derive p values. The fibroblasts were CD40-L non-transfected 
(CD40L-NT) or transfected (CD40L-T).  More proliferative forms of MCL have a variable, but higher 
intrinsic rate of apoptosis than the indolent cases (mean = 44%).  In the presence of CD40L this is 
significantly reduced (21%) p<0.001.  Indolent cases have a relatively low rate of apoptosis (mean = 
4.6%), this is unaffected by the presence of CD40L (mean =5.5%) (p=n.s.)  
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3.6.2 Rates of proliferation are significantly increased by CD40-L in MCL 
cells from both indolent and aggressive forms of MCL 
With respect to proliferation, CD40-L significantly increases proliferation in both 
indolent and aggressive cases.  The mean proliferation rates for indolent and 
aggressive cases without CD40L were 1.4% and 3% respectively, increased to 11% 



















































Figure 3.12  Comparison of effect of CD40L on proliferation of primary MCL cells from clinically 
aggressive versus indolent cases of MCL.  MCL cells were co-cultured on murine fibroblasts for 8 
days prior to harvest and assay for Ki-67 positivity by flow cytometry.  The fibroblasts were CD40-L 
non-transfected (CD40L-NT) or transfected (CD40L-T).  Scatter dot plots showing percentage Ki-67 
positive cells in each environment with mean and standard deviation. A Wilcoxon t-test (paired 
signed rank) was used to derive p values.  CD40L significantly increases proliferation in both 
indolent and aggressive cases.  The mean proliferation rates for indolent and aggressive cases 
without CD40L were 1.4% and 3% respectively, increased to 11% (p=0.009) and 10% (p=0.006) 




 Culture of Primary MCL PBMCs on Human versus Murine Stroma 
3.7
From the data obtained hitherto, it appears that survival and proliferation of primary 
MCL PBMCs was enhanced when cells were cultured with CD40L-T murine stroma 
compared with CD40L-NT and no stromal support.  The addition of the cytokine IL-4 
also appeared to improve MCL cell survival during ex vivo culture. The next step was to 
assess the effect of human bone marrow stroma on survival and proliferation and to 
establish whether or not this is a superior system for the culture of MCL PBMCs ex 
vivo.  In addition, an attempt was made to establish whether or not the addition of IL-4 
exerts any effect on the human bone-marrow culture system. 
Primary MCL PBMCs from subjects MCL02 and MCL07 were selected for culture based 
on previous data suggesting that MCL02 cells demonstrate increased proliferation 
reflecting a more aggressive clinical phenotype and MCL07 cells demonstrate low rates 
of apoptosis and proliferation reflecting a more indolent clinical phenotype.  The 
effects of culture on human stroma were compared with culture on CD40L-T murine 
stroma with and without the addition of IL-4. 
Confluent monolayers of human and CD40-L fibroblasts were grown in separate 
standard 24 well plates before being seeded with MCL cells and cultured for 4 days 
before being assessed for apoptosis and proliferation as previously described. Rates of 
apoptosis and proliferation after 4 days of co-culture with and without IL-4 stimulation 
at baseline are shown in Figure 3.13. 
The rate of apoptosis observed after 4 days of culture did not differ between human 
and murine stromal co-culture (mean apoptosis 6.75% at baseline and 3.75% versus 
2.65% in CD40L-T murine and human stromal culture respectively).  No differences 
were observed with IL-4 stimulation. 
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The proliferation rates observed in the cells from the indolent subject (MCL07) were 
consistently low in all microenvironments (mean 4.3%). In the cells from the more 
proliferative case, (MCL02), the rate of proliferation after 4 days co-culture appeared 
higher in the human stromal culture in the presence of IL-4 (77.8%) compared with 
human stroma without IL-4 (55%) or CD40L-T murine stroma with or without IL-4 (51% 
and 50.6% respectively) (Figure 3.13).  Due to the low number of samples, statistical 
comparison was not possible. 
Thus from initial observations human stroma seems to be as effective as murine 
CD40L-T stroma at enhancing survival and promoting proliferation with some early 
results showing a greater proliferation with the combination of human stroma with IL4  
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Figure 3.13  Human stroma increases proliferation rates of primary MCL cells in combination with 
IL-4 Stimulation.  MCL cells from 2 subjects (MCL02, a clinically aggressive case and MCL07, a 
clinically indolent case) were cultured on human and CD40-T murine stroma for 4 days with and 
without interleukin 4 stimulation at baseline.  Survival and proliferation was measured on CD5/19 
labelled PBMCs using annexin-V and Ki-67 positivity by FACS.  
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 The Morphological Effects of Culturing MCL Cells Ex vivo on Murine 
3.8
Stroma 
In order to further characterise the microscopic features of primary MCL cells after 8 
days co-culture with murine fibroblasts, cell suspension samples from four cases were 
removed and spun onto glass slides for fixation and staining with haematoxylin and 
eosin to examine cellular morphology. 
3.8.1 Light Microscopy Reveals Clustering in some cases of Primary MCL 
cells after co-culture with murine fibroblasts 
When clusters of cells containing 10 or more lymphoma cells in contact with each 
other were counted, a tendency towards cluster formation could be observed in the 
CD40-Ligand positive culture conditions.  Light microscopy images of cells from subject 
MCL06 (aggressive MCL phenotype) which have been harvested after 8 days co-culture 
with murine stroma and spun onto glass slides before fixation and staining are 
displayed in Figure 3.14.  Cell clustering can be observed in the cells from the CD40L-T 
environment. 
The mean number of cell clusters of more than 10 cells per cluster observed in each 
culture environment is displayed in Figure 3.15.  A Wilcoxon non-parametric t-test has 
been applied demonstrating the tendency towards cluster formation in the CD40-L 
positive environment that is not statistically significant (p=0.065).  No significant 







Figure 3.14  Primary MCL cells from subject MCL06 demonstrate a tendency towards cluster 
formation in the presence of CD40 ligand.  Primary MCL PBMCs were co-cultured for 8 days with 
murine fibroblasts (CD40L-non-transfected (A) and CD40L-transfected (B)).  Cells were harvested 
and spun onto glass slides before being fixed and stained with modified Wright’s stain.  Clusters of 
cells were defined as 10 cells in direct contact with each other determined by light microscopic 




Figure 3.15  CD40L and cell cluster formation of primary MCL cells.  Primary MCL PBMCs were co-
cultured for 8 days with murine fibroblasts CD40L-NT or CD40L-T.  Cells were harvested and spun 
onto glass slides then fixed and stained with modified Wrights stain.  A cluster of cells were defined 
as 10 cells in direct contact with each other determined by light-microscopy (a Wilcoxon t-test was 






The data obtained and presented has revealed several notable observations 
concerning the behaviour of primary MCL cells during ex vivo culture, and adds to the 
limited body of work in this area.  
It is clear from work with primary cells that there is marked variation between primary 
MCL cells from different subjects in their ability to survive ex vivo.    Marked genetic 
heterogeneity between MCL cases is well described in the literature, with an 
accumulation of mutations in addition to the hallmark t(11;14) translocation being 
observed.  Secondary chromosome alterations targeting genes involved in cell cycle 
control, DNA damage responses and cell survival pathways are frequently observed in 
aggressive MCL cases which may be responsible for the marked variation observed 
between cases in these experiments.5,7,93,95  
A clinical correlation is that cells from subject MCL08 which demonstrate high levels of 
apoptosis, were obtained at the point of relapsed disease, with rapid clinical 
progression despite the use of a BTK-inhibitor, compared to the relatively low levels of 
apoptosis observed in 3 other cases, 2 of which were from subjects with indolent 
disease and one which was previously untreated. 
It is important to note that many patients with MCL do not demonstrate a peripheral 
lymphocytosis which means that this study has a particular selection bias for cases 
with a leukaemic presentation.  Although this bias is unavoidable for this particular 
study it is important to bear in mind when considering these data in the general 
context of MCL. 
Studies suggest a pro-survival and protective effect of stromal cells on malignant B-
lymphocytes, probably due in part to stromal cell secretion of pro-survival cytokines 
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such as IL-6, IL-8 and vascular endothelial growth factor.30,96,97 The survival and 
proliferative advantage conferred by activation of the CD40 synapse, normally 
provided by FTH cells in-vivo, is well described in both normal and malignant B-
cells44,49,63,90,98.  Furthermore the ex vivo culture of CLL cells, a closely related 
lymphoproliferative disorder to MCL, show dependence on CD40L92, although CLL cells 
can survive when cultured at high density suggesting a role in for CLL homotypic 
interactions.99  Given this we analysed the effects of stroma and CD40L on the survival 
and proliferation of MCL cells.   
Marked heterogeneity was observed, however cells co-cultured on a murine stromal 
layer transfected with CD40L had the best overall survival. Interestingly similar rates of 
apoptosis were observed in cells cultured in media alone or on a CD40L-NT stromal 
layer suggesting that accessory cell support in the absence of CD40L offers no 
significant survival advantage over the culture of cells in media alone (Figure 3.2). 
Survival though was only assessed for a short period  given the concerns over viability 
and only a limited number of cases were analysed, but there is a suggestion that in 
some cases, culture in media alone is adequate for cell survival and would be similar to 
that observed in the ex vivo culture of CLL cells.  
The analysis of a further 12 cases of MCL is a significant number of cases given the 
availability of MCL cases with peripheral lymphocytosis. This further analysis confirmed 
the significance of CD40L on enhancing survival and promoting proliferation.  Indeed in 
the presence of CD40L survival and proliferation appear linked; cells which are actively 
proliferating have a low rate of apoptosis whereby cells which are not proliferating 
have a reduced survival. Thus strengthening the significance of CD40L in the ex vivo 
culture of MCL cells.  
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When the cases were analysed based on our clinical phenotypic description it was 
clear that the indolent cases, those which could be considered most like CLL, have very 
low apoptotic rates and show little benefit of the addition of CD40L. The proliferative 
/aggressive cases however have much higher intrinsic rates of apoptosis, not surprising 
maybe, but in these cases CD40L significantly reduces apoptosis.  One possible 
explanation for the association between higher rates of apoptosis in the proliferative 
cases is the accumulation of additional mutations affecting cell survival in cells from 
subjects with particularly aggressive disease.  Additional mutations affecting survival 
pathways are well described in association with blastoid MCL.5,95 
For proliferation, indolent and proliferative/aggressive cases appear to respond 
similarly to the effect of CD40L, equally promoting proliferation, perhaps indicating a 
continued dependence on external signalling through the CD40 synapse for cell 
division in MCL. 
In addition to the effect of CD40L, the presence of IL-4 appears to significantly enhance 
survival of primary MCL cells ex vivo and is consistent with other reports in the 
literature which suggest a protective effect of IL-4 on B lymphocytes, probably due to 
the activation of multiple intracellular pathways, including the upregulation of pro-
survival BCL-2 protein transcription.60,61  This is, however, an extrapolation from other 
B-cell lymphomas. However, no obvious associative effect could be demonstrated 
according to the presence of CD40L to either proliferation or survival.  This is 
interesting as other studies have demonstrated an augmented effect of IL-4 and CD40L 
on proliferation in primary MCL cells.49 
The effects of TLR9-L on the ex vivo culture of MCL cells demonstrated some 
interesting results. The presence of TLR9-L appeared to significantly impair survival of 
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primary MCL cells during ex vivo culture in both CD40-L positive and negative 
environments, with a greater effect observed in the CD40L-NT microenvironment, 
suggesting that CD40L can in some way protect the cells against TLR9 effects. With 
respect to proliferation of primary MCLs ex vivo, TLR9-L appears to significantly 
improve proliferation in the CD40L-negative environment (although the effect is small) 
and is an observation  in contrast to other published studies of the effects of TLR-9-L 
which has been shown to have a synergistic effect with CD40L on proliferation.52,55,56  
However on pooled analysis no significant effect on proliferation could be 
demonstrated. 
A comparison of human stroma to murine CD40L –T stroma was assessed as it was 
anticipated that human stroma might better support the ex vivo culture of MCL cells. 
Although preliminary and over a short culture period (due to technical difficulties) 
survival does not appear to be altered by culture with human stroma compared with 
CD40L positive murine stroma.  However, in the cells from the more proliferative, 
clinically aggressive case, (MCL02), proliferation rates appear to be higher in the 
human-stroma cultured cells when IL-4 is added (Figure 3.13).  Repeating this 
experiment with more primary MCL cases, assessing CD40L expression in the human 
stroma and culturing over a longer time period may help to establish if this is a 
significant pattern. 
Given the results seen with CD40L microscopic examination was performed to 
determine whether any changes in morphology could be seen. Microscopic 
examination of MCL cells in ex vivo culture revealed a non-significant tendency 
towards cell clustering in the CD40L-T microenvironment.  It is already established that 
cell to cell contact is a requirement for survival and proliferation in other related 
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haematological malignancies, such as CLL.100  Therefore cell clustering could potentially 
be a microscopic indicator of increased survival and proliferation although further 
work is need with greater numbers to establish the significance of this observation in 
MCL. 
Overall this chapter has shown that CD40L- T murine stromal cells are able to support 
the survival and proliferation of MCL cells ex vivo with a suggestion that cellular 
behaviour following CD40L is affected with cluster formation implying an additional 
role for adhesion. This 2D model of the microenvironment seems to have a greater 
support on aggressive proliferative cases. Not surprisingly there is marked 
heterogeneity between cases. The low proliferative nature of these cases was 
disappointing, surprising and requires further development but the tools and findings 








Classical mantle cell lymphoma usually presents with generalised adenopathies, often 
there is also bone marrow and gastro-intestinal tract involvement.4,101  A purely 
leukaemic presentation is relatively uncommon, but up to 52% of cases have a 
lymphocyte count ≥5 x 109/L and one case series of 48 patients circulating mantle cells 
were found in 92% when analysed by flow-cytometry, including 17% of cases with no 
morphological involvement detected.102 Several studies have also identified a distinct 
subtype of MCL with leukaemic, non-nodal disease often associated with 
splenomegaly.103,104  From a clinical perspective, it has been suggested that cases with 
a non-nodal phenotype characterised by leukaemic involvement and splenomegaly 
with minimal lymphadenopathies have a more indolent course.10,103,104 
The pathobiology of the leukaemic subtype and the reasons for its more indolent 
clinical course remain unclear.  Several studies have revealed distinct genetic and 
molecular patterns, but a single unifying pattern is yet to be identified.  Lower rates of 
unmutated IgVH genes have been observed in some leukaemic case series, indicating 
experience of the germinal centre.103,105,106  Other studies have shown leukaemic MCL 
cases to have a distinct genetic signature from nodal cases with patterns such as 
8p21.3 deletion and gain of 8q24.1 at the MYC locus.10  Others have demonstrated 
down modulation of genes involved in cell projection through actin cytoskeleton 
organisation and cell adhesion / tumour invasion molecule expression, suggesting that 
leukaemic MCL cells lack tumour invasion properties that might contribute to the 
absence of nodal involvement and to a less aggressive clinical course.107  Other 
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investigators have identified a subset of patients with indolent disease and a low 
signature of SOX11, HDGFRP3 and DBN1 genes.9 
Whatever the reason for differences in invasive MCL subtypes, it is logical that the 
persistence of disease and early relapses characteristic of nodal MCL indicate that 
neoplastic cells in vivo must be partly protected from the effect of 
immunochemotherapy by their tissue microenvironment. One of the reasons for this 
relative resistance to therapy could be the ability of MCL cells to enter and colonise 
extra-nodal sites, such as the bone marrow where the microenvironment has proven 
protective effects.4  In vitro studies have demonstrated that adhesion to cultured 
stromal cell layers can protect malignant B cells from apoptosis induced by 
chemotherapy.  Equally, blockade of the BCR, which down-regulates expression of 
receptors such as CD184 (CXCR4), which promotes entry of MCL cells to bone marrow 
and nodal stromal cells, has been shown to reverses these protective effects.28,30,67 
In vivo, evidence of a role of cellular adhesion in MCL comes from observations of the 
effects of BCR blockade within clinical trials.  Peripheral blood lymphocytosis is a 
characteristic feature of therapy with the BTK-inhibitor ibrutinib, which blocks the BCR 
receptor pathway downstream of the surface receptor.  Patients receiving ibrutinib 
experience a transient increase in peripheral absolute lymphocyte counts which, in the 
phase II study of ibrutinib for relapsed MCL, peaked at a median of 4 weeks of 
treatment and gradually decreases over subsequent months.64  This was associated 
with a reduction in the expression of the chemokine receptor molecule, CD184, and a 
fall in the plasma chemokines, CCL22, CCL4 and CXCL14.65 
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This rise in lymphocytes in the blood appears to be particularly marked in patients with 
disease involving the bone marrow, particularly those with ≥30% marrow 
involvement.66 
Therefore it is hypothesised that expression of CAMs and chemokine receptors, such 
as CD184, play an important role in protecting MCL cells from therapy by maintaining 
malignant cells within the relative sanctuary of sites such as the bone marrow, leading 
to residual disease and early relapse after treatment.  Therefore mobilisation of MCL 
cells away from sites of protection from chemotherapy or immune-surveillance could 
represent a therapeutic target. 
However, the expression of CAMs by primary MCL cells is not well characterised in the 
literature, particularly in relation to the effect of stromal-cell co-culture and the effects 
of drugs.  This chapter aims to characterise the surface adhesion molecules profile of a 
series of primary MCL cases both on MCL cells from the peripheral blood and bone 
marrow with the aim of identifying any common adhesion receptors or patterns of 
receptor expression which may be candidates for future study. 
A more detailed review of the CAMs involved in B-NHL is given in the introductory 
chapter (1.3).  Briefly, CAMs are groups of ligands and receptors involved particularly in 
cell homing and migration.  Their expression on the cell surface is dynamic and 
dependent on external signals such as cytokine release.  This process of dynamic 
expression allows the cells of the normal immune system to circulate freely as non-
adherent cells in the blood and lymph, patrolling the body for infectious organisms and 
congregate as adherent cells in lymphoid organs as well as crossing endothelial and 
basement membrane barriers to aggregate at sites of infection.  A brief overview of 
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the CAMs considered important in B-NHL and analysed in primary MCL cells in this 




Molecule Description Ligand 
CD11a 
 
An integrin alpha L chain which combines with the beta 2 chain (CD18) to form the integrin 
lymphocyte function associated antigen, LFA-1.  Expressed on all leukocytes.  Involved in 
leukocyte extravasation, antigen presentation and T-lymphocyte alloantigen-induced 
proliferation.75  Reportedly expressed on MCL and marginal zone NHL cells (MZL) more than 




CD11c CD11c combines with integrin beta 2 subunit (CD18) to form Mac-1, expressed mainly on 
myeloid lineage cells and involved in phagocytosis of infectious agents; transendothelial 
migration of phagocytes and activation of neutrophils and monocytes.  High rates of splenic 
involvement in CLL patients are associated with strong CD11c expression.  Also  over 
expressed in hairy cell leukaemia (HCL) and splenic marginal zone lymphoma, but conflicting 









The integrin alpha-4 subunit (CD49d) combines with B1 subunit (CD29) to form VLA-4.  VLA-4 
(CD49d/CD29) is expressed on resting lymphocytes and monocytes and functions as both a 
matrix and cell receptor.  As a matrix receptor it binds to fibronectin at a different site than that 
recognised by VLA-5 (CD49e).  As a cell receptor, it binds to VCAM-1, a member of the 
immunoglobulin superfamily.  VCAM-1 is induced by inflammatory mediators on endothelium.  
CD49d is reportedly expressed on MCL and MZL cells more than CLL and thought to facilitate 





A fibronectin receptor, integrin alpha-5 combines with beta 1 to form CD49e which binds the 




A member of the immunoglobulin superfamily, normally with a lower expression in peripheral 
blood compared with lymph node mononuclear cells.  Lower expression has been 
demonstrated to correlate with leukaemic / disseminated disease, bone marrow and 




A member of the immunoglobulin superfamily expressed on antigen presenting cells (APCs), 
particularly macrophages, which binds to LFA-2 on T cells and reinforces adhesion between T 
cells and APCs.80  It is expressed on haematopoietic and non-haematopoietic cells and 





A single chain transmembrane protein found in granulocytes, monocytes and most 
lymphocytes.  Low affinity binding facilitates the capture, rolling and slow-rolling steps of 
leukocyte recruitment to the region of inflammation which in turn is followed by firm adhesion 





A G-protein-coupled transmembrane receptor expressed primarily on activated T lymphocytes 
and Natural Killer (NK) cells, preferentially on Th1 T-cells.  It binds to CXCL-9, -10 and -11 
through which it is able to elicit influx of intracellular calcium and activate phosphoinositide 3-
kinase as well as mitogen-activated protein kinase (MAPK).  CXC ligands are IFN-induced and 
produced locally in the tissues. 
CXCL9, 10 and 11 
CD184 
(CXCR4) 
High level expression of CD184 has been demonstrated on primary MCLs.  It is down-regulated 
by BTK-inhibition.65  Stromal cells in secondary lymphoid tissues constitutively express its 
corresponding chemokine CXCL12, providing guidance for B cell positioning within distinct 
nodal compartments.   CXCL12 has been demonstrated to induce actin polymerisation in MCL 
cells and induce a chemotactic response which can be inhibited by blocking the receptor 




A G-protein-coupled transmembrane receptor. High level expression has been demonstrated 
on primary MCLs together with CD184 and VLA-4 whereas expression of CD183 and CD62L is 
largely negative in some reports.28  It is thought to be used by MCL cells to disseminate by 
interaction, trafficking and homing to secondary lymphoid tissues via ligands CXCL12 and 
CXCL13.  The MCL cell line, Granta 519, displays low levels of CD184 and is negative for CD185 
(possibly due to Epstein Barr virus-infection causing down-regulation).   
Ligands for CD184, 5 and VLA-4 may trigger the pseudoemperipolesis phenomenon.33 
CXCL12, 13 
Table 4-1.  A summary of the adhesion molecules and their respective ligands which have been 




 Summary of Experimental Methods 
4.2
A clinical and biological summary of the MCL subjects is included in Table 4-2. 
Fluorescence associated cell sorting (FACS) was used to profile the expression of a 
series of CAMs on a panel of cases of primary MCL.  Peripheral blood mononuclear 
cells or marrow mononuclear cells were harvested from consenting subjects with MCL 
and ficoll-separated from blood and plasma as previously described (Methods 2.7).  A 
panel of ten cellular adhesion molecules were chosen to study in these subjects (see 
Table 4-3) These molecules were chosen based on previously published data on the 
relevant surface adhesion molecules in B-NHL and more specifically, previously 
published profiles of primary MCL surface adhesion molecules.33,74,108–111  
For each case, mononuclear cells were resuspended in warmed, complete RPMI 
medium and the cell density was adjusted to 1x106/100µL in accordance with the 
recommendations of the manufacturers of the monoclonal antibodies used for flow 
cytometry.  Ten microlitres of FITC- or APC-conjugated mouse anti-human CD5 and 
CD19 mononuclear antibody were added to 12 labelled, 1.5mL Eppendorf tubes.  To 
the first 10 tubes, 10µL of PE-conjugated, mouse anti-human monoclonal antibody 
specific to individual cellular adhesion molecules was added.  To two tubes, 10µL of 
appropriate isotype control antibodies were added and one tube was labelled as an 
unstained control with no antibodies.  A list of the monoclonal antibodies used is 
shown in Table 4-3. To each labelled tube, 100µL of cell suspension was added and the 
tubes were gently vortexed to mix before being incubated at room temperature in the 
dark for 20 minutes.  Three hundred microlitres of staining buffer (0.5% BSA in PBS) 
was added to each tube before analysis by FACS. 
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Within the chapter the expression of CAMs was analysed after co-culture with CD40L-T 
or CD40L-NT murine stromal cells. In these experiments MCL PBMCs were suspended 
in complete RPMI medium and seeded at a density of 5x106 cells per mL on confluent 
monolayers of CD40L -T and CD40L-NT murine stromal cells (pre-irradiated with 15Gy) 
and incubated (5% CO2, 37
oC) for 6 days.  100µL samples were removed at baseline, 24 
hours, 3 days and 6 days, incubated with PE-conjugated mouse-anti-human 
monoclonal antibodies against the target CAMs or corresponding isotype control 
before analysis by flow cytometry. 
The expression level of CAM or other molecules was assessed on primary MCL cells 
following treatment with the BTK inhibitor ibrutinib when co-cultured on human bone 
marrow stroma. For these experiments human stromal cells derived under ethical 
permission from aspirated bone marrow sample, excess to clinical need were ficoll-
separated from blood and plasma and cultured in 25cm2 vented flasks in modified 
IMDM long-term culture medium until reaching confluence as described in the 
materials and methods chapter (2.7.3).  The monolayer was then loosened by 
trypsinisation, washed and resuspended in modified IMDM before seeding wells of a 
standard 24 well plate.  Once confluence had been achieved, the wells were washed 
and seeded with primary MCL cells in complete RPMI medium and seeded at a density 
of 5x106 cells per mL before being returned to the incubator.  After 24 hours culture, 
cells were treated with 100nm ibrutinib (Selleckchem, Houston, Texas, USA), control 
wells were treated with the same volume of DMSO vehicle control.  The MCL cell 
suspension was sampled at baseline, 24 and 56 hours, co-labelled for CD5 / 19 and the 




4.2.1 Deriving the Fluorescent Intensity Ratios 
An Accuri C6 flow cytometer and Accuri CFlow Plus software (BD Biosciences) was used 
for analysis.  Wherever possible, 10,000 events were collected per tube to obtain the 
median fluorescence intensity (FI) value for each CAM of the population of CD5/CD19 
positive mononuclear cells (MCL cells) within the lymphocyte gate as defined by the 
forward / side scatter plot. The median FI value was used instead of the mean because 
the distribution of peaks for the fluorescence intensity were not always evenly 
distributed, thus skewing the mean value.  The median was therefore deemed to be a 
more reliable estimate of fluorescent intensity.  In accordance with other published 
data on CAMs in MCL, the median fluorescence intensity ratio (MFIR) was calculated 
by dividing the mean fluorescence intensity of the analysed marker by the median 











Prior Treatment Indolent / 
aggressive 
disease 
MCL04 65 f (t11;14)+ CD19+ Leukaemic, MCL; 
WCC 280x109/L 
None Indolent 
MCL07 65 m t(11;14)+ 
cyclin D1+ 
CD19+ Leukaemic MCL; 
WCC 30x109/L 
None Indolent 
MCL13 64 m cyclin D1; 
t(11;14) 
CD5/19+ Leukaemic; WCC 
152x109/L 
None Indolent 
MCL14 62 m cyclin D1; 
t(11;14) 
CD5/19+ Leukaemic; Stage 
II  
Local radiotherapy to 
eye 
Indolent 
MCL01 66 f t(11;14)+ CD5/19+ Stage IV, nodal; 
WCC 300x109/L 
None Aggressive 
MCL02 68 m (t11;14)+ 
cyclin D1 










MCL11 60 f cyclin D1+ CD5/19+ Stage IV, nodal Immunochemotherapy Aggressive 
MCL15 70 f cyclin D1; 
t(11;14) 
CD5/19+ Stage III, nodal None Aggressive 
MCL16 70 f cyclin D1; 
t(11;14) 
CD5/19+ Stage IV, nodal None Aggressive 
MCL17 74 m cyclin D1; 
t(11;14) 
CD5/19+ Stage IV, nodal Immunochemotherapy Aggressive 
MCL18 91 m cyclin D1; 
t(11;14) 
CD5/19+ Stage IV, nodal Immunochemotherapy Aggressive 
MCL19 71 m cyclin D1; 
t(11;14) 
CD5/19+ stage IV, nodal Immunochemotherapy Aggressive 
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MCL20 63 m cyclin D1; 
t(11;14) 
CD5/19+ stage III, nodal  Immunochemotherapy Aggressive 
MCL21 70 m cyclin D1; 
t(11;14) 
CD5/19+ stage III, nodal Immunochemotherapy Aggressive 
MCL22 60 m cyclin D1; 
t(11;14) 
CD5/19+ stage IV, nodal Multiple lines including 
BTK-inhibitor 
Aggressive 
MCL23 60 m cyclin D1; 
t(11;14) 
CD5/19+ stage IV, nodal Allogeneic Stem cell 
transplant 
Aggressive 
MCL24 77 f cyclin D1; 
t(11;14) 
CD5/19+ stage III, nodal None Aggressive 
MCL10 54 m cyclin D1; 
t(11;14) 
CD5/19+ stage IV; nodal Immunochemotherapy Aggressive 
Table 4-2  Primary MCL Subjects’ Clinical and Biological Characteristics.  MCL subject 
demographics, diagnostic molecular data, immunophenotyping of PBMCs and clinical disease 
summary of cases of MCL from which PBMCs and / or bone marrow MCL cells were obtained for 
use in adhesion profile experiments.  
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CD19 mouse anti-human IgG1k 555412 BD Biosciences  FITC 10 
CD5  mouse anti-human IgG1k 555355 BD Biosciences  APC 10 
CD3  mouse anti-human IgG2ak 555342 BD Biosciences  APC 10 
CD11c mouse anti-human  IgG1k 555392 BD Biosciences  PE 10 
CD62L (L-selectin) mouse anti-human IgG1k 555544 BD Biosciences  PE 10 
CD49d (Integrin α4 chain) mouse anti-human 
IgG1k 
555503 BD Biosciences  PE 10 
CD49e (Integrin α5 chain) mouse anti-human 
IgG1k 
555617 BD Biosciences  PE 10 
CD11a (LFA 1α; ITGAL) mouse anti-human 
IgG1k 
555384 BD Biosciences  PE 10 
CD58 (LFA-3) mouse anti-human IgG2ak 555921 BD Biosciences  PE 10 
CD54 (ICAM-1) mouse anti-human IgG1k 555511 BD Biosciences  PE 10 
CD183 (CXCR3) mouse anti-human IgG1k 557185 BD Biosciences  PE 10 
CD184 ( CXCR4) mouse anti-human IgG2ak 555974 BD Biosciences  PE 10 
CD185 (CXCR5) mouse anti-human IgG2b FAB190P-
100 
R & D Systems PE 10 
Mouse anti-human IgG1k isotype control 556026 BD Biosciences  FITC 10 
Mouse anti-human IgG1k isotype control 559320 BD Biosciences  PE 10 
Mouse anti-human IgG1k isotype control 555751 BD Biosciences  APC 10 
Mouse anti-human IgG2aκ isotype Control 555574 BD Biosciences  PE 10 
Table 4-3  Fluorescein-conjugated human monoclonal antibodies employed in labelling and 
adhesion experiments including isotype controls.   FITC - fluorescein isothiocyanate; PE - 
phycoerythrin; APC –allophycocyanin 
 
 Baseline expression of cellular adhesion molecules on MCL cells 
4.3
The expression profile of a panel of 10 cellular adhesion molecules was assessed on 
the neoplastic lymphocytes taken from peripheral blood of 17 MCL cases (Table 4-4).  
A further assessment of adhesion molecule expression of the neoplastic lymphocytes 
taken from bone marrow was performed in 4 MCL cases (Table 4-5), in three cases 
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peripheral blood, marrow samples were matched.  Patient MCL10 had no peripheral 
lymphocytosis at the time of marrow sampling and is therefore unmatched. 
These data show the wide variation in adhesion molecule expression between cases.  
The mean values of the pooled median fluorescence intensity ratios for both 
peripheral blood and bone marrow primary MCL cells are shown in Figure 4-1. The 
highest expressions of CAMs are CD11a, CD49d and CD54 with low level expression 
observed in the rest of the panel.  Comparison of the CAM expression on the bone 
marrow neoplastic lymphocytes shows a greater expression of integrin molecules, 
particularly CD11a and not surprisingly CD54 and CD183 (CXCR3).  Comparison of the 
overall expression of adhesion molecules (mean expression for each molecule in all 
cases) between peripheral blood MCL cells and bone marrow cells showed a significant 
difference (Wilcoxon matched-pairs signed rank test p=0.0098) (Figure 4-2).  However 
as the number of paired samples were only 3, so the comparison of each individual 
adhesion molecule between blood and marrow was deemed unsuitable for statistical 
comparison. 
Further analysis of the adhesion molecule expression depending on the clinical and 
biological features of the cases was assessed and divided into leukaemic (indolent) or 
nodal (aggressive) disease.  The nodal cases are denoted in Table 4-4 shaded red, and 
the leukaemic cases shaded green for ease of interpretation. The mean values of the 
pooled median fluorescence intensity ratios are shown in Figure 4-3.  Cells from 
subjects with nodal disease appear to demonstrate a higher expression of CD11a 
compared with cells from leukaemic MCL cases and when the mean median 
fluorescence intensity ratio for each adhesion molecules was compared for leukaemic 
or nodal cases (Figure 4-4) there was a significant difference in the expression profiles 
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(Wilcoxon matched-pairs signed rank test p=0.002).  However, when nodal and 
leukaemic MCL fluorescence intensity was compared for each adhesion molecule using 
a Mann Whitney test, no significant difference was observed (Table 4-6); this may 
reflect the low number of leukaemic cases.   
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Subject CD11a CD11c CD49d CD49e CD54 CD58 CD62L CD183 CD184 CD185 
MCL01 3.7 2.6 11.7 2.7 5.4 0.8 1.9 4.4 2.4 3.3 
MCL02 5.4 3.0 6.4 2.9 9.0 0.9 1.9 5.2 4.2 14.4 
MCL24 39.2 3.6 23.3 4.4 6.6 2.2 4.9 25.2 1.1 2.6 
MCL17 225.0 12.8 40.9 58.0 23.5 31.3 8.9 32.7 5.7 0.2 
MCL15 22.4 4.0 21.1 3.9 8.0 3.1 6.7 6.4 3.3 10.7 
MCL16 16.7 3.7 15.5 3.7 13.2 1.7 3.2 6.4 11.0 6.4 
MCL18 3.4 2.4 6.2 2.2 11.5 2.2 2.1 4.3 2.4 10.3 
MCL19 152.4 2.6 19.6 5.6 5.3 6.3 1.5 4.2 0.5 1.0 
MCL20 14.8 3.5 17.0 3.6 24.5 2.3 14.8 4.9 3.0 9.2 
MCL11 10.0 3.7 10.5 4.4 17.3 2.0 3.5 7.2 4.4 10.4 
MCL21 11.4 2.6 11.0 3.3 13.4 1.3 1.2 6.3 1.6 2.2 
MCL22 131.0 3.1 17.3 3.0 15.4 2.5 14.1 7.9 0.4 1.1 
MCL23 5.0 3.5 12.8 3.8 7.1 1.5 2.1 5.1 7.5 3.5 
MCL13 4.1 2.8 8.1 2.9 6.4 1.2 2.3 5.1 6.1 3.4 
MCL14 58.2 3.2 14.2 4.5 6.3 1.8 5.0 4.8 0.9 1.1 
MCL07 20.4 3.6 19.3 4.2 6.7 2.9 3.5 6.4 1.9 6.0 
MCL04 6.7 3.8 5.8 3.7 6.3 1.4 2.1 5.0 1.4 4.1 
Mean 42.9 3.8 15.3 6.9 10.9 3.8 4.7 8.3 3.4 5.3 
Table 4-4  The median fluorescence intensity ratios (analysed marker/isotype control) for 10 
adhesion molecules of peripheral blood MCL cells from 17 subjects. Nodal cases shaded red, 
Leukaemic (indolent) cases are shaded green. (Units are arbitrary).   
 
Subject CD11a CD11c CD49d CD49e CD54 CD58 CD62L CD183 CD184 CD185 
MCL10 3.9 2.2 2.7 2.5 8.0 1.1 7.0 1.4 2.0 1.2 
MCL17 310.8 14.7 67.6 60.0 34.8 29.2 13.0 25.4 6.4 0.6 
MCL21 20.4 1.2 15.0 27.9 7.2 3.0 1.4 24.6 1.1 7.2 
MCL18 3.7 2.7 6.8 2.9 11.0 2.4 2.1 4.3 2.0 9.5 
Mean  84.7 5.2 23.0 23.3 15.3 8.9 5.9 13.9 2.9 4.6 
Table 4-5  The median fluorescence intensity ratios (analysed marker/isotype control) for 10 
adhesion molecules of bone marrow MCL cells from 4 subjects. All are nodal (aggressive) cases 











































































































































Figure 4.1.  Comparison of adhesion marker expression on MCL lymphocytes taken from blood 
and bone marrow. The mean (bars indicate standard error of the mean) of the pooled median 
fluorescence intensity ratios for each analysed cellular adhesion molecular marker is displayed  for 
17 cases of primary MCL peripheral blood mononulear cells (left) and 4 cases of bone marrow MCL 
cells ().   
 
 
Figure 4.2 Comparison of adhesion molecule profile on MCL cells from peripheral blood vs bone 
marrow.  The mean median FI ratio for all adhesion molecules for either neoplastic cells in 
peripheral blood or bone marrow are compared using a Wilcoxon matched-pairs signed rank test 
and shows significance (p=0.0098).  










































































































































































Figure 4.3 Assessment of adhesion marker expression on peripheral blood MCL lymphocytes 
based on clinical phenotype.  The mean (with SEM) of the pooled median fluorescence intensity 
ratios for each analysed cellular adhesion molecular marker is displayed  for 17 cases of primary 




Figure 4.4 Comparison of adhesion molecule profile on leukaemic vs nodal cases of MCL.  The 
mean median FI ratios for all adhesion molecules considered together from either leukaemic or 
nodal cases. All were higher on nodal cases with a significant difference (Wilcoxon matched-pairs 














































































Mann Whitney test 





0.9549 0.6104 0.5335 0.6919 
Exact or approximate P 
value? 
Gaussian Approximation 
P value summary ns ns ns ns ns ns ns ns ns ns 
Are medians signif. 
different? (P < 0.05) 
No No No No No No No No No No 
One- or two-tailed P value? Two-tailed 






















Mann-Whitney U 24 22 17 23 9 20 25 21 20 22 
Table 4-6  Comparison of expression of cellular adhesion molecules between nodal and 
leukaemic cases of MCL:  No significant differences between expressions of individual adhesion 
molecules were observed between the two groups (Two-tailed Mann Whitney test). 
 
 The expression of surface adhesion molecules after co-culture of 4.4
with stromal cells 
Having obtained a profile of the baseline expression of CAMs in primary MCL cells, it 
was considered important to explore the effect of the MCL microenvironment on 
surface adhesion molecule expression.  Therefore an experiment was designed in 
which MCL PBMCs from 4 subjects (3 subjects with a nodal and aggressive clinical 
phenotype (MCL03, MCL08 and MCL23) and 1 subject with a leukaemic and indolent 
clinical phenotype (MCL04) were co-cultured with murine stromal cells for 6 days with 
surface adhesion molecular profiling at set points within the time period.  Both CD40L-




When analysed over time, the only cellular adhesion molecules that changed  were 
CD184  which showed a pattern of rising expression with CD40L-T and NT stroma 
during culture, but more significantly on CD40L-NT; and CD54 which increased in 
expression over 3 days  in the MCL cases co-cultures on CD40L-T stroma ( Figure 4-5 ). 
When adhesion molecule expression of cases was compared between CD40L-T and 
CD40L-NT stroma both CD184 and CD54 show significance (Figure 4-6). The mean 
expression of CD184 when analysed over all time points is significantly lower in the 
presence of CD40L (paired Wilcoxon signed rank sum p=0.0137) and CD54 significantly 






Figure 4.5 Patterns of expression of cellular adhesion molecules co-cultured on CD40L-T and 
CD40L-NT stroma. CD184 expression was upregulated after 24 hours by co-culture with stromal 
cells showing reducing expression over prolonged culture (A and B). CD54 upregulation requires 
the presence of CD40-L (B). All other adhesion markers show no change in expression levels over 
time when cultured on either CD40L-NT ( C) or CD40L-T (D) stroma. Primary MCL peripheral blood 
mononuclear cells co-cultured on CD40-L-NT ( A,C) and CD40L-T (B,D) stroma for 6 days.  Cultures 
were sampled and analysed for expression of CAMs at baseline, 24 hours, 3 days and 6 days. The 
mean (with SEM) of the pooled median fluorescence intensity ratios from 4 patients for each 
analysed cellular adhesion molecular marker is displayed. 
 
Figure 4.6 Comparison of adhesion molecule expression in the presence of CD40L. Expression of 
both CD184 (CXCR4) and CD54 differ significantly in the presence of CD40L. CD184 MFIR (pooled 
mean from 4 patients) is significantly lower at all time points in the presence of CD40L ( paired 
Wilcoxon signed rank sum  p=0.0137) and CD54 significantly higher (paired Wilcoxon signed rank 
sum p=0.0005).  
CD40L-NT






















































































































































































































 The effect of BTK-inhibition on cellular adhesion molecules 
4.5
Ibrutinib is an orally active small molecule which binds irreversibly to the cysteine 
residue (C481) at the activating phosphorylation site of Bruton’s tyrosine kinase (BTK), 
leading to irreversible inactivation and disruption of the signalling pathway from the 
BCR to the nucleus.112,113  The BCR pathway plays a crucial role in cell division, 
differentiation, homing and survival and is constitutively activated in MCL cells.114,115 
Inhibiting cell signaling via the BCR not only impairs proliferation and attenuates cell 
survival, but also impairs the ability of MCL cells to home to and remain in their normal 
protective niche in lymphoid tissue or bone-marrow.66  
As the pattern of adhesion molecule expression had not previously been studied in 
detail in MCL we undertook a comparison of adhesion molecule expression on 
neoplastic lymphocytes from a nodal and leukaemia MCL case when co-cultured on 
human stroma and following in-vitro treatment with ibrutinib. In this part of the study, 
primary MCL cells from subject MCL15 (leukaemic) and MCL02 (nodal) were cultured 
on human stromal cells and treated after 24 hours with 100nm ibrutinib. The adhesion 
molecule profile of the MCL cells was assessed by flow cytometry, as before, at 
baseline, 24 hours and 56 hours with and without treatment with ibrutinib (Figure 4-7).  
There is baseline variation in the adhesion molecule profile between cases.  After 24 
hours the profiles are similar but with prolonged co-culture on a stromal layer the 
leukaemic case shows increased expression of CD62L (L-selectin) and CD184 (CXCR4) 
compared to the nodal case.  Although ibrutinib treatment results in very little change 
in the expression profile there is a trend in fact for the expression levels to increase in 
the leukaemic case compared with the nodal case which, changes may be more 
apparent with a longer ibrutinib treatment period. Numbers of cases in this 
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experiment are too low, for statistical comparison but it is of interest that there are 
differences detected between leukaemic, indolent cases and nodal, aggressive cases 


























































































































































Figure 4.7  Co-culture of primary MCL cells with human stromal cell support.  Expression profiles 
between cases show variation with a marked elevation of expression of CD62L and CD184 seen 
with prolonged culture in the leukaemia case.  The expression profile changes little with ibrutinib 
treatment. Human primary MCL cells were cultured on human bone marrow stromal cells for 56 
hours with the addition of 100nM of ibrutinib after 24 hours.  Cultures were sampled at baseline, 





The profile of CAMs on PBMCs has been performed in a large number (17) of MCL 
patients including both aggressive (nodal) and indolent (leukaemic) cases with a 
comparison with bone marrow where possible.  This is a unique and extensive profile 
of CAMs based on the known literature.  It has demonstrated extensive inter-patient 
variability in the expression profile of CAMs. 
In this series, the most highly expressed CAMs in peripheral blood are CD11a, CD49d 
and CD54 which is consistent with previously published case series of adhesion 
molecule profiles of B-cell non-Hodgkin’s lymphomas in the leukemic phase, although 
the panel of markers assessed differed slightly.76  In this published study, significantly 
greater expression of CD49d was observed than that seen in CLL samples with no 
significant differences in expression of CD11a or CD54. 
CD11a, which is highly expressed in this series, forms the alpha L chain of integrin 
molecule LFA-1 and is universally expressed on leucocytes.  It is involved in 
extravasation, antigen presentation and T-lymphocyte alloantigen-induced 
proliferation.75  It is also thought to facilitate lymphocyte adhesion to FDCs via ICAMs 
(including CD54) within the lymph node.76   Variations in expression are well 
recognised in NHL subtypes.110  Low level expression of CD11a has been demonstrated 
in CLL whereas higher levels are described in its nodal counterpart, small lymphocytic 
lymphoma (SLL) and other predominantly nodal diseases such as diffuse large B-cell 
lymphoma (DLBCL).116  
CD49d is the α4 subunit of the integrin heterodimer α4β1 (VLA-4) and is expressed on 
resting lymphocytes and monocytes and functions as both a matrix and cellular 
receptor.  As a matrix receptor it binds to fibronectin.  As a cellular receptor, it binds to 
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VCAM-1, a member of the immunoglobulin superfamily.  VCAM-1 is induced by 
inflammatory mediators on endothelium.  Together with CD11a, CD49d  is thought to 
facilitate lymph node adhesion to follicular dendritic cells (FDCs) via VCAM-1.76,108,109  
Interestingly CD49d can differentiate indolent and aggressive subgroups in CLL,117 
however no significant difference can be seen by clinical phenotype in this case series. 
CD54 (ICAM-1) is a member of the immunoglobulin superfamily and expressed on 
APCs.  It is involved in reinforcing adhesion between T-cells and APCs 80 . Expression on 
fibroblasts can be regulated by CD40L.118 
One of the aims of this study was to identify differences in expression of CAMs 
between blood and marrow MCL cells.  However, the bone marrow sample acquisition 
was low (4) and therefore comparison in the expression of individual markers showed 
no statistical differences.  However when the profiles were pooled and analysed they 
were statistical different. In particular there was higher expression of CD11a, CD54 
and, not surprisingly, CD183 (CXCR3) in the bone marrow MCL cells.   Further study of 
marrow adhesion molecule expression is therefore warranted.  This is a particularly 
important correlation to study, given the relative sanctuary which MCL cells enjoy in 
the bone marrow. 
Comparison of CAM expression between leukaemic (indolent) and nodal (aggressive) 
MCL cells also highlighted important differences which could be explored in further 
studies.  Although no individual marker differed between groups, again perhaps 
because of the low number of indolent cases, the pooled profiles between the groups 
differed significantly. Again CD11a and CD54 were noticeably higher in the nodal cases.  
This may be significant in that CD11a is thought to facilitate lymph node adhesion via 
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ICAMs 1-3 and could be important in maintaining a nodal distribution of MCL cells in 
this subgroup. 
If these differences were confirmed when analysed in a greater number of samples, it 
could be explored as a biomarker to predict need for treatment. 
The observation in Chapter 3 that cells from subjects with more proliferative, nodal 
disease appear to form clusters when cultured ex-vivo (Figures 3.1, 3.14 and 3.25) may 
relate to the increased expression of CD11a and CD54 which may be required for 
homotypic cellular adhesion and cluster formation in MCL. 
The assessment of CD40L on the CAM expression profile was analysed in 4 cases of 
MCL. This showed that the pattern of CXCR4 expression, the receptor ligand for the 
chemokine CXCL12 found in the microenvironment, was similar between CD40L-T and 
NT microenvironments.  Expression of CXCR4 rose acutely in both conditions after 24 
hours of culture. However when compared at all time points, the level of CXCR4 
expression was significantly higher in cells cultured with the CD40L-NT stroma.  
Expression of CD54, however, was significantly higher on CD40L-transfected stroma 
demonstrating a dependency on CD40L.   No other adhesion molecules differed 
significantly either over time or with CD40L. 
Stromal cells in secondary lymphoid tissues constitutively express chemokines such as 
CXCL12 and 13, the corresponding ligands for CD184, providing guidance for B cell 
positioning within distinct nodal compartments.   CXCL12 and 13 have been 
demonstrated to induce actin polymerisation in MCL cells and induce a chemotactic 
response which can be inhibited by blocking the receptor CD184, indicating an 
important role in migration and localisation.33  High level expression of CD184 has 
been demonstrated on primary MCLs in other published studies together with a down-
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regulation with ibrutinib exposure.65  Interestingly, the pooled median fluorescence 
intensity ratio for CD184 is higher for the nodal cases (17.4) than the leukaemic case 
(14.7) after co-culture with stroma, suggesting a dependence on CD184 in nodal cases 
within the microenvironment. 
There is an associative link between interference of CAM expression and BCR blockade 
with ibrutinib in MCL cells.  In vivo, ibrutinib treatment is associated with a reduction in 
the expression of CD184, CD38 and Ki-67 as well as a significant reduction in plasma 
chemokines CCL22, CCL4 and CXCL13.65  This shift in CAM expression manifests itself 
clinically as a rapid reduction in tissue burden in association with a marked peripheral 
lymphocytosis, which is dependent on continuous administration of the drug.66,112,119–
121  In vitro, blockade of the BCR signal of primary MCL cells with ibrutinib impairs 
adhesion to stromal cell layers and reverses the protective effect of stromal cells on 
MCL cells.67  It has also been demonstrated that direct blockade of CD184 and VLA-4 
with receptor-specific antibodies impairs adhesion to stroma and cell survival in MCLs 
ex vivo.33  In CLL, a direct link between blockade of the BCR by ibrutinib and 
interference of cellular adhesion has been demonstrated in mouse models.  Ibrutinib 
treatment has been demonstrated to impair CD184 receptor surface expression but 
not expression of CD185 or CD49d on CLL cells.122 
However, the study of adhesion molecule expression in MCL cells following treatment 
with ibrutinib has not been studied in detail particularly in cells cultured in an in vitro 
model of microenvironment and was the rationale behind the treatment of MCL cells 
cultured on human stroma. 
In these experiments the culture of MCL cells on human stroma produced some 
interesting and intriguing results. In the leukaemic case there was a marked rise in the 
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expression of CD62L (L-selectin) and CD184 after 56 hours of culture compared to the 
nodal case co-cultured on human stroma. 
The effects CD62L is a single chain transmembrane protein found in granulocytes, 
monocytes and most lymphocytes.  Low affinity binding by CD62L facilitates the 
capture, rolling and slow-rolling steps of leukocyte recruitment which in turn is 
followed by firm adhesion and transmigration.  Low expression has been 
demonstrated in MCL, CLL and MZL in other studies.76  It is therefore interesting that 
expression appears upregulated in the cells from the leukaemic MCL case cultured on 
human stroma but not on murine stroma.   
The effects of ibrutinib are subtle. There is a possible trend to increased expression of 
CAMs in the leukaemic case over the nodal case which could help explain some 
differences in biology between groups and further study is warranted. 
This thesis chapter has characterised the adhesion molecule profile of circulating MCL 
cells and shown it to be different to MCL cells from bone marrow and between clinical 
subgroups of indolent and aggressive lymphoma. The profile is dynamic and changes 
with changes within the microenvironment.  Further studies to characterise these 
changes in more detail particularly following BCR-targeted treatment would help in 





5. CHAPTER 5 - Developing a 3-Dimensional Module for the Study 
of Mantle Cell Lymphoma 
 Introduction 
5.1
The aim of these experiments was to develop a three dimensional model for the study 
of MCL ex vivo.  This was a novel concept and therefore this chapter mainly describes 
the steps involved in trying to develop this model, rather than on data obtained from a 
3-dimensional (3-D) model.  The chapter is divided into a discussion of the relevance of 
3-D models for the study of cell biology; a brief overview of the models already in 
development and the justification for the choice of model for this work followed by the 
sequential experiments performed in order to explore and optimise this model for the 
study of MCL, predominantly using primary MCL cells. 
5.1.1 Why Development of a 3-Dimensional Model for Cell Biology is 
Important 
Mantle cell lymphoma cells normally reside within the supportive 3-D structures of the 
lymph-node or bone marrow.  Within these structures, survival and proliferation of 
malignant cells is heavily influenced by stromal cells and other components of the 
tissue micro-environment (Figure 5-1).29  This relationship with the tissue 
microenvironment has been extensively studied in CLL and this knowledge has helped 
to establish a reproducible in vitro tissue model that mimics the in vivo 
microenvironment of the disease.27  In comparison, few studies have been performed 
in MCL and there is a real need for well-defined tissue models to form the basis for 
studying how different microenvironmental factors influence the biology and 
behaviour of the cells.  In the era of targeted molecular therapies such as BTK-
inhibitors, which are known to disrupt the relationship between malignant cells and 
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their extra-cellular environment, the need for a model to study this relationship is of 
particular importance. 
A large amount of data and subsequent understanding of cellular interactions in 
tumour biology has been gained from 2-dimensional (2-D) cell culture methods.  
However, it is generally recognised that the hard, flat, plastic or glass surface 
commonly used for cell culture is not representative of the complex 3-D 
microenvironment found in living organisms.  Indeed many of the functional structures 
studied in 2-D cell biology have specifically developed in the cell to allow it to 
proliferate, differentiate, interact with and migrate through the 3-D tissue 
microenvironment biochemical cues may be lost under 2d conditions.123  In studies of 
cancer cells, growing cells within 3-D models has demonstrated significant differences 
in preservation of morphology124,125, triggers of proliferation126, differentiation of stem 
cells127, protein expression and sensitivity to therapy128 and cellular metabolism129 
when compared with 2-D culture. 
While attempts have been made to develop models with the 3-D characteristics of the 
bone marrow microenvironment in other diseases130,131, there is little or no published 
data on 3-D culture models in MCL.  Given the differences in cellular behaviour 
demonstrated in other malignancies in 2-D and 3-D models, it would seem logical to 




Figure 5.1 MCL microenvironment.  The diagram (adapted from29) reflects the important cellular, 
soluble and molecular interactions known to be important in the interaction between MCL 
lymphocytes and the tissue microenvironment.  The chemoattractant chemokines CXCL12 and 
CXCL13 secreted by stromal cells such as mesenchymal stromal cells (MSC) and lymphoma-
associated macrophages (LAM) attract MCL lymphocytes via G-protein coupled receptors CXCR4 
and CXCR5.  Adhesion molecules such as VLA-4 are important in binding to the extracellular matrix 
and stromal cells within the microenvironment.   Complex intracellular signaling pathways 
following stimulation via the BCR, chemokine receptors, TLR or CD40 L are also involved in the 
proliferation and survival of MCL with the microenvironment. 
 
5.1.2 An Overview of 3 Dimensional Models in Current Cellular Research 
A 3-D model form MCL would need to be able to accommodate the complex structure 
of the bone marrow, which can be subdivided into cellular constituents and 
extracellular matrix (ECM).  The cellular components are subdivided into 
haematopoeitic cells and stromal cells including fibroblasts, adipocytes, macrophages 
and osteoblasts.132  The ECM is formed predominantly by collagens (predominantly 
type 1), glycoproteins such as fibronectin and laminin and proteoglycans such as 
heparin sulphate.133  These structural components also form a reservoir for cytokines, 
chemokines and growth factors.  Collectively, the bone marrow microenvironment 
contains complex cellular, structural and chemical factors which interplay in 
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maintaining homeostasis.  Additional factors such as matrix stiffness and flow rates of 
interstitial fluid play important roles in tumorigenesis.134,135   
Numerous 3-D models have been established for the study of various tissue types, and 
these, together with the rationale for selecting a model for experimentation with 
primary MCL cells are briefly described below.123,136 
5.1.2.1 Organotypic Explant Culture 
Organotypic explant culture is a model in which dissected organ slices are placed on a 
porous substrate, supported by a rigid mesh and cultured at the air/liquid-growth-
medium interface.  This preserves the architecture and cellular differentiation of the 
original tissue and is particularly useful in studying brain physiology.137  However, 
initiation of this model requires solid tissue samples and is therefore not applicable to 
liquid bone marrow or peripheral blood samples obtained in this project and are 
therefore discussed no further. 
5.1.2.2 Spheroid Formation using the Hanging Drop Method 
In the spheroid model, large cellular spheroids are formed by aggregation of tumour 
cells from a suspension, either within a “hanging drop” of liquid media or within a flask 
of medium which rotates to prevent adhesion.138  Suspended cells cluster and 
aggregate and can re-establish contact-dependent interactions. 
This is a relatively simple method which does not require an external scaffold for 
aggregation.  Bone marrow fibroblast spheroids have been cultured in 3-D models 
using the hanging-drop method predominantly for the study of tissue engineering and 
chondrogeneisis.139  Drawbacks of this method in the context of this project may 
include difficulties in preventing contamination during routine examination of the 
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droplets by microscopy; the relative fragility of the culture droplets during the 
handling process and the requirement for specialist equipment to incubate and roll 
flasks simultaneously.  However, this method in its application to a MCL model is 
explored briefly at the end of this chapter (5.4). 
5.1.2.3 The Use of Microporous Membranes 
Three-dimensional epithelial structures can also be grown on microporous membranes 
by culturing immortalised epithelial cells as polarised monolayers on microporous 
membranes.  This method is particularly suited to cells from epithelial organs such as  
glandular breast or kidney tissue which form acinus or tubular structures 
respectively.140  However, an epithelial-like model is probably not a suitable choice as a 
3-D model in the study of lymphoma cells due to histological differences in the 
architecture of the lymphoma microenvironment. 
5.1.2.4 Biological Scaffolds 
A potentially suitable method for the study of MCL employs the use of a ready-made 
biological scaffold which mimics the lymph node or bone marrow architecture onto 
which stromal and lymphoma cells can potentially adhere and ultimately colonise 
within a suitable culture medium.  Various materials have been explored in producing 
a scaffold which has the necessary qualities, such as thermo-reversible collagen-
containing hydrogels, fibrous scaffolds derived from methoxy-copolymers and alginate 
sponge matrices.141–143 
5.1.2.5 Macroporous Alginate Scaffold as a Candidate Model for 3-
Dimensional Culture  
One readily available and relatively inexpensive model for studying 3-D cell culture is 
the alginate macroporous scaffold model.  Alginates are polysaccharides consisting of 
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linear linked residues of β-D-mannuronic acid (M) and its C5-epimer α-L-glucuronic 
acid (G).  The molecular structure contains blocks of consecutive (-GGG- or –MMM-) or 
alternating G or M monomers (–MGMG-).  Cells do not have receptors that recognise 
alginates and therefore commercially available alginates can be considered inert.  
Alginate matrices are available in hydrogel form, as beads or as macroporous scaffolds. 
Macroporous scaffolds have the advantage of allowing larger cellular constructs  
because the mass transfer of nutrients and waste products is enhanced by a larger 
pore size than in hydrogel models and have been used as a model for 3-d cell culture in 
both human and animal cell experiments.144,145 
A challenge with the macroporous scaffold approach is cell seeding efficiency and 
cellular distribution as the pores are often either too big to retain cells or too small to 
admit them.  However, a variety of cell-seeding approaches have been used to 
overcome this including cell seeding devices, bioreactors, centrifugal force and 
vacuum.146 
5.1.2.6 Thermo-reversible collagen-containing hydrogels (Matrigel) 
Matrigel is a soluble extracellular matrix system comprised of gelatinous protein 
mixtures secreted by Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells which 
resemble the extracellular matrix found in many tissue types.142  It contains a sterile 
extract of basement membrane proteins derived from the EHS tumour which forms a 
gel at 37oC and supports cell morphogenesis, differentiation and tumour growth.  It is 
stored as a frozen solution, is thawed at 4oC and gels at 24-37oC in 30 minutes.  It does 
not redissolve readily on cooling.  Cells are generally plated on top of the gel but can 
be mixed with the matrix prior to gelling.  Many cell lines and primary cells do not 
proliferate but differentiate when exposed to Matrigel and the morphology often 
139 
 
reflects a more differentiated phenotype.  Matrigel, like other basement membranes 
represent a rich source of angiogenic and growth factors which can be used by tumour 
and other cell types.  Laminin-1, collagen IV and other matrix proteins can contribute 
to growth-promoting signals and may affect the expression of adhesion molecules.147 
Because of the potential effects on expression of surface markers by growth factors 
and matrix proteins within the gel and because of the potential difficulties in cell 
retrieval and analysis of expression of surface markers which can be encountered with 
Matrigel148, this method may not be suitable for the culture and assessment of MCL 
primary cells ex vivo. 
5.1.2.7 AlgiMatrix® Bioscaffold 
AlgiMatrix® (Gibco) is an animal origin-free bioscaffold that facilitates three-
dimensional cell culture.  AlgiMatrix® is based on ionically gelled and dried alginate 
scaffolds, available as sterile discs in standard culture well plates.  The matrix itself 
returns to a hydrogel substance on rehydration and can be stained and microscopically 
evaluated or dissolved for retrieval of cells. 
Each bioscaffold is an individual alginate sponge with a pore size of 50 – 200 microns.  
A concentrated cell suspension is absorbed by the dry sterile disc as it is applied to the 
top surface and the cells are subsequently trapped inside the scaffold. 
5.1.3 Justification for Selecting AlgiMatrix for this Project 
This system has several qualities that make it a suitable for testing in the context of 
this project: 
 it is a chemically defined animal-origin free material therefore limiting 
interaction and cross reactivity of antigens with MCL or stromal cells; 
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 after re-constitution with firming buffer and cell suspension, its translucency 
allows relatively easy visualisation of cells by light-microscopy; 
 it may also be possible to dissolve the bioscaffold non-enzymatically without 
disrupting cell spheroids, clusters or other 3D structures using an enzyme-free 
dissolving buffer in order to retrieve the cells for viability assays and other 
experiments; 
 it is possible to retrieve the sponge from the standard well plate after a period 
of cell culture for fixation, dehydration and paraffin embedding prior to staining 
and microscopic examination of cellular colonisation; 
 although the sponges are packaged in a single standard 24 well plate, individual 
sponges can be removed from the original plate under sterile conditions and 
placed into a second plate allowing multiple sequential experiments. 
Therefore a series of experiments using AlgiMatrix® discs were designed.  
141 
 
5.1 General AlgiMatrix® culture, fixation and staining 
Below is a description of the reagents and equipment used in the development of a 3-
D model for MCL culture. 
5.1.4 Reagents and equipment 
AlgiMatrix system 
AlgiMatrix® disc culture system (Gibco); 
AlgiMatrix® firming buffer (Gibco) 
AlgiMatrix® dissolving buffer (Gibco) 
General suspension media  
RPMI Media + glutamax (Gibco) containing 10% FCS (heat inactivated, qualified grade) 
(Fisher Scientific), and 1% Streptomycin/penicillin (Sigma) 
Modified IMDM culture medium containing 10% FCS, 10% horse serum, 1% pen/strep 
and   5x10-7 M hydrocortisone 
Fixation 
100nM barium chloride solution (in distilled H2O) 
Neutral buffered formalin (NBF) (Genta Medical); 
Paraffin Wax, Granular, (ACROS Organics™). 
Staining 
Harris Haematoxylin (supplied by Fisher Scientific at working concentration) 
1% hydrochloric acid alcohol (Fisher Scientific) 
Eosin-Y working solution (Fisher Scientific) 20% in ethanol. 
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Mounting media (Histomount). 
Cell lines 
Murine stromal cells: CD40-ligand-transfected (CD40L-T) (kind gift from Professor M 
Dyer, Leicester, UK) 
Granta-519 (G519) human mantle cell lymphoma cell line (Deutsche Sammlung von 
Mikroorganismen and Zelkulturen GmbH (DSMZ) (Braunschweig, Germany)) 
Equipment 
Embedding cassette (Sigma-Aldrich) 
Tissue processor (Sakura TISSUE-TEK VIP E300) 
Tissue embedder (Leica Biosystems EG1150) 
Cold plate (Leica Biosystems EG1150 C) 
Manual rotary microtome (Mircom Heidelberg HM 320) 
DM IL LED phase-contrast light microscope (Leica Microsystems) 
CCD grayscale camera (Leica DFC3000 G) (Leica Microsystems) 
LAS AF Version: 2.6.3 software (Leica Microsystems)  
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5.1.5 AlgiMatrix® disc. 
The optimisation of seeding the AlgiMatrix® discs is described in the following sections.  
The lyophilised AlgiMatrix® sponges require rehydration with cell suspension media, 
firming using the AlgiMatrix® firming buffer and seeding with a cellular suspension at 
an optimal cellular concentration. Following the manufacturers recommendations an 
initial seeding concentration of 1x106 cells/mL was used.149  Cells were suspended in 
RPMI media with glutamax (Gibco) containing 10% FCS (heat inactivated, qualified 
grade, (Fisher Scientific), and 1% streptomycin/penicillin (Sigma).  Individual 
AlgiMatrix® sponges (Gibco) were transferred from the manufacturer’s plate to a 
sterile 24 well flat-bottomed plate (Fisher Scientific) in a laminar flow hood.  The 
lyophilised sponge was initially rehydrated with 500µl media then once all bubbles had 
dispersed a further 500µl of media was slowly pipetted onto the top of the sponge.  
The percentage of firming buffer and cell concentration is described in more detail in 
the following experiments. 
The sponge was inspected by light microscopy on a daily basis and twice weekly media 
changes were performed by gently moving the matrix to one side of the well with a 
200µL pipette tip whilst aspirating the spent culture medium from the other side of the 
well, being careful to avoid aspirating or damaging the sponge.  The spent media was 
then replaced with 500µL of warmed suspension media and the plate returned to the 
incubator. 
5.1.1 Disc Fixation, Paraffin Embedding and Sectioning 
5.1.1.1 Fixation methods 
In order to visualise colonisation of the AlgiMatrix® system, the sponges were 
examined by phase-contrast light microscopy (Figure 5-2).  However, only limited 
views of the outer parts of the sponge were possible with this method.  In order to 
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visualise the inner parts of the matrix, the sponges required fixation and sectioning.  
Because the sponge was soft and friable once rehydrated, sectioning could only be 
performed after fixation and paraffin embedding. 
Fixation of tissues is necessary to inhibit decay or autolysis of tissues in order to 
preserve samples for future study.  It can be achieved by cross-linking agents, e.g. PFH, 
which is effective at preserving cell structure but can obstruct antibody binding, 
therefore antigen retrieval techniques are sometimes required.  Fixation is achieved by 
immersion of the specimen in a 4% paraformaldehyde (PFH) solution. 
Neutral buffered formalin (NBF) was used to fix the AlgiMatrix® sponges in this project.  
Neutral buffered formalin is equivalent to 4% PFH in a buffered solution plus a 
preservative (methanol) which prevents the conversion of formaldehyde to formic 
acid.  Because of this preservative, NBF has a shelf life of several months compared 
with 4% PFH which must be made fresh. 
The AlgiMatrix® manufacturer suggests that fixation, paraffin embedding and 
sectioning is feasible,149 however because this part of the method required 
development, it is described in detail below. 
5.1.5.1 Establishing an optimal fixation time 
Fixation times vary depending on tissue thickness: if specimens are very large, longer is 
required for the fixative to penetrate the inner portion of the sample.  Under-fixation 
can lead to edge staining (strong-staining at the edge but none in the middle) whereas 
over fixation can mask any epitopes being studied.  A guideline for fixation time is one 
hour of fixation for every 0.5mm of specimen thickness.72  As the alginate discs 
measured approximately 3-4mm thick once rehydrated, a fixation time of at least 6 
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hours was initially considered necessary.  However the optimal time for fixation 
remained to be established. 
In the initial experiments, after 6 days of culture, the sponge was transferred to a fresh 
well in the 24 well plate.  To fix the cells, 500µL of 4% NBF solution was added to the 
well for overnight (12 hour) fixation.  However, after twelve hours, the tissue was 
friable and broke up, even with careful handling. 
Because there were no calcified or fibrous components in the tissue, a shorter fixation 
time of 2 hours was tested.  A 2 hour fixation appeared to be adequate in terms of 
balance between maintaining the integrity of the tissue and allowing adequate fixation 
to prevent degradation of the sections over time.  However, because no antigen 
labelling was performed in these experiments, further work is required in establishing 
the optimal time for fixation for epitope preservation.  For the purposes of paraffin 
embedding and haematoxylin and eosin staining, a 2 hour fixation time was employed 
in this research.  After fixation, the disc was transferred to the tissue processor for 
dehydration and paraffin infiltration. 
5.1.2 Paraffin Infiltration 
Before paraffin infiltration can take place, the fixed specimen must be dehydrated 
through a series of graded ethanol baths to displace water.  The infiltrated tissue can 
then be embedded in wax blocks where it can remain stable for many years.  
Commercial paraffin wax is commonly used for infiltration, usually a mixture of straight 
chain or n-alkanes with a carbon length of 20 to 40 atoms.  Melting temperature for 
histological use is usually between 56 – 58oC. 
After tissue fixation, the disc was transferred to a labelled embedding cassette and 
placed into the tissue processor.  A standardised dehydration and embedding protocol 
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was used throughout the project (See Appendix 4). 
After paraffin embedding, the disc was removed from the cassette and the lid of the 
cassette discarded.  The cassette was transferred to a pre-heated tissue embedder.  A 
small amount of molten paraffin was poured into a metal mould from the paraffin 
reservoir.  The tissue was transferred into the mould using warmed forceps.  The 
mould was transferred to the cold plate where the paraffin solidified in a thin layer 
holding the disc in position.  The cassette, minus the lid, was then placed on top of the 
disc in the mould and hot paraffin was added to the mould from the dispenser to cover 
the face of the plastic cassette.  The mould was then transferred to a cold plate and 
left to solidify for 30 minutes before the block was popped out of the mould and ready 
for sectioning. 
5.1.3 AlgiMatrix® Disc Sectioning 
Paraffin blocks are best sectioned cold as sectioning is generally optimal when the 
specimen and wax are well matched in hardness.  Cold wax provides better support to 
the tissue allowing thinner sections to be taken. 
The disc was sectioned using a manual rotary microtome.  After removing excess wax, 
the block was inserted into the clamp in a horizontal orientation.  The microtome was 
set to cut at a section thickness of 10µM.  Once the block was correctly orientated and 
perpendicular to the cutting blade, a ribbon of tissue sections was cut.  Using brushes 
and forceps to handle the cut ribbon of sections, two to three sections were 
transferred to a water-bath set at 50oC (4-8 degrees below the melting point of the 
wax). 
The sections were then quickly transferred to a frosted glass microscopy slide 
(Corning™) by gently floating the section onto the slide using a brush to guide the 
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section.  The slide was then removed from the water bath, carefully dried and labelled 
and the wax section was baked onto the surface of the slide ready for staining for 2 
minutes using a hotplate. 
5.1.4 Staining 
Haematoxylin and eosin staining is the most commonly used staining method in 
histopathology because it gives a good general overview of the structure of tissues.  It 
was selected as the staining method of choice in this project in order to visualise the 
colonisation of the disc by both fibroblasts and MCL cells as these cells are readily 
distinguished using this staining method. 
Haematoxylin Staining 
Haematoxylin is a natural dye.  It does not stain tissue well until it is combined with a 
metallic salt (iron or aluminium).  It is used to dye cell nuclei by binding to histones via 
the metallic salt.  In the regressive staining method used in this project, the slides are 
initially over-stained with haematoxylin by submerging them in the stain for 5-8 
minutes.  At this stage, the nuclei are stained a deep purple but the next stage renders 
the stained nuclei dark blue.  Achieving a blue nucleus is a two stage process.  In the 
first (differentiation) stage, the slides are placed in an acid alcohol solution which 
removes excess stain.  The second stage involves rinsing the slides in tap water, a step 
called “blueing”.  This is done by running the slide under a gentle stream of alkaline tap 
water. 
Eosin Staining 
Eosin is a counterstain used to stain cytoplasm.  The pink counterstain also helps to 
differentiate between nuclei and non-nuclear components in cells.  The most 
commonly used eosin dye is eosin-Y (eosin-Yellowish), derived from fluorescein.  The 
exact mechanism of staining is not fully understood but is thought to be electrostatic.  
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The slides are usually immersed in eosin for two minutes before being rinsed in tap 
water.  Sections can be inspected at intervals during the staining process to prevent 
overstaining and a certain amount of overstain can be removed by placing the slides in 
a container with running water. 
5.1.4.1 Haematoxylin and Eosin Staining Protocol 
The mounted tissue-sectioned slides (10 micron sections of paraffin-embedded 
AlgiMatrix® disc) were first heated briefly at 65oC to soften the wax.  With appropriate 
safety precautions, the slides were then immersed twice in xylene for 5 minutes; 95% 
ethanol for 2 minutes; 70% ethanol for 2 minutes and then washed in distilled water. 
The slides were then stained with 1mL of haematoxylin stain with for 5-8 minutes 
before being run gently under tap water 5 minutes to wash off excess stain.  The slides 
were then immersed in 1% acid alcohol for 30 seconds to regress the haematoxylin 
stain before “blueing” by immersion in tap water for 5 minutes.  The slides were then 
dipped in 95% ethanol 10 times before staining with eosin-Y working solution for 2 
minutes. The slides were then immersed in 95% ethanol twice for 5 minutes; then 
100% ethanol twice for 5 minutes before immersion in xylene twice for 5 minutes. 
Slides were mounted with glass cover slips (Fisher Scientific) using mounting media 
(Histomount) and examined by light microscopy. 
5.2 Cellular colonisation 
5.2.1 Murine stromal cells 
In order to test the ability of murine fibroblasts to colonise the alginate sponge an 
initial experiment was designed with murine stroma which are abundantly available 
and known to proliferate well in 2-D culture conditions. 
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Adherent CD40-ligand-transfected murine stromal cells (kind gift from Professor M 
Dyer, Leicester, UK), were cultured to 100% confluence in a vented, 75cm2 plastic flask, 
maintained in complete 1640 RPMI medium at 100% humidity, 5% CO2 and 37
oC, as 
previously described (Methods 2.6).  A cell suspension at 1 x 10 6 cells/ml was prepared 
in warmed suspension media (Reagents and equipment 5.2.1) following trypsin 
digestion (Methods 2.6.2).  Individual AlgiMatrix® sponges were rehydrated with 500µl 
of 10% AlgiMatrix® firming buffer in media and seeded with 500µl of cell suspension 
( 5 x 105 cells) as previous described. 
As a 2-dimensional control, 10mLs of the same murine stromal cell suspension was 
transferred to a 25cm2 vented flask.  Both flask and sponge-containing plate were then 
maintained in an incubator at 5% CO2, 100% humidity, 37
oC. 
The flask and sponge were inspected for colonisation by phase-contrast microscopy 
every 24 hours.  After 6 days, the sponge was fixed, embedded in paraffin, sectioned 
and stained with haematoxylin and eosin for microscopic assessment of colonisation. 
At first attempt the fixation time chosen was 12 hours, however, this made the disc 
too fragile and it disintegrated on handling.  Therefore the experiment was repeated 
under the same conditions but with a 2 hour fixation time which preserved disc 
integrity. 
Phase contrast observation highlighted differences in both morphology and 
proliferation. The observed cells in the 2D system are flat spindle shaped cells 
compared to the development of small clusters of cells observed in the 3D system 
(Figure 5-2).  However the colonisation of cells appeared markedly reduced in the 3-D 
culture system in comparison to the 2D system and indeed a significant proportion of 
the fibroblasts were observed on the well floor rather than in the sponge.  Possible 
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explanations for this were failure of cells to migrate into and adhere to the matrix, 
suboptimal cellular density or failure of proliferation.  Higher cell densities, addition of 
extracellular matrix proteins or different seeding techniques may be required.  
Images from light-microscopy of the stained sections demonstrate suboptimal 
preservation of the structure following tissue processing (Figure 5-3).  Further 
optimisation of the method to improve the structural integrity of the matrix was 
required and is described in below. 
 
Figure 5.2 Culture of murine stromal cells for 5 days reveals flat spindle-shaped cells in 2-D 
culture conditions (A) compared with small clusters of spheroidal cells in the 3-D matrix (B).  Light 
microscopy comparison of (A) murine stromal cells grown on the bottom of a 25cm
2
 vented flask in 
complete RPMI medium in comparison with the same cells cultured within an AlgiMatrix® sponge 
matrix in a 24 well plate in  RPMI medium(B).  Images taken after 5 days of growth (sponge and 





Figure 5.3. Haematoxylin and eosin-stained sections of a 3-dimensional culture of murine 
fibroblasts using an AlgiMatrix® scaffold.  Images demonstrate disintegration of matrix structure 
during the dehydration and embedding process.  The AlgiMatrix® disc was seeded with CD40L-
transfected murine bone-marrow stromal cells at a density of 1x10
6
/mL in complete RPMI culture 





media changes every 3 days before being fixed for 2 hours in 4% neutral buffered formalin, 
embedded in paraffin, sectioned (10 microns) and stained with haematoxylin and eosin.  





5.2.2 Seeding the AlgiMatrix® with a MCL cell line 
The aim of this chapter was to explore the development of a 3-D model for the study 
of MCL, in particular, to establish a model that could be used to test the effects of 
different micro-environmental conditions on the growth and survival of primary MCL 
cells.  However, primary MCL cells obtained from subject donors are a precious 
resource.  Therefore an experiment with a rapidly proliferating and readily available 
MCL cell line (G519) was conducted. 
Building on the observations from the initial murine fibroblast culture, several changes 
were made to the initial seeding protocol in an attempt to improve proliferation and 
colonisation of the disc. The AlgiMatrix® disc was not rehydrated with complete RPMI 
medium containing 10% firming buffer.  Instead, a suspension of G519 cells in RPMI 
culture medium containing 10% firming buffer was used to rehydrate and seed the 
sponge simultaneously.  The aim of this modification was to improve colonisation of 
the disc by absorption of cells with liquid into in the disc during the rehydration 
process. A two hour fixation time was used prior to paraffin embedding, sectioning and 
staining. A longer culture period of 21 days was used in order to give the G519 cells 
more time to form proliferative centres in 3-D.  
The basic protocol was as previously described. A 1 ml suspension containing 1 x 106 
G519 MCL cells was prepared in suspension media containing 10% AlgiMatrix® firming 
buffer.  500µL of this cell suspension was then seeded onto a lyophilised AlgiMatrix® 
sponge in a 24 well plate as previously described.  Once any bubbles had dispersed, a 
further 250µL of cell suspension was added to the well (to ensure adequate media and 
cell numbers for colonisation). 
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The sponge was incubated at 37oC, 5% CO2.  Culture medium changes were performed 
every 2-3 days and visual inspection by light-microscopy every 48hrs.  The discs were 
maintained in incubation for a total period of 21 days prior to tissue fixation, paraffin 
embedding, sectioning and staining. 
Microscopic phase contrast examination of the AlgiMatrix® disc demonstrated the 
formation of spheroid clusters after 21 days of culture but proliferation rates within 
the matrix appeared slower than expected when compared to cells grown  in 
suspension culture (Figure 5-4) . The main challenge encountered from the prolonged 
culture was deterioration in disc integrity.  The disc was rendered extremely fragile and 
disintegrated during transfer to the paraffin embedding cassette therefore sectioning 




Figure 5.4   Phase Contrast Images of G519 MCL Cells in 3-D Culture on AlgiMatrix®. Granta-519 
MCL cells demonstrate formation of spheroid clusters when cultured in an AlgiMatrix® 3-D culture 
system over 21 days.  AlgiMatrix® discs were seeded with G519 MCL cells at a density of 1x106/mL 
and incubated at 37oC, 5% CO2 in complete RPMI medium for 21 days with media changes every 48 
hours.  Phase-contrast images taken at serial time points in culture: top left - 3 days(mag. x20); top 
right - 7 days (mag x20), middle row - 12 days (mag x20 left and x40 right); bottom row - 21 days 
(mag. x 20 left & x40 right).  
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5.2.1 3D culture using human fibroblast cells 
With modification of the methods initially employed, the AlgiMatrix® bioscaffold has 
demonstrated an ability to support the culture of both murine fibroblasts and G519 
MCL cells.  It was decided to test this system in respect to the growth of primary 
human bone marrow cells.  Primary human fibroblasts were cultured in vitro as a 
potential stromal support for future primary MCL culture.  The following experiment 
explores the AlgiMatrix® system’s ability to support a human fibroblast culture ex vivo. 
Our ethically approved tissue bank allows the collection and storage of liquid human 
bone marrow  aspirated during the course of a routine investigative bone marrow 
biopsy from patients with underlying lymphoproliferative disorders. Human bone 
marrow stromal cells were established as previously described (Methods 2.7).  The 
proliferative capacity of the resultant fibroblasts was variable in line with clinical 
heterogeneity (Figure 5-5).  Upon achievement of a confluent layer of human 
fibroblasts the cells were washed, trypsinised and resuspended in 1000µL of modified 
IMDM culture medium containing 10% FCS, 10% horse serum, 1% pen/strep, 5x10-7 M 
hydrocortisone and 10% AlgiMatrix® firming buffer. 500µL was then seeded onto a 
lyophilised AlgiMatrix® disc.  Once any bubbles had been dispersed, an additional 
500µL of IMDM culture medium without cells was added for nutritional support and to 
prevent drying out. The disc was incubated at 37oC, 5% CO2.  Regular examinations by 
light-microscopy and media changes were performed. After six days of incubation, the 
disc was fixed for 2 hours in NBF, dehydrated and embedded as previously described 




Figure 5.5  Examples of 2-D culture of human bone marrow fibroblasts from 3 different subjects.  
Phase contrast images of samples taken after 21days (A), 28 days (B) and 35 days (C) (magnification 
10x).  A 25cm
2
 vented flasks was seeded with PBMCs from fresh human bone-marrow (density 
5x10^6 cells/mL) in 10mLs of long-term culture medium after ficoll-separation from whole bone 
marrow aspirate.  Cells were maintained at 37oC, 5% CO2 for 10 days without disturbance and then 








Figure 5.6.  Human bone marrow fibroblasts cultured using the 3-D AlgiMatrix® scaffold.  A 
paucity of fibroblasts and diffuse disintegration of the matrix scaffold is demonstrated.  Human 
bone-marrow stromal cells (from a subject with lymphoma but without marrow infiltration) were 
cultured in 25cm2 vented flasks to confluence before being removed and resuspended at a density 
of 1x10
6
/mL in complete IMDM culture medium with 10% FCS, 10% horse serum, 1% pen/strep 
5x10-7 M hydrocortisone and 10% AlgiMatrix® firming buffer.  The cell suspension was seeded on to 





C) with media changes every 3 days before being fixed for 2 hours in 4% neutral buffered 
formalin and embedded in paraffin, sectioned (10 microns) and stained with haematoxylin and 
eosin.  (Magnification A x4, B x10, C x20, D x40) 
 
Although colonisation with human bone marrow fibroblasts is apparent within the 
AlgiMatrix® system (Figure 5-6), cell numbers are poor suggesting the 
microenvironment is hostile to human stromal cell proliferation. A higher density of 
cells may be required for successful colonisation. Unfortunately the matrix integrity is 
again degraded after 6 days culture following the fixation, paraffin embedding and 
staining process. 
5.2.2 3-D Culture of MCL Marrow Buffy Coat  
To establish whether the matrix would be suitable model for MCL and in an attempt to 
address the issue of low cell numbers within the AlgiMatrix® bioscaffold after culture, 







subject with MCL was used to create the seeding solution applied to the lyophilised 
disc. It was hypothesised that cells other than fibroblasts, such as T-cells and 
macrophages may be required for colony formation when using human bone marrow 
within the 3-D bioscaffold. 
The buffy-coat layer was prepared at a cell density of 3.5x107 cells/mL in 500µL of 
IMDM culture medium with 10% FCS, 10% horse serum, 1% pen/strep, 5x10-7 M 
hydrocortisone and 10% AlgiMatrix firming buffer.  This cell suspension was then 
seeded on to a lyophilised AlgiMatrix® disc and maintained at 37oC, 5% CO2, 100% 
humidity for 6 days.  A media change was performed on day 3. 
After 6 days, media was carefully removed and the disc was fixed for 2 hours in neutral 
buffered formalin (NBF).  The sponge was then dehydrated and embedded in paraffin 




5.7 Fresh whole marrow buffy-coat cells cultured using the 3-D AlgiMatrix® bioscaffold.  Fresh 
human bone-marrow buffy coat from a patient with MCL with marrow infiltration was washed and 
resuspended at a density of 3.5x10
7
/mL in complete IMDM culture medium with 10% FCS, 10% 
horse serum, 1% pen/strep, 5x10-7 M hydrocortisone  and 10% AlgiMatrix firming buffer.  The cell 
suspension was seeded on to lyophilised alginate sponges (500µL per sponge) in a 24 well plate and 
maintained for 6 days  in 5% CO
2
,  at 37
o
C with a media change every 3 days before fixation for 2 
hours in 4% neutral buffered formalin and embedded in paraffin, sectioned (10 microns) and 








Whereas in previous experiments, scant clusters of fibroblasts were observed 
throughout the disc, when a higher density of cells was used including the whole buffy 
coat from ficoll separation, multiple aggregates of bone marrow cells were observed 
throughout the disc after 6 days of culture (Figure 5-7). The matrix integrity continues 
to show evidence of significant deterioration after 6 days culture after fixation, 
paraffin embedding and staining process. 
5.1.6 Improving the structural integrity of the AlgiMatrix® culture system 
using barium chloride 
An obstacle encountered in the development of a 3-D culture model using the 
AlgiMatrix® system was the disintegration of the disc after cell culture and during 
handling for the fixation, dehydration and paraffin embedding steps.  This appeared to 
be a particular problem with culture periods longer than a week. 
The AlgiMatrix® disc is composed of 1, 4 linked β-D mannuronic acid (M) and α-L-
glucuronic acid (G) residues which form a mesh by cross-linking with divalent ions such 
as calcium.  Alginates have a high affinity for alkaline earth metals and 3-D structures 
can be formed in the presence of most divalent cations.  In the AlgiMatrix® system, 
calcium is the cross-linking ion of choice and this can be dissolved by treatment with 
chelating agents for divalent ions such as EDTA.  However alginates have different 
affinities for divalent cations.  Barium has the highest affinity and forms the strongest 
cross-linkages.150  With the aim of making the AlgiMatrix® disc more durable 
throughout the dehydration and paraffin embedding process, the disc was immersed 
in a 100mMolar solution of barium chloride to reinforce the matrix cross-linkages prior 
to fixation and paraffin embedding. 
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CD40 ligand-transfected murine fibroblasts were cultured in a 75cm
2





C) in complete RPMI media before being trypsinised, washed and resuspended 
in complete RPMI culture medium.  A cell suspension was prepared in RPMI with 10% 
AlgiMatrix® firming buffer at cell density of 1x107/mL.  Two AlgiMatrix® sponges were 





with media changes every 3 days. 
After seven days, the culture medium was removed from the well carefully using a 
pipette and the solution was replaced with 1000µL of 100mM barium chloride in 
distilled water for 30 minutes prior to fixation for 2 hours in 4% NBF.  The disc was then 
transferred to an embedding cassette and placed in the tissue processor for 
dehydration and paraffin embedding.  The disc was then cut into 10 micron sections 
which were mounted and stained with haematoxylin and eosin as previously described.  
Immersion in 100mmol barium chloride solution for 30 minutes appears to improve 
the structural integrity of the disc for the fixation, embedding and sectioning steps 
(Figure 5-8). 
Further work is required to establish whether the use this method of matrix 
reinforcement with barium chloride prior to fixation in its current form has an effect 




Figure 5.8  Barium chloride fixation of AlgiMatrix disc. Barium Chloride improves cross-linking of 3-
Dimensional Alginate Scaffold Prior to Fixation and Preserves Sponge Structure during fixation and 
paraffin embedding.  CD40L-transfected murine bone-marrow stromal cells were seeded onto an 
AlgiMatrix disc in a standard 24 well culture plate at a density of 1x107/mL.  The disc was then 
maintained at 5% CO2, 37
oC for 7 days with media change every 3 days.  The media was removed 
and the disc was immersed in a 100mM solution of barium chloride for 30 minutes prior to fixation 
for 2 hours in 4% neutral buffered formalin, dehydration, embedding in paraffin, sectioning (10 






5.2.3 Improving Colonisation by increasing the seeding cell density  
The AlgiMatrix® manufacturer recommends using a cell suspension with a density of 
1x106 cells/mL to seed the disc.149  However, initial experiments revealed a paucity of 
stromal and lymphoid cells within the matrix after culture at this cell density. 
Explanations for this could include an inability of the cells to penetrate the mesh-work 
of the matrix or cells falling through the mesh and subsequently colonising the floor of 
the well.  However, on sectioning the disc it is possible to observe small clusters of cells 
throughout the matrix, suggesting that some cells do penetrate the disc and remain in 
the mesh. 
In order to address this problem and given the better colonisation of the matrix when 
a higher concentration of cells (marrow  buffy coat) was used, an experiment with a 
series of cell-suspension densities was performed to establish the optimal seeding 
density. 
Three suspensions of CD40 ligand-transfected murine fibroblasts were prepared in 
RPMI suspension media with 10% AlgiMatrix® firming buffer at cell densities of 
5x106/mL, 1x107/mL and 2x107/mL.  Three sponges were seeded using 500µL of each 




C) with media changes every 3 
days.  After seven days, the culture medium was carefully removed from the well using 
a pipette and the solution was replaced with 1000uL of 100mM barium chloride for 30 
minutes prior to fixation for 2 hours in 4% neutral buffered formalin.  The disc was then 
transferred to an embedding cassette and placed in the tissue processor for 
dehydration and paraffin embedding.  The disc was then cut into 10 micron sections 
which were mounted and stained with haematoxylin and eosin. 
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A cell density of 5x106/mL was deemed optimal in terms of colonising the sponge.  
Seeding densities above this concentration resulted in dense sheets of cells in the 
peripheries of the sponge with no significant colonisation of the sponge itself (Figure 5-
9). 
 
Figure 5.9.  Varying the seeding density of stromal cells to improve matrix colonisation.  Cell 
densities above 5x106/mL resulted in dense sheets of cells which did not appear to penetrate the 
sponge.  Three dehydrated alginate sponges were seeded (500µL per sponge) in a 24 well plate at 
the following cell densities: 5x106/mL 1x107/mL and 2x107/mL.  Sponges were then cultured for 7 
days (5% CO2, 37
oC) with media change every 3 days before being immersed in 1mM solution of 
barium chloride for 30 minutes prior to fixation for 2 hours in 4% neutral buffered formalin and 
embedded in paraffin, sectioned (10 microns) and stained with haematoxylin and eosin.  Images A-





5.2.4 Centrifugation to improve distribution of cells through the AlgiMatrix® 
Although increasing the density of the cell suspension used to seed the AlgiMatrix® 
disc appears to improve colonisation of the disc, sectioning reveals the centre of the 
disc remains largely empty of cells when examined by light microscopy.  In an attempt 
to improve distribution of the cells within the disc, the manufacturer recommends 
gentle centrifugation of the 24 well-plate holding after seeding. 
Two AlgiMatrix® discs were seeded with identical suspensions of human bone marrow 
fibroblasts from a fresh, ficoll-separated, bone marrow aspirate sample as previously 
described.  The discs were seeded in separate standard 24 well plates.  One plate was 
subjected to gentle centrifugation prior to culture. 
Mononuclear cells from a bone marrow aspirate were separated from red cells and 
plasma by ficoll-separation, washed and resuspended at a density of 5x106/mL in 
complete IMDM long term culture medium (Dulbecco’s Iscove’s Modified Dulbecco’s 
Medium (IMDM) containing hydrocortisone (5x10-7M); 10% FCS; 10% Horse Serum) 
containing 10% AlgiMatrix® firming buffer as previously described and subsequently 
seeded onto two lyophilised AlgiMatrix® discs in separate, standard 24 well plates.  
One plate was then centrifuged at 500 rpm for 5 minutes prior to incubation.  Both 
plates were then maintained at 5% CO2, 37
oC for seven days with media changes every 
3 days before being fixed for 2 hours in 4% neutral buffered formalin, embedded in 
paraffin, sectioned (10 microns) and stained with haematoxylin and eosin. 
Gentle centrifugation does not appear to enhance distribution throughout the disc.  
Diffuse colonisation is observed throughout the sections using both centrifuged and 




Figure 5.10  Distribution of cells within the AlgiMatrix® following centrifugation. Images A, C, E 
are from uncentrifuged discs; images B, D, F are from centrifuged discs.  Gentle centrifugation does 
not appear to enhance distribution throughout the disc.  Diffuse colonisation is observed 
throughout the sections using both centrifuged and uncentrifuged methods with two different 
patient samples.  Human PBMCs isolated from fresh bone marrow aspirate were seeded onto two 
lyophilised AlgiMatrix® discs at a density of 5x106/mL in long-term IMDM culture medium with 10% 
firming buffer in separate standard 24 well plates.  One plate was then subjected to centrifugation 
at 500 rpm for 5 minutes before both plates were maintained  at 5% CO2, 37
oC for seven days with 
media changes every 3 days before being fixed for 2 hours in 4% neutral buffered formalin, 






5.2.5 Fibronectin to aid adhesion to the AlgiMatrix® 
Given the evidence from the previous chapter of MCL cells dependence on interactions 
with CD40-ligand and accessory cells for survival and proliferation, an experiment was 
designed to culture both primary MCL cells and stromal cells together using the 
AlgiMatrix® 3-D system. In this experiment, colonisation and visualisation of discs was 
performed using PBMCs from a patient with aggressive, nodal MCL together with CD40 
ligand-transfected murine fibroblasts. 
Primary MCL cells from a proliferative case were selected because it was postulated 
that cells from a more aggressive case would proliferate more rapidly within the 
culture system. 
Fibronectin (FN) is a large, cell-surface and plasma protein which is important for cell 
adhesion, migration and proliferation  Adherent cells constitutively produce FN and 
deposit it into the ECM  which further aids adhesion and has been demonstrated to 
stimulate proliferation in human fibroblasts.151 
In order to enhance adhesion and proliferation within the AlgiMatrix® system, FN was 
also added at a concentration of 25µg/mL to the seeding solution for this and 
subsequent experiments. 
In order to ensure that the cells retrieved from the culture system at the end of 
incubation were from the disc and not the floor of the well, the disc was suspended in 
culture medium on a 5 micron filter and immersed in complete RPMI culture medium 
within the well of a 6 well plate.  At the end of a 10 day culture period, the disc 




CD40-ligand-transfected murine fibroblasts were suspended in complete RPMI 
medium at a density of 5x106 cells per sponge (density based on the optimum seeding 
density observed in the previous experiment) containing10% firming buffer as 
previously described.  In addition, 100µL of 1:40 FN was added to the seeding 
suspension.  A lyophilised AlgiMatrix® disc was seeded with 500µL of the cell 
suspension and the disc was transferred to a 5-micron filter and inserted into a well of 
a standard 6 well plate before being immersed in complete RPMI medium.  The disc 
was maintained at 5% CO2, 37
oC for 10 days to allow stromal cell colonisation. 
Primary MCL PBMCs were purified from peripheral blood and cryopreserved as 
previously described.  The PBMCs from subject MCL016 (an aggressive MCL case) were 
thawed and resuspended in RPMI medium at a density of 1x107/mL in before being 
seeded onto the AlgiMatrix® disc and maintained at 5% CO2, 37
oC for a further 5 day 
incubation period.  The disc was then transferred to the well of a standard 24 well 
plate and immersed in 100mM BaCl for 30 minutes prior to fixation for 2 hours in 4% 
neutral buffered formalin, dehydration, paraffin embedding and sectioning (10 
microns per section) and staining with haemotoxylin and eosin. 
Aggregates of small lymphocytes with basophilic nuclei admixed with lighter-coloured 
purple stromal cells are visible in the stained sections demonstrating the feasibility of 





Figure 5.11  Co-culture of murine fibroblasts with primary human MCL cells for 5 days with the 
addition of fibronectin.  MCL cells from subject MCL016 (aggressive, nodal MCL) were cultured 
with CD40-L transfected murine stroma with fibronectin (25µg/mL) for 5 days on AlgiMatrix® discs 
in 5 micron filters immersed in complete RPMI culture medium before being reinforced with 
barium chloride solution, fixed, paraffin embedded and sectioned and stained with haematoxylin 
and eosin. (Note aggregates of small lymphocytes with basophilic nuclei admixed with lighter-







5.3 Cell retrieval 
According to the manufacturer, one of the potential advantages of using the 
AlgiMatrix® system as a model for studying MCL cells in 3-D culture is the option of cell 
retrieval from the matrix via non-enzymatic degradation of the matrix after culture.149 
In order to test whether MCL cells could be retrieved from AlgiMatrix® and analysed 
for cell surface markers, rates of proliferation and apoptosis after culture the following 
experiment was performed.  Two AlgiMatrix® discs were seeded with CD40L-
transfected murine stromal cells at a density of 5x106/mL in complete RPMI medium 
with 10% firming buffer.  The sponges were allowed to settle for two hours before 
200µL of complete RPMI medium was gently added in order to prevent drying out 
during incubation.  Discs were then incubated for 24 hours at 37oC, 5% CO2. 
Two cell suspensions at a density of 5x106/mL of primary MCL cells from two different 
cases (MCL16, nodal case and MCL07, leukaemic case) were prepared in complete 
RPMI media. 
The sponges were retrieved from the incubator; excess media was removed from the 
well of each sponge by careful pipetting.  The stromal-seeded discs were then seeded 
with 500µL of the MCL cell suspension by pipetting onto the disc within the well of the 
24 well plate.  To a second disc for each case, the disc was seeded with MCL cells alone 
in RPMI complete medium containing 10% firming buffer as previously described. 
All discs were then dynamically seeded by centrifugation (100G for 4 minutes) before 
being returned to the incubator for 3 days. 
On day 5 the sponges were retrieved from the culture wells and transferred to sterile 
empty wells on the same plate.  1mL of non-enzymatic dissolving buffer (provided by 
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Gibco ready for use) was added directly onto each disc to fully submerge the disc as 
per manufacturer’s instructions.  The discs were dissolved for 5 minutes.  The discs 
visibly degraded within 5 mins and were completely degraded after 10 mins.  The now 
liquid contents of the well were transferred to a sterile centrifuge tube, and 1000µL of 
complete RPMI culture medium was added before centrifugation at 1600rpm for 5 
minutes to pellet the released cells.  The supernatant was removed and the cells were 
resuspended in complete RPMI media and adjusted to an approximate density of 
5x106/mL of PBMCs and 5x106/mL of stromal cells. 
Three sterile 1.5mL Eppendorf tubes containing the following antibodies and reagents 
were prepared for each sample: 
1. Unstained 
2. Isotype controls 
3. FITC-AV, CD5 PE and CD19 APC; 
100µL from each cell suspension was then added to each tube and incubated in the 
dark for 20 minutes before flow cytometry was performed. 
The forward / side scatter plots and mean fluorescent intensity peaks for cells from 
subjects MCL07 and MCL16 after cell retrieval from culture in AlgiMatrix® with murine 
stroma are displayed in Figures 5-12 and 5-13.  The cells have been labelled with 
fluorochrome-labelled anti-CD 5 and 19 antibodies, corresponding isotype controls and 




Figure 5.12  MCL peripheral blood mononuclear cells can be retrieved from the AlgiMatrix® disc 
and visualised by flow cytometry for labelled surface markers and annexin-V expression after co-
culture with murine stromal cells.  The forward / side scatter plot (A) and mean fluorescent 
intensity peaks for MCL07 after cell retrieval from culture in AlgiMatrix® with murine stroma are 
displayed (B-D).  The cells have been labelled with APC-conjugated anti-CD19 (D) and 
corresponding isotype control (C) plus annexin V FITC (B) after cell retrieval from the matrix using 
non-enzymatic degradation after 3 days co-culture with CD40L-transfected murine stroma.  A 
distinct and viable population of CD19 positive MCL cells can be seen, demonstrating the ability to 






Figure 5.13  Primary MCL cells from subject MCL16 retrieved from the AlgiMatrix® disc and 
visualised by flow cytometry for labelled surface markers and annexin-V expression after co-
culture with murine stromal cells.  The forward / side scatter plot (A) and mean fluorescent 
intensity peaks for MCL16 after cell retrieval from culture in AlgiMatrix with murine stroma are 
displayed (C-H).  The cells have been labelled with APC-conjugated anti-CD19 (F) and  PE-
conjugated anti-CD5(G) and corresponding isotype controls (C & D) plus annexin V FITC (B) after cell 
retrieval from the matrix using non-enzymatic degradation after 3 days co-culture with CD40L-
transfected murine stroma.  A distinct and viable population of CD 5 / 19 positive MCL cells can be 
seen (H) in contrast to isotype controls (E), demonstrating the ability to label and analyse surface 
markers on PBMCs after culture in the AlgiMatrix® 3-D system.  
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A distinct and viable population of CD5 / CD19 positive MCL cells can be observed in 
Figure 5-13 and CD19 positive cells in Figure 5-12 (MCL07 did not express CD5).  This 
demonstrates that surface markers can be preserved and analysed by flow cytometry 
on MCL cells retrieved from the AlgiMatrix® system to identify and distinguish the cells 
from other cells cultured simultaneously.  
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5.4 Alternative 3D model systems 
In addition to the AlgiMatrix® method explored above, the hanging drop method was 
explored using primary lymphocytes from a patient with CLL.  CLL cells were used in 
this section because, unlike primary MCL cells, there is good evidence that these cells 
survive and proliferate more readily without stromal support and were therefore 
deemed more suitable to use as cell type in exploratory experiments.92 
The hanging drop method involves the culture of large cellular spheroids formed by 
aggregation of tumour cells from a suspension within a “hanging drop” of liquid media 
or within a flask of medium which rotates to prevent adhesion.138  Suspended cells 
cluster and aggregate and can re-establish contact-dependent interactions. 
5.4.1 Hanging Drop Culture 
In this experiment a cell suspension of PBMCs from a patient with untreated CLL were 
ficoll-separated from red cells and plasma and prepared at density of 1x106 cells per 
mL in complete RPMI media.  In order to establish the optimal seeding density for the 
hanging drops a series of dilutions of the cell suspension were prepared (2x103, 
10x103, 20x103, 30x103, 40x103, 50x103/50µL). 
50µL of each dilution was carefully pipetted on to the underside of a 96 well plate 
within the condensing rings of individual wells.  The lid was then gently inverted so the 
drops hung upside down and stacked on top of another lid before being returned to 
the incubator.  Because the overall drop volume was small, significant evaporation and 
drying out while being incubated at 37oC, 5% CO2 was anticipated.  The drops were 




Figure 5.14  Initial hanging drop method experiment with primary CLL cells.  Top left: the lid of a 
96 well plate with hanging-drops seeded onto the under-side of the lid within the condensing ring 
of each well (A).  B: hanging drop with 1x104 cells visualised by phase-contrast microscopy (10x 
magnification) after 24 hours of culture.  C: hanging drop with 1x104 cells after 24 hours of culture 
(20x magnification). 
 
An example of the initial hanging drop method experiment is displayed in Figure 5-14.  
A cell density of 1x104 cells per 50µL appeared to yield a reasonable sized aggregate of 
CLL cells. 
5.4.1.1 Problems Encountered with the Hanging Drop Method 
Initially, the drops in the 40x103 and 50x103 wells lost surface tension and ran into the 
adjacent wells.   Therefore a volume of 50µL appears to be vulnerable to loss of 
surface tension in this system.  Secondly, despite twice daily media top-ups, the drops 
evaporated significantly overnight when cultured by this method. 
Maintaining drop integrity whilst performing media top-ups was difficult because 





replenishing with culture medium.  It was also difficult to accurately estimate the 
amount of medium required to replenish the drop: too little increased the risk of 
excess evaporation overnight; too much risked breaking the surface tension of the 
drop and causing it to smear across the plate. 
Finally, this method required the lid of the 96 well plate to be rested upon the 
upturned lid of another plate.  Because these surfaces were not compatible, risk of 
upsetting the plate on transfer or in the incubator was high and this could lead to 
disastrous evaporation.  This method was therefore abandoned. 
5.4.1.2 Revised Hanging Drop Method 
In this method, three separate cell suspensions were prepared in RPMI at a cell density 
of 3x104/mL, 3x105/mL and 3x106/mL using primary CLL cells from the same untreated 
subject.  Smaller (40µL) drops of CLL cells suspended in RPMI media were carefully 
pipetted onto the upturned lid of a petri culture dish within the laminar flow cabinet.  
Provided the drops were not in contact with each other, a large number, 20 – 30 could 
be pipetted onto the same plate with ease (Figure 5-15). 
In order to prevent excess evaporation during incubation, a humidity reservoir of 
10mLs of sterile PBS was added to the culture dish before the lid was smoothly and 
moderately quickly inverted and placed onto the dish before incubation. 
The drops were incubated for 48 hours and inspected for CLL cell aggregation / 
spheroid formation at 24 and 48 hours.  Images taken after 24 hours by phase contrast 




Figure 5.15  Revised hanging drop method in which 40µL drops of CLL cell suspension in RPMI 
were carefully pipetted onto the underside of the lid of a standard petri dish before careful 
inversion and replacement on the dish.  A 10mL humidity reservoir containing sterile 1x PBS was 
added to the dish before incubation. 
 
 
Figure 5.16  Images of hanging drops taken at 24 hours using revised method.  Primary CLL cells 
were ficoll separated and suspended in complete RPMI before dropping onto the underside of a 
sterile petri-dish lid in 40µL volumes.  The lid was inverted and replaced on the dish containing a 
10mL humidity reservoir prior to incubation. Cells were suspended at a density of 3x104/mL (A) 
3x10
5
/mL (B) and 3x10
6








Figure 5.17  Primary CLL cells cultured by revised hanging drop method after 56 hours at density 
of 3x10^6 (A) and 3x10^5 (B) demonstrate aggregates of cells within the drop. (Cells visualised at 
2.5x by phase-contrast light-microscopy). 
 
5.4.1.3 Viability of CLL cells cultured in hanging drops for 5 days using second 
method 
After five days of culture using this method, there was no evidence of significant 
evaporation or contamination.  The lids were inverted in the laminar flow hood and 
500µL of sterile PBS was used to wash the drops into the bottom of the angled lid.  The 
resulting cell suspension was collected into a 15mL falcon and a cell count was 
performed.  Negligible numbers of cells were observed in the 3x104/mL suspension.  
From the 3x105/mL suspension, approximately 5x104 cells were harvested and 1x106 
cells were harvested from the 3x106/mL suspension.  The resulting cell suspensions 
were analysed by flow cytometry.  The scatter plot characteristics of cells retrieved 
from hanging drop culture after 5 days are displayed in Figure 5-18.  This shows that at 
both cell densities there is a similar degree of apoptosis/cell death represented on the 
plots in the area outlined in blue. This suggests that the cell density and culture time 





Figure 5.18   Flow cytometry scatter plots for CLL cells reovered from culture in hanging drops. 
Viability of cells  recovered following culture in hanging drops is similar at both cell density 
concentrations, shown in the plots in the area outlined in blue.   Primary CLL cells were cultured  
for 5 days in hanging drops at different cell densities, cells were harvested and assessed by flow 
cytometry. Cells cultured at 3x105/mL  (A)  have  similar scatter plot characteristics to those 




5.1.7 Culturing stromal and MCL cells in 3-D model alters cell morphology 
and proliferation rates 
Observation of phase contrast images of stromal cells cultured in 3-D versus 2-D 
highlighted differences in both morphology and rates of proliferation. Culture of cells 
on 2-D surface results in flat cells through simple geometry – there is only one surface 
on which the cells can adhere resulting in a default, apical-based polarity.  The 
observed stromal cells in the 2-D system were flat spindle shaped cells compared to 
the development of small spheroidal clusters of cells observed in the 3D system (Figure 
5-2).  This was effectively demonstrated by phase contrast light microscopy during the 
culture period but was not clearly demonstrated by the fixed, stained sections, mainly 
due to a paucity of cells at this stage. 
Colonisation and proliferation rates of stromal cells also appeared lower than expected 




stromal cells which proliferate rapidly in 2-D culture.  This was an unexpected finding 
as other studies have demonstrated that 3-D culture increases rates of proliferation of 
tumour cells, in part due to adhesion-receptor-dependent changes in intracellular 
signalling.152,153 
When G519 MCL cells were cultured in isolation within the AlgiMatrix® disc, 
microscopic phase contrast examination revealed the formation of spheroid clusters 
after 21 days of culture but proliferation rates within the matrix appeared slower than 
expected when compared to cells grown  in suspension culture (Figure 5-4). The 
prolonged culture time required also led to deterioration in disc integrity.  The disc was 
rendered extremely fragile and disintegrated during transfer to the paraffin 
embedding cassette therefore sectioning and staining was not possible. 
When human marrow fibroblasts were cultured within the AlgiMatrix® system, 
although colonisation is apparent (Figure 5-6), cell numbers are poor suggesting the 
microenvironment is hostile to human stromal cell proliferation. Unfortunately the 
matrix integrity was again degraded after 6 days culture following the fixation, paraffin 
embedding and staining process. 
When a higher density of cells was used including the whole buffy coat from ficoll 
separation, multiple aggregates of bone marrow cells were observed throughout the 
disc after 6 days of culture (Figure 5-7). 
The formation of spheroids is a well-recognised characteristic of tumour cells in 3-D 
cell culture and usually increases proliferation rates and cellular drug resistance 
through upregulation of transcription pathways through activation of surface adhesion 
molecules.128,138,154  Possible explanations for the slow proliferation rates observed 
were a failure of cells to migrate into and adhere to the matrix during the seeding 
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stage and a lack of cell-cell contact, both of which are important factors in survival and 
proliferation of tumour cells in 3-D culture.155–158 
Higher stromal cell densities for seeding the matrix; the addition of extracellular matrix 
proteins to aid adhesion, such as fibronectin and different seeding techniques may be 
required are areas which require further exploration in order to optimise proliferation 
and survival within this model. 
5.5.1 Increasing the seeding cell density from 1x106/mL to 5x106/mL 
appears to improve colonisation of the AlgiMatrix® 3-D system 
The AlgiMatrix® manufacturer recommended using a cell suspension with a density of 
1x106 cells/mL to seed the disc.149  However, initial experiments revealed a paucity of 
stromal and lymphoid cells within the matrix after culture at this cell density. 
In order to address this problem and given the better colonisation of the matrix when 
a higher concentration of cells (marrow buffy coat) was used, an experiment with a 
series of cell-suspension densities was performed to establish the optimal seeding 
density. 
A cell density of 5x106/mL yielded optimal results in terms of disc colonisation.  
Seeding densities above this concentration resulted in dense sheets of cells in the 
peripheries of the sponge with no significant colonisation of the sponge itself (Figure 5-
9). 
5.5.2 Centrifugation of the AlgiMatrix® Disc does not appear to improve 
colonisation 
Although increasing the density of the cell suspension used to seed the AlgiMatrix® 
disc appeared to improve colonisation of the disc, sectioning revealed the centre of 
the disc remains largely empty of cells when examined by light microscopy.  In an 
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attempt to improve distribution of the cells within the disc, the manufacturer 
recommended gentle centrifugation of the 24 well-plate holding after seeding. 
However, gentle centrifugation (500 rpm for 5 minutes prior to incubation) did not 
appear to enhance distribution throughout the disc in these experiments.  Diffuse 
colonisation was observed throughout the sections using both centrifuged and 
uncentrifuged methods with two different patient samples (Figure 5-10). 
5.5.3 Co-culture of primary MCL cells with stromal cells is possible within 
the AlgiMatrix® system 
Given the evidence from the previous chapter of MCL cells dependence on interactions 
with CD40-ligand and accessory cells for survival and proliferation, an experiment was 
designed to culture both primary MCL cells and stromal cells together using the 
AlgiMatrix® 3-D system.  After a 5 day incubation period, aggregates of small 
lymphocytes with basophilic nuclei admixed with lighter-coloured purple stromal cells 
were visible in the stained sections demonstrating the feasibility of culturing primary 
MCLs together with murine stromal cells in the 3-D model (Figure 5-11). 
5.5.4 Optimising AlgiMatrix® disc integrity prior to sectioning and staining 
Optimising the conditions for disc fixation, embedding, sectioning and staining was one 
of the challenges encountered in the 3-D culture model and significant progress was 
made in fixation and reinforcement of the disc structure.   
Fixation times vary depending on tissue thickness and density.  In the initial 
experiments on AlgiMatrix, after 6 days of culture, the disc was fixed with PFH 




Because there were no calcified or fibrous components in the tissue, a shorter fixation 
time of 2 hours was tested and appeared to be adequate in terms of balance between 
maintaining the integrity of the tissue and allowing adequate fixation to prevent 
degradation of the sections over time.  However, because no antigen labelling was 
performed in these experiments, further work is required in establishing the optimal 
time for fixation for epitope preservation. 
5.5.5 AlgiMatrix® disc reinforcement with barium chloride improved disc 
integrity 
Prolonged incubation times also had detrimental effects on the disc integrity causing 
deterioration during the fixation and embedding phases.  Images from light-
microscopy of the stained sections demonstrated suboptimal preservation of the 
structure following tissue processing (Figure 5-3).  With the aim of making the 
AlgiMatrix® disc more durable throughout the dehydration and paraffin embedding 
process, the disc was immersed in a 100mMolar solution of barium chloride to 
reinforce the matrix cross-linkages prior to fixation and paraffin embedding.  This 
appeared to improve the structural integrity of the disc for the fixation, embedding 
and sectioning steps (Figure 5-8). 
Further work is required to establish whether the use this method of matrix 
reinforcement with barium chloride prior to fixation in its current form has an effect 
on antigen expression and binding. 
5.5.6 Cell retrieval from the AlgiMatrix® disc is possible using non-
enzymatic degradation. 
After 5 days of co-culture of primary MCL cells with murine stromal cells, the discs 
were dissolved using non-enzymatic dissolving buffer (Gibco).  The discs visibly 
degraded within 5 minutes and were completely degraded after 10 minutes.  
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Fluorescein associated cell sorting of the resulting cell suspension demonstrated a 
distinct and viable population of CD5 / CD19 positive MCL cells (Figures 5-12 and 5-13).  
This demonstrates that surface markers can be preserved and analysed by flow 
cytometry on MCL cells retrieved from the AlgiMatrix system to identify and 
distinguish the cells from other cells cultured simultaneously. 
5.5.7 Hanging Drop Method 
Culturing primary CLL cells within the hanging drop method demonstrated the 
formation of aggregates of viable cells when the revised method using a 9cm diameter 
petri dish with a humidity reservoir was used.  FACS analysis of cells retrieved from 
hanging drop culture after 5 days are displayed in Figure 5-17.  Despite the significant 
apoptosis seen in these cultures it shows that viable cells can be recovered. 





6. CHAPTER 6.  Summary and Discussion 
This thesis represents a significant body of work on the characterisation of the 
behaviour of primary cells from what is a relatively rare disease.  Compared with other 
studies in this field, this is one of the largest case sets of primary MCL cases 
characterised and studied ex vivo. 
6.1.1 Developing a 2-D model for primary MCL culture 
One of the most striking observations from a general perspective is how differently 
these cases behave ex vivo.  The observation that, on the whole, survival is better and 
proliferation rates are lower ex vivo in cells from the indolent leukaemic cases is not 
surprising, given the indolent nature of the disease in these subjects.  However there is 
also significant heterogeneity in the survival and proliferation rates observed in some 
of the aggressive cases which may underline the fact that characteristics of indolent 
and aggressive MCL are not very well defined in the literature and outcomes do vary 
between cases.  The marked genetic heterogeneity of MCL has already been alluded 
to, with some cases carrying the t(11;14) chromosomal aberration in isolation whereas 
others also carry mutations in key genes such as p53 and SOX-11.21,22  Future work may 
include further definition of the genetic and molecular-genetic profile of the cases 
studied here in order to establish any patterns between molecular genetics, clinical 
phenotype and rates of survival and proliferation in our ex vivo system. 
One of the primary aims of this thesis was to develop a model which reflects the in vivo 
lymphoma microenvironment for in vitro study.  Significant progress has been made in 
this regard.  Initially it was noted that MCL cells from peripheral blood generally 
require an accessory cell for sustained survival and proliferation, probably due to 
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stromal cell secretion of pro-survival cytokines such as granulocyte-macrophage colony 
stimulating factor (GM-CSF), IL-6 and B-cell activating factor.39,159,160 
Both murine and human stromal layers appear capable of supporting survival and 
proliferation.  However when murine stroma are used, this study has demonstrated 
that additional CD40 signalling is necessary in order to sustain survival and growth, 
especially in the nodal, proliferative cases.   
The costimulatory signal of the CD40 synapse is well recognised as a necessary signal 
for the initiation and progression of adaptive immune response and as a necessity for 
normal B-cell proliferation.45,62  However previous studies have demonstrated diverse 
outcomes of malignant B-cells after CD40 ligation.  For example, in Burkitt’s 
lymphoma, a tumour of the germinal centre, CD40 ligation results in FAS-induction and 
initiation of apoptosis.46  Cell growth is also directly suppressed by CD40 ligation in 
other aggressive forms of B-cell lymphoma.47  However, in more indolent forms, such 
as CLL, CD40 ligation can inhibit apoptosis and prolong cell survival in vitro.48  A 
positive role for CD40-L in MCL cells has been demonstrated previously in a small 
number of cases and has been shown to facilitate entry into the S-phase of the cell 
cycle.49  In this study, the CD40-ligand appeared critical for sustained survival and 
proliferation in many but not all of the cases but particularly the nodal / aggressive 
ones.  The reasons for the varied responses to CD40-L observed here are not known, 
and would be a consideration for future work; however, on the whole, CD40-ligation 
appears to have a positive effect without any obvious detrimental effects and should 
probably be incorporated into a model for the study of MCL ex vivo when murine 
stromal cells are used. 
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The addition of IL-4 is known to stimulate the clonal expansion and continued 
proliferation of normal B cells in association with CD40 ligation. 62  This may be due to 
the activation of pro-survival protein transcription.60,61  However, the impact of IL-4 in 
B-NHL proliferation is also controversial.  In some studies, IL-4 has demonstrated an 
inhibitory effect on proliferation of human NHL cases.161  Whereas others demonstrate 
that proliferation of CLL cells can be induced in the presence of IL-4 and CD40 
agonists.162   In this study, IL-4 with CD40L appears to have a uniformly positive effect 
and significantly enhances survival of primary MCL cells ex vivo supporting and 
augmenting data already published on a small series of MCL cases and suggesting an 
ongoing role for IL-4 and CD40-ligation in the development of a model for MCL culture 
ex vivo.49 
Toll-like receptor-9 ligation did not appear to enhance the culture model for primary 
MCL cases in this study.  In fact, survival was significantly impaired and no significant 
effect on proliferation was noted.  Although TLR9 ligation is well known to increase 
proliferation in CLL cells,163,164 the response is mixed in other B-NHL subtypes and 
previous data sets have shown no increase in proliferation in MCL cells.165  This, large 
data set reflects this pattern and it is therefore unlikely that TLR9-ligation would make 
up part of future work on this model of MCL study. 
Only a very limited amount of data is available from this study on the culture of 
primary MCL cells on human stroma.  The results, however, were promising in terms of 
survival and the use of human stroma as a culture model would definitely be part of 
the future work. 
The higher intrinsic rate of apoptosis exhibited by the primary MCL cells from the more 
nodal and proliferative clinical cases is an interesting observation and may represent a 
189 
 
more mutated and unstable MCL genotype compared with the more indolent cases.  
This remains to be established and would be an interesting hypothesis to pursue in 
future work. 
6.1.2 Profiling the cellular adhesion molecules of primary MCL cells 
The profiling of CAMs has been performed on primary, peripheral blood MCL cells from 
17 cases with paired bone marrow and peripheral blood adhesion profiles in four 
cases.  Again, this is a large case series for MCL, a relatively rare disease, and 
significantly augments the literature on CAM expression.28,76 
In this series, CD11a, CD49d and CD54 were consistently expressed at a high level.  
CD11a, which forms part of the LFA-1 molecule, is thought to facilitate adhesion to 
FDCs via ICAMs 1-3.  LFA-1 is normally expressed by reactive B-cells in lymph nodes 
and variably expressed in NHL lymphocytes.110  The relatively high expression of CD11a 
seen here corresponds with greater expression observed in other nodal diseases such 
as SLL and DLBCL.116  This in itself is an important observation in adding to the 
characterisation of MCL cells. 
CD49d, which makes up part of VLA-4, is commonly expressed on resting lymphocytes 
and monocytes, functioning as a matrix and cellular receptor.  The high expression 
observed in this series is probably to be expected, given VLA-4’s role in facilitating 
lymph node adhesion to FDCs via ICAM-1.108 
In addition to the baseline adhesion characteristics of MCL, the dynamic increase in 
expression of CD184 in response to stromal cell co-culture is an important observation 
which reinforces previously published data on the high level expression of CD184 and 
VLA-4 by MCL cells.28  It is thought that this dynamic expression facilitates drug-
resistance in MCL through adherence and migration beneath the stromal cell layer, a 
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phenomenon termed pseudoemperipolesis, which can be blocked by CD184 inhibition 
or VLA-4 antibodies.28 The increase of CD54 expression by CD40L is intriguing and may 
contribute to retention of cells within the tissue microenvironment.  
BTK inhibitors have revolutionised the treatment of patients with MCL. However 
resistance to therapy is observed and complete remissions rare.  Improving responses 
using synergistic drug combinations are being assessed. This study has shown 
differences in expression of CAM based on clinical phenotype following ibrutinib 
treatment of MCL cells cultured on human stroma and although results are preliminary 
could provide targets for therapy to overcome resistance and/ or improve treatment 
response.  
6.1.3 Developing a 3-D model for primary MCL culture 
The exploration of a 3-D model for MCL culture ex vivo is a novel method.  Because this 
model had not been previously tested in primary MCL, and only limited published data 
exists for any 3-D culture method for lymphoma cells in general, a relatively high 
number of variables (seeding suspension composition and density; length of culture 
time; the addition of supplements; methods for enhancing colonisation and alterations 
to methods for fixation, staining and embedding) were tested with limited time and 
materials. 
Colonisation of a 3-D matrix does appear possible with both primary MCLs and stromal 
cells.  Interesting changes in morphology of stromal cells were noted, with the 
formation of discrete spheroids compared with the flat, spindle-shaped cells seen on 
flat-surface culture and the development of clusters of MCL cells were observed by 
phase-contrast microscopy.  Preservation of disc integrity, a significant challenge, was 
improved by applying relatively short fixation times and reinforcing the disc structure 
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by cross linking the matrix with barium chloride.  Morphologically recognisable cell 
colonies were preserved in stained sections of the cultured disc.  Importantly, this 
study has demonstrated that is possible to retrieve and identify MCL cells by flow 
cytometry after culture within the 3-D system therefore enabling future work to 
examine dynamic changes to survival, adhesion marker expression and proliferation in 
3-D culture by this method.  This would be an interesting avenue for future work. 
 Overview and Future Directions 
6.2 The observations demonstrated in this thesis and how these could be developed in 
future work can be summarised in the following points: 
 Cells from subjects with more indolent, leukaemic forms of MCL demonstrate 
more prolonged survival in ex-vivo culture compared with cells from subjects 
with a more aggressive, proliferative disease type; 
 both murine and human stromal layers are able to support survival and 
proliferation of primary MCL cells ex-vivo, however, when murine stroma are 
used, additional CD40 signalling is necessary in order to sustain survival and 
growth, particularly in cells from subjects with more proliferative MCL; 
 the soluble cytokine IL-4 appears to have a synergistic effect with CD40-L on 
enhancing the survival of MCL cells and could be used in future work to 
enhance and develop an ex-vivo culture model for primary MCL cells; 
 observations from light microscopy of cell culture and cytospin preparations 
demonstrate that cells from proliferative cases exhibit cell clustering during 
times of cell division whereas non-proliferating cells do not form tight clusters; 
 profiling of cellular adhesion molecules on a large series of MCL cases 
demonstrates increased surface expression of CD11a and its respective ligand 
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CD54.  This may be relevant to the cell clustering behaviour visualised by light 
microscopy and may represent a biological rationale for this behaviour as a 
point of focus for future research; 
 early work on a 3-D model has demonstrated the possibility of colonisation of a 
3-D alginate matrix with both primary cells and cell lines.  Although it remains 
necessary to overcome several key challenges, such as improving colonisation 
and cell viability throughout the matrix, important progress has been made, 
including new methods for cell-seeding, tissue fixation and cell retrieval.  
 Conclusions 
6.3
Primary MCL cells exhibit significant heterogeneity in their ability to survive and 
proliferate when cultured in an ex vivo microenvironment.  This reflects the clinical 
heterogeneity often seen in patients with MCL.  Cells from subjects with indolent, 
leukaemic disease demonstrate a greater ability to survive ex vivo but with low 
proliferation rates. Cells from subjects with aggressive nodal disease generally have 
higher intrinsic rates of apoptosis associated with higher rates of proliferation. Both 
survival and proliferation can be significantly enhanced in ex vivo culture by the 
addition of CD40-ligand.  This effect appears more marked in primary MCL cells from 
nodal, clinically aggressive cases. Within the stromal cell co-culture model, survival is 
improved by the addition of IL-4 whereas TLR-9 stimulation attenuates survival with no 
significant increase in proliferation. 
Primary MCL cells express a characteristic profile of CAMs in which CD11a, CD49d and 
CD54 were consistently expressed at a high level.  The profile of CAM expression 
differed between peripheral blood and bone marrow and between clinical phenotypes 
although no individual adhesion molecule expression differed significantly likely as a 
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result of case numbers. These results together with the increased level of expression of 
CD184 and CD54 seen in MCL cells when co-cultured on stroma highlight the 
importance of further studies to understand adhesion molecule expression within 
tissue microenvironments of MCL.  The observation that MCL cells express CD11a and 
CD54 may be important in relation to the cell-clustering behaviour demonstrated by 
microscopy in proliferative cases.  This could represent an avenue of future work.  
The AlgiMatrix® 3-D culture system is a potentially useful model for the study of MCL 
ex vivo.  It is possible to culture primary MCL cells within this 3-D system both alone 
and in association with bone marrow fibroblasts.  It is also possible to analyse cellular 
behaviour within this model after fixation, by paraffin embedding, sectioning and 
staining and by live cell retrieval and flow cytometry. 
Taken together this thesis has contributed new data to this under-explored area on the 
biology of MCL cells within in vitro models of the tissue microenvironment. The study 
particularly identifies a role for CD40L and links this to the intrinsic clinical variability of 
the disorder-this dependence may suggest future treatment strategies directed against 
the CD40 signalling pathway. The success and characterisation of the culture model 
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